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 El síndrome Noonan (SN) es un síndrome autosómico dominante caracterizado por 
dismorfia facial, baja estatura, alteraciones cardiacas, anomalías esqueléticas y retraso mental, 
presentando además una predisposición moderada a desarrollar desórdenes proliferativos, como 
la leucemia juvenil mielomonocítica y el desorden mieloproliferativo. Seis genes de la ruta de 
señalización RAS-MAPK, entre los que se incluyen PTPN11, SOS1, K-RAS, N-RAS, RAF1 y B-
RAF, se han asociado con el SN (1). Recientemente, se han encontrado mutaciones en RIT1, un 
miembro perteneciente a la subfamilia de RAS, en pacientes con SN (2). Aunque K-RAS se 
encuentra mutado en un pequeño porcentaje de pacientes (<2%), estas mutaciones se asocian a 
con un fenotipo más severo. Se han descrito 14 mutaciones del gen K-RAS en pacientes con SN. 
Todas ellas resultan en una activación intermedia de la proteína en comparación con la 
mutaciones típicamente oncogénicas y son distintas a las descritas en tumores humanos (3). 
 En este trabajo, hemos generado un modelo knock-in que expresa la mutación de K-
RAS más frecuentemente asociada a pacientes con SN, la sustitución V14I (4). Estos ratones 
desarrollan muchas de las alteraciones típicas del SN, como retraso en el crecimiento, dismorfia 
facial, alteraciones cardiacas y desorden mieloproliferativo. Además, los ratones homocigotos 
presentan letalidad perinatal cuya penetrancia depende del fondo genético. Aparte del desorden 
mieloproliferativo, los ratones mutantes muestran una predisposición al desarrollo tumoral, 
presentando una reducción de su supervivencia debido al desarrollo de múltiples neoplasias 
como leucemias, sarcomas histiocíticos y carcinomas. Así mismo, esta mutación coopera con 
genes supresores de tumores (p16Ink4a/p19Arf y Trp53) y con eventos de tipo no genético que 
causan daño tisular y/o respuesta inflamatoria, como la pancreatitis, inducida por el tratamiento 
con ceruleína y el tratamiento con nicotina, uno de los principales componentes del tabaco. 
Finalmente, el tratamiento prenatal con el inhibidor de MEK PD0325901 rescató la letalidad 
perinatal y  previno el retraso en el crecimiento y las alteraciones craneofaciales y cardiacas. Sin 
embargo, ninguna de estas alteraciones se corrigieron cuando los ratones fueron tratados al 
destete. El tratamiento este inhibidor tampoco permitió prevenir el desarrollo del desorden 
mieloproliferativo independientemente del tiempo de inicio del mismo. Sin embargo, retrasó el 
desarrollo de la enfermedad, incrementando ligeramente la supervivencia.  
 
Referencias:  
1. Rauen, K.A. 2013. The RASopathies. Annu Rev Genomics Hum Genet 14:355-69 
2. Aoki, Y., et al. 2013. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway 
syndrome. Am J Hum Genet 93:173-80. 
3. Schubbert, S., et al. 2007. Biochemical and functional characterization of germ line KRAS mutations. Mol Cell 
Biol 27:7765-70. 
4. Lo, F.S., et al. 2009. Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and 
a review of the literature. Eur J Pediatr 168:919-23. 
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 Noonan syndrome (NS) is an autosomal dominant disorder characterized by a broad 
number of alterations including facial dysmorphia, short stature, congenital heart disease, 
skeletal abnormalities and learning disabilities. Noonan patients are associated with a moderate 
risk for proliferative disorders such as Juvenile Myelomonocytic Leukemia (JMML) and 
myeloproliferative disorders (MPD) (1). Six genes of the RAS-MAPK signaling pathway have 
been associated with NS including PTPN11, SOS1, K-RAS, N-RAS, RAF1 and B-RAF (1). 
Recently, mutations in RIT1, a member of the RAS subfamily, have been also described in 
Noonan patients (2). Although K-RAS mutations are found in low percentage of clinical 
diagnosed patients (<2%), they usually correlate with more severe symptoms. 14 different K-
RAS mutations have been described in Noonan patients. They result in milder activation of the 
protein compared to the oncogenic form and have not been identified in human tumors (3).  
 Here we describe the generation of a K-Ras knock-in mouse model induced by the 
expression of the most frequent K-RAS mutations in Noonan patients, the substitution V14I (4). 
Mutant mice displayed multiple NS-associated developmental defects such as growth delay, 
craniofacial dysmorphia, cardiac defects and hematological abnormalities, MPD. Homozygous 
animals had perinatal lethality whose penetrance varied with genetic background. Mutant mice 
had increased predisposition to tumor development other than MPD. These mice presented 
reduced life span due to the development of multiple malignancies including lymphomas, 
sarcomas and carcinomas. Moreover, this mutation cooperated with tumor suppressor genes 
such as p16Ink4a/p19Arf and Trp53 and with non-genetic events involving tissue damage 
and/or inflammatory response, like pancreatitis induced by caerulein treatment and nicotine 
administration. Finally, prenatal exposure to the MEK inhibitor PD0325901 rescued the 
perinatal lethality and prevented the growth defects, craniofacial dysmorphia and cardiac 
defects. However, these alterations were not corrected when mice were treated after weaning. 
Indeed, this MEK inhibitor treatment failed to prevent development of MPD independently of 
the time of the initiation of the treatment, but slowed the development of the disease since a 
small benefit in the survival was found.  
 
 
References:  
1. Rauen, K.A. 2013. The RASopathies. Annu Rev Genomics Hum Genet 14:355-69 
2. Aoki, Y., et al. 2013. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway 
syndrome. Am J Hum Genet 93:173-80. 
3. Schubbert, S., et al. 2007. Biochemical and functional characterization of germ line KRAS mutations. Mol Cell 
Biol 27:7765-70. 
4. Lo, F.S., et al. 2009. Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and 
a review of the literature. Eur J Pediatr 168:919-23. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          1. Index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
                                                                                                                                                Index 
	   7	  
RESUMEN/SUMMARY                  1 
 
1. INDEX                     7 
 
2. ABBREVIATIONS                 15 
 
3. INTRODUCTION                  23 
 
3.1 RAS PROTEINS                  23 
 3.1.1 The superfamily of RAS proteins               24 
 3.1.2 RAS proto-oncogenes structure              24 
 3.1.3 RAS proteins structure               25 
 
3.2 SIGNALING DOWNSTREAM RAS               26 
 3.2.1 Aberrant signaling in human tumors              28 
 
3.3 RAS IN HUMAN DEVELOPMENTAL DISORDERS             29 
 3.3.1 Neurofibromatosis type 1 (NF1)               30 
 3.3.2 Cardio-facio-cutaneus (CFC) syndrome              31 
 3.3.3 Costello syndrome (CS)                32 
 3.3.4 Noonan syndrome (NS)                32 
  3.3.4.1 Molecular pathogenesis               34 
  3.3.4.2 Cancer in Noonan syndrome              37 
 3.3.5 LEOPARD syndrome                38 
 3.3.6 Legius syndrome                 39 
 3.3.7 Noonan syndrome-like with loose anagen hair (NS/LAH)            39 
 3.3.8 Noonan-like/multiple giant cell lesion syndrome (NL/MGCLS)           39 
 3.3.9 Noonan-like syndrome                40 
  
3.4 ANIMAL MODELS OF NOONAN SYNDROME              40 
 
4. OBJECTIVES                  45 
 
5. MATERIALS AND METHODS                49 
 
5.1 GENERATION OF THE CONDITIONAL K-RasLSLV14I KNOCK-IN MOUSE MODEL   49 
 5.1.1 Generation of the targeting DNA vector to modify the endogenous locus of  
                                                                                                                                                Index 
	   8	  
 K-Ras                  49 
 5.1.2 Homology recombination in ES cells              49 
 5.1.3 Identification of the homologous recombinant clones by Southern blot         50 
  3.1.3.1 Genomic DNA isolation              50 
  3.1.3.2 Genomic analysis by Southern blot             51 
 5.1.4 Generation of chimeric mice              52 
 5.1.5 Germline K-RasV14I expression               53 
 
5.2 MICE: MAINTENANCE AND GENOTYPING              54 
 5.2.1 Maintenance of mice               54 
 5.2.2 PCR genotyping                 55 
 
5.3 BODY WEIGHT AND SIZE ANALYSIS              55 
 
5.4 BLOOD EXTRACTION AND NECROPSY             55 
 5.4.1 Blood extraction and analysis              55 
 5.4.2 Necropsy                 55 
 
5.5 HISTOPATHOLOGY AND IMMUNOHISTOCHEMISTRY           56 
 5.5.1 Histopathology                 56 
 5.5.2 Blood smear preparation and staining              56 
 5.5.3 X-Gal staining on cryosections              56 
 5.5.4 Immunohistochemistry                57 
 5.5.5 Ki67 and cardiomyocyte quantification              57 
 
5.6 MOLECULAR ANALYSIS OF THE K-RasV14I MUTATION            57 
 5.6.1 Protein extraction                57 
 5.6.2 Protein quantification                58 
 5.6.3 Western blot: identification of Ras proteins and members of the Ras  
 signaling pathway                 58 
 5.6.4 Determination of the Ras activation levels              59 
 
5.7 RNA ISOLATION AND QUANTITATIVE REAL TIME RT-PCR            59 
 
5.8 MEFS ISOLATION AND IMMORTALIZATION              60 
 
5.9 IN-VIVO IMAGING METHODS                60 
                                                                                                                                                Index 
	   9	  
 5.9.1 Micro X-ray computed tomography (micro-CT)            60 
 5.9.2 PIXImus Densitometry                60 
 5.9.3 Magnetic Resonance Imaging (MRI) study             61 
 
5.10 ANALYSIS OF HEARING PARAMETERS              61 
 
5.11 HEMODYNAMIC STUDY                62 
 
5.12 FLOW CYTOMETRY ANALYSIS              62 
 5.12.1 Flow cytometry analysis: spleen               62 
 5.12.2 Flow cytometry analysis: bone marrow              63 
 5.12.3 Flow cytometry analysis: blood               63 
 5.12.4 Flow cytometric analysis and sorting: heart             64 
 5.12.5 Apoptosis assay                 64 
 5.12.6 Proliferation assay                65 
 
5.13 COLONY FORMING ASSAY                66 
 5.13.1 BM colony assay                66 
 5.13.2 CFU-F colony assay of cardiac stem cells            67 
 
5.14 BONE MARROW TRANSPLANTATION              67 
 
5.15 MICE PROTOCOLS TO CONTROL THE CRE RECOMBINASE ACTIVITY          67 
 5.15.1 Polyinosinic-polycytidylic acid (pI-pC) treatment            67 
 5.15.2 Tamoxifen diet treatment               67 
 5.15.3 Adenovirus intratracheal infection              68 
 
5.16 INDUCTION OF PANCREATITIS BY CAERULEIN TREATMENT           68 
 
5.17 NICOTINE TREATMENT                68 
 
5.18 MEK INHIBITOR TREATMENT               68 
 
5.19 STATISTICS                  69 
 
6. RESULTS                   73 
 
                                                                                                                                                Index 
	   10	  
6.1 GENERATION OF A CONDITIONAL K-RAS KNOCK-IN MOUSE MODEL  
FOR NOONAN SYNDROME                 73 	   6.1.1 Conditional knock-in mouse model K-RasLSLV14I             73 
 
6.2 K-RasV14I EXPRESSION IS COMPATIBLE WITH EMBRYO AND  
POSTNATAL STAGES                 74 	   6.2.1 Perinatal lethality of K-RasV14I/V14I mice              75 
 
6.3 MOLECULAR ANALYSIS OF THE K-RasV14I MUTATION AND THE  
K-Ras SIGNALING PATHWAY                76 
 6.3.1 Molecular analysis of the K-RasV14I mutation             76 
 6.3.2 Molecular analysis of the K-Ras signaling pathway            77 
 
6.4 ROLE OF K-RasV14I IN PROLIFERATIVE SENESCENCE            78 
 6.4.1 Molecular analysis of the K-RasV14I mutation in MEFs            79 
 
6.5 K-RasV14I DISPLAYED REDUCED BODY SIZE              80 
 
6.6 K-RasV14I MICE DISPLAYED FACIAL DYSMORPHIA AND NO  
SKELETAL ABNORMALITIES                81 
 6.6.1 K-RasV14I mice displayed normal skeleton              81 
 6.6.2 K-RasV14I mice displayed facial dysmorphia             82 
 
6.7 K-RasV14I MICE DISPLAYED NORMAL AUDITORY PARAMETERS           83 
 
6.8 K-RasV14I MICE DEVELOPED HEART ABNORMALITIES            84 
 6.8.1 K-RasV14I mice displayed an expansion of the cardiac stem cells           85 
 6.8.2 Hemodynamic study, cardiac morphology and function analysis           87 
 6.8.3 Myocardial expression of the K-RasV14I mutation             88 
 
6.9 HEMATOLOGICAL DEFECTS OF K-RasV14I MICE             89 
 6.9.1 Cytokines response of bone marrow progenitors             91 
 6.9.2 Germline K-RasV14I mutation increased HSC and lineage  
 progenitor population                 93 
 6.9.3 Stem cell origin of K-RasV14I-driven MPD             95 
 6.9.4 Activation of K-RasV14I mutation in hematopoietic cells            97 
 
                                                                                                                                                Index 
	   11	  
6.10 EFFECT OF MODIFIER ALLELES: GENETIC BACKGROUND AFFECTS  
NS PHENOTYPE                100 
 6.10.1 Phenotypic consequences of the genetic backgrounds on the body size  
 and facial dysmorphia               100 
 6.10.2 Phenotypic consequences of the genetic backgrounds on cardiac  
 and hematopoietic alterations              101 
 
6.11 CANCER RISK IN K-RasV14I mice             103 
 6.11.1 Role of K-RasV14I in lung tumor development           105 
 6.11.2 Role of K-RasV14I in pancreatic tumor development          106 
 6.11.3 K-RasV14I expression increased tumor risk in combination with  
 nicotine administration               109 
 6.11.4 Loss of heterozygosity (LOH)             110 
 6.11.5 Cooperation between K-RasV14I mutation and tumor suppressors genes        111 
 6.11.6 Somatic expression of the K-RasV14I mutation           113 
 6.11.7 Cooperation between K-RasV14I mutation and the oncogenic  
 mutation PI3KCAH1047R              114 
 
6.12 THERAPEUTIC STRATEGIES: MEK INHIBITOR TREATMENT OF K-RasV14I  
MICE AT DIFFERENT DEVELOPMENTAL STAGES           115 
 6.12.1 Prenatal MEK inhibitor treatment prevents the developmental defects             116 
 6.12.2 Postnatal MEK inhibitor treatment does not rescue any defects of K-RasV14I  
 mice                      119 
 6.12.3 Adult inhibitor treatment does not have any therapeutic effects to treat MPD  121  
 
7. DISCUSSION               125 
 
7.1 K-RasV14I EXPRESSION IS COMPATIBLE WITH EMBRYO AND  
POSTNATAL DEVELOPMENT              125 
 
7.2 GROWTH DEFECTS AND CRANIOFACIAL ALTERATIONS: TWO  
IMPORTANT FEATURES IN NCFC SYNDROMES            126 
 
7.3 CARDIAC ALTERATIONS: DIFFERENTIAL EFFECTS OF THE  
SPECIFIC MUTATIONS              127 
  7.3.1 K-RasV14I expression in adult myocardial cells does not induce an alteration of  
  the heart development               129 
                                                                                                                                                Index 
	   12	  
 
7.4 ROLE OF K-RasV14I AND K-RasG12V MUTATIONS IN THE DEVELOPMENT  
OF HEMATOLOGICAL ALTERATIONS             129 
 
7.5 THE HEMATOLOGICAL DISORDER DISPLAYED BY K-RasV14I MICE IS  
SIMILAR TO THOSE INDUCED IN MICE THAT EXPRESSED MUTATION OF  
THE RAS-MAPK PATHWAY              131 
 7.5.1 Aberrant hematopoiesis induced by K-RasV14I mutation: mutation specific  
 or RAS-MAPK pathway specific?             132 
 
7.6 IS THE K-RASV14I MUTATION A MILD ONCOGENIC SUBSTITUTION?        133 
 7.6.1 The K-RasV14I mutation cooperated with loss of tumor suppressor genes  
 but does not cooperate with activating Pi3kca mutation           135 
 
7.7 IS THE MEK INHIBITOR PD0325901 A GOOD DRUG TO PREVENT  
OR AMILORATE NOONAN SYNDROME ALTERATIONS?           136 
 
7.8 EFFECT OF THE MEK INHIBITOR PD0325901 IN THE MDP DEVELOPMENT       138 
 
8. CONCLUSIONES/CONCLUSIONS             143 
 
9. BIBLIOGRAPHY               149 
 
APPENDIX I: FIGURES AND TABLES             179 
 
APPENDIX II: PUBLICATIONS               203 
 
 
 
 
 
 
 
 	  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       2. Abbreviations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
                                                                                                                                  Abbreviations 
	   15	  
α−MHC:  α Myosin Heavy Chain 
ABR:   Auditory Brainstem Response 
AF6:   ALL-1 fused gene on chromosome 6 protein 
AML:   Acute Myeloid Leukemia 
ALL:   Acute Lymphoblastic Leukemia 
AP1:   Activator Protein 1 
APC:   Allophycocyanin (FACS analysis) 
APC:   Adenomatous Polyposis Coli (Gen) 
ARF:   ADP Ribosylation Factors 
BAD:   Bcl-2 Associated Death protein 
BM:   Bone Marrow 
BMC:   Bone Mineral Content  
BMD:   Bone Mineral Density 
BSA:   Bovine Serum Albumin 
CAPRI:  Ca2+ Promoted RAS Inactivator 
CBL:   Casitas B-Lineage Lymphoma 
CFC:   Cardio-Facio-Cutaneous syndrome 
CFU-F:  Colony Forming Units- Fibroblast 
CFU-GM:  Colony Forming Unit-Granulocyte Macrophage 
CLP:   Common Lymphoid Progenitors 
CMP:   Common Myeloid Progenitors 
CO:   Cardiac Output 
CS:   Costello Syndrome 
Ct:   Cycle threshold 
CT:   Computed Tomography 
DAPI:   4’, 6-diamidino-2-phenyldole 
DORV:  Double Outlet Right Ventricle 
DMEM:  Dulbecco’s Modified Eagle Medium 
                                                                                                                                  Abbreviations 
	   16	  
DMSO:  Dimethyl Sulfoxide 
CMV-Cre:  Cytomegalovirus Cre 
ECL:   Enhanced Chemiluminiscence System 
EDTA:  Ethylene Diamine Tetraacetic Acid 
EDV:   End-diastolic volume 
EF:   Ejection Fraction 
EGFR:   Epidermal Growth Factor Receptor  
EGTA:  Ethylene Glycol Tetraacetic Acid  
ELK1:   ETS domain-containing transcription factor 
ER:   Estrogen Receptor 
ERBB:  v-erb-b2 avian Erythroblastic Leukemia Viral Oncogen Homolog 
ERK:   Extracellular Signal Regulated Kinase 
ESV:   End-Systolic Volume 
ETS:   E26 Transformation-specific Sequence 
FACS:   Fluorescence Activated Cell Sorting	   
FBS:   Fetal Bovine Serum 
FCS:   Fetal Calf Serum 
FITC:   Fluorescein Isothyocyanate  
FKHR:  Forkhead Transcription Factor 
FOS:   FBJ murine osteosarcoma viral oncogene homolog 
FOXO:  Forhead box class O transcription factors 
FMO:   Flourescense Minus One 
FS:   Fractional Shortening 
GAP:   GTPase Activating Protein 
GDP:   Guanosine Diphosphate 
GEF:   Guanine Exchange Factor 
GEMM:  Genetically Engineered Mouse Model 
GH:   Growth Hormone 
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GM-CSF:  Granulocyte-Macrophage Colony Stimulating Factor 
GMP:   Granulocyte Macrophage Progenitor 
GRB2:   Growth Factor Receptor-bound protein 2 
GTP:   Guanosine triphosphate 
HCM:   Hypertrophic Cardiomiopathy 
HIF1α:  Hypoxia-Inducible Factor 1α 
HMG-CoA:  3-Hydroxy-3-Methylglutamyl Coenzyme A  
HR:   Heart Rate 
HSC:   Hematopoietic Stem Cell 
Hyg:   Hygromicin 
H&E:   Hematoxylin and Eosin 
IL3:   Interleukin 3  
IL6:   Interleukin 6  
IMDM:  Iscove's Modified Dulbecco's Medium 
JMML:  Juvenile Myelomonocytic Leukemia 
LIF:   Leukemia Inhibitory Factor 
LOH:   Loss Of Heterozygosity 
LS:   LEOPARD Syndrome 
LSK:  Lineage–/Sca-1+/c-Kit+ 
LSL:   Lox-STOP-Lox 
LVM:   Left Ventricle Mass 
MAP:   Mitogen Activating Protein 
MAPK:  Mitogen Activating Protein Kinase 
MDS:   Myelodisplastic Syndrome 
MEF:   Mouse Embryonic Fibroblast 
MEK:   Mitogen Activating Protein (MAP) kinase kinase  
MEP:   Megakaryocyte-Erythroid Progenitors 
MKK6:  Mitogen Activated Protein Kinase Kinase 6 
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MPD:   Myeloproliferative Disorder 
MPP:   Multipotent Progenitor Population  
MRI:   Magnetic Resonance Imaging  
NCFC:  Neuro-Cardio- Facio-Cutaneous  
NFR:   Nuclear Fast Red 
NF1:   Neurofibromatosis type 1/ Neurofibromin 1 
NF-kB:  Nuclear Factor- kB 
NL/MGCLS:  Noonan-like/ Multiple Giant Cell Lesions Syndrome 
NS:   Noonan Syndrome 
NS/LAH:  Noonan Syndrome-like with Loose Anagen Hair  
PanIN:   Pancreatic Intraepithelial Neoplasias 
PBS:   Phosphate Buffered Saline 
PCR:   Polymerase Chain Reaction  
PDAC:  Pancreatic Ductal Adenocarcinoma 
PDK1:   3-Phosphoinositide-Dependent protein Kinase 1 
PE:   Phycoerythrin  
PerCP:   Peridinin Chlorophyll Protein 
PGK:   Phosphoglycerate Kinase 
PIP2:   Phosphatidylinositol-3,4,- Biphosphate 
PIP3:   Phosphatidylinositol-3,4,5- Triphosphate 
PI3K:   Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PS:   Phosphatidylserine 
PTEN:   Phosphatase and Tensin Homolog 
PTP:   Protein Tyrosine Phosphatase 
PTPN11:  Protein Tyrosine Phosphatase Non- receptor type 11 
RALBP1:  RAL Binding Protein 1 
RALGDS:  RAL Guanine nucleotide Dissociation Stimulator  
RASGRF:  RAS-specific Guanine nucleotide-Releasing Factor  
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RASGRP1/4:  RAS Guanyl- Releasing Protein 
RASSF:  RAS association domain-containing family 
RBD:   RAS Binding Domain 
RIN-1:   RAS interaction/interference protein 1 
RIT:   RAS like protein In Tissues 
RSK:   Ribosomal S6 kinase 
RT:   Room Temperature 
SCC:   Saline Sodium Citrate 
SDS:   Sodium Dodecyl Sulfate 
SHC:   Src Homology 2 domain Containing protein 
SHOC2:  Soc2 Suppresor of Clear Homolog 
SHP-2:  Src Homology Protein- 2 
SH2:                 Src Homology 
SOS1:   Son of Sevenless 1 
SPRED1:  Sprouty-related, EVH1 domain-containing protein 1 
STAT3:  Signal Transducer and Activator of Transcription-3 
TAE:   Tris Acetate EDTA 
TAM:   Tamoxifen 
TBS:   Tris Buffered Saline 
TCEP:   Tris (2’ Carboxyethyl) phosphine 
TE:   Echo Time 
TGF-α:  Transforming Growth Factor α 
TIAM1:  T-cell lymphoma Invasion And Metastasis 1 
TK:   Thymide Kinase 
TR:   Repetition Time 
VPR:   Volume Pressure Recording 
UV:   Ultraviolet 
WBC:   White Blood Cell 
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WT:   Wild Type 
WTd:   Wall Thickness in diastole 
WTn:   Systolic wall thickening 
WTs:   Wall Thickeness in systole 
ZONAB:  ZO-1 Nucleic Acid Binding protein  
4OHT:   4-Hydroxy-tamoxifen  
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 Oncogenic properties of RAS genes and RAS signaling pathway have been deeply 
studied (132). In 1990 germline mutations in NF1 gene (neurofibromin 1) was associated with 
the Neurofibromatosis type 1 (NF1) (34) and in 2001, PTPN11 (Protein tyrosine phosphatase 
non-receptor type 11) was described in more than 50% of patients with Noonan syndrome (NS) 
(211). These studies provided the first association between activated mutations in RAS 
signaling members and developmental disorders. In 2005, H-RAS oncogene was found mutated 
in Costello syndrome (CS) patients (12). More recently, mutations in the K-RAS and N-RAS 
oncogenes have been found in NS patients (41, 188).  
 These findings provide strong indication that developmental disorders result from the 
novo germline mutations that alter the RAS/MAPK signaling pathway. These syndromes 
[Cardio-facio-cutaneous syndrome (CFC), Costello syndrome (CS), LEOPARD syndrome (LS), 
Neurofibromatosis type 1 (NF1) and Noonan syndrome (NS)] share phenotypic features: facial 
abnormalities, heart defects, impaired growth, cancer predisposition and neurocognitives 
alterations. Based on these phenotypic similarities these congenital alterations are known as 
‘Neuro-Cardio-Facial-Cutaneous’ (NCFC) and due to their association with the RAS/MAPK 
pathway dysregulation they are also called ‘RASopathies’ (165).  
 The generation of mouse models expressing different mutations identified in these 
patients help to understand the developmental and physiological defects associated with each 
syndrome and to evaluate preventative and therapeutic strategies. This thesis presents the 
generation and characterization of a K-Ras knock-in mouse model for NS.   
 
3.1 RAS PROTEINS 
 
 Rat sarcoma (RAS) proteins are signaling switch molecules that regulate proliferation, 
differentiation and survival in response to extracellular stimuli. RAS proteins are small GTPase 
proteins that cycle between inactive guanosine diphosphate (GDP)-bound and active 
guanosinetriphosphate (GTP)-bound conformations (RAS–GDP and RAS–GTP, respectively). 
In absence of stimuli (including soluble growth factors), the RAS proteins are inactive and 
bound to GDP. The stimulation takes place when GDP is exchanged by GTP driving by the 
guanine-exchange factors (GEFs). These proteins displace guanine nucleotides from RAS and 
permit passive binding to GTP, which is abundant in the cytosol (Figure 1). In the presence of 
stimuli, the active receptors create intracellular docking sites for adaptor molecules and signal 
relay proteins, such as GRB2 and SHC that recruit and activate GEFs, such as SOS1/2, 
RASGRF and RASGRP1/4 (132). RAS signaling is finished by hydrolysis to RAS-GDP driven 
by their intrinsic GTPase activity. Several GTPase activating proteins (GAPs) markedly 
stimulate intrinsic GTPase activity by stabilizing a high-energy transition state that occurs 
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during the RAS–GTP hydrolysis reaction (Figure 1). Some of these proteins are NF1, 
p120GAP, GAP1m, GAPIII and CAPRI (132). 
 
 
 The RAS wild type forms are called proto-oncogenes due to their oncogenic potential 
after acquisition of mutations that inhibit the GTPase activity and lock the protein in the active 
GTP bound conformation. The mutant forms of the RAS genes that confer a constitutive active 
form of the proteins are called RAS oncogenes. 
 
3.1.1 The superfamily of RAS proteins 
  
 The Ras superfamily comprises over 150 members with evolutionarily conserved 
orthologs (44). This superfamily is divided in 5 families: Rho, Rab, Ran, Arf and Ras (231). 
 The Rho family is involved in signaling networks that regulate actin organization, cell 
cycle progression and gene expression. In addition they are implicated in hematopoiesis. The 
Rab family, the largest family of the Ras superfamily, participates in vesicular transport and the 
trafficking of proteins between different organelles of the endocytic and secretory pathways. In 
eukaryotas, Ran family only comprises one member, the RAN proteins. By contrast, these 
proteins are the most abundant and are involved in nuclear transport. Finally, the Arf family is 
involved in vesicular transport regulation of the exocytic and endocytic pathways (176). 
 Ras family comprises 36 genes, which encode 39 proteins. These members are included 
in seven subgroups based on the homology of their effector domain: RAP (RAP-1A, RAP-1B, 
RAP-2A and RAP-2B), R-RAS (R-RAS and TC21/R-RAS2), RIT (RIT1 and RIT2), M-RAS, 
E-RAS, RAL (RAL and RALB) and RAS (55, 44, 97). The subfamily RAS includes 3 genes, 
which encode 4 small proteins (21 kDa): H-RAS, N-RAS, K-RAS 4A and K-RAS 4B (124). 
 
3.1.2 RAS proto-oncogenes structure 
  
 RAS proto-oncogenes are highly conserved from yeast to human and play a key role in 
signal transduction. The RAS subfamily includes 3 genes: H-RAS1 (in this thesis H-RAS), K-
RAS2 (in this thesis K-RAS) and N-RAS and 2 pseudogenes: H-RAS2 y K-RAS1. In humans H-
Figure 1. Schematic representation of RAS 
regulation. RAS cycling between an inactive state 
bound to GDP and an active state bound to GTP. 
Guanosine-exchange factors (GEF) promote the 
exchange of GDP for GTP. GTPase activating proteins 
(GAPs) catalyze the hydrolysis of GTP. Adapted from 
Repasky et al., 2004 (169). 
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RAS, K-RAS y N-RAS genes are located in chromosomes 11, 12 and 1, respectively. In mice, H-
Ras, K-Ras and N-Ras genes are located in chromosomes 7, 6 and 3, respectively (17).  
 The structure of the RAS genes is highly conserved, with a first non-coding exon (exon 0) 
and four coding exons. K-RAS presents two alternative forms (4A and 4B), which leads through 
an alternative splicing to the synthesis of two isoforms, K-RAS 4A and K-RAS 4B, that differ 
in the last 25 carboxy terminal amino acids (17, 80). However, RAS genes differ significantly in 
the intron sequence and size, resulting in a marked gene length difference: K-RAS (35 kb), N-
RAS (7 kb) and H-RAS (3 kb) (124).  
 
3.1.3 RAS proteins structure 
 
 The three RAS genes encode four highly homologous 21 kDa proteins with 188 amino 
acids (K-RAS 4B) and 189 amino acids (H-RAS, N-RAS y K-RAS 4A). The N-terminal portion 
(residues 1–165) of H-RAS, K-RAS and N-RAS comprises a highly conserved G domain that 
has a common structure. RAS proteins diverge substantially at the C-terminal end, which is 
known as the hypervariable region (residues 165-188/189). 
 The first 85 aminoacids of the G domain contain the GDP and GTP binding sites. This 
region is identical in all the RAS proteins and presents the phosphate-binding loop (P-loop) 
(residues 10-16) and the nucleotide-sensitive switch I (residues 32–38) and II (residues 59-67) 
regions. The P-loop is the binding site of the γ phosphate of the GTP. The nucleotide-sensitive 
switch regions are essential for the control of RAS signaling durations. Switch I controls the 
binding of GAPs and switch II is involved in the interaction with the GEFs (93, 160, 235). The 
next 80 amino acids define a second region where mammalian RAS proteins diverge only 
slightly from each other, exhibiting an 85% homology.  
The remaining C-terminal sequence, the hypervariable region, contains sequences that 
specify post-translational modifications that are essential for targeting RAS proteins to the 
cellular membranes. All RAS proteins present a CAAX motif, in which C is cysteine, A is 
usually an aliphatic amino acid and X is residue that contributes to substrate specificity. In the 
case of H-RAS is a Serine and in the case of K-RAS and N-RAS a Methionine (72, 234). The 
initial modification is directed by the farnesyl transferase, a cytosolic enzyme that attaches a 
farnesyl group to the cysteine of the CAAX motif (71). In H-RAS, N-RAS and K-RAS4A, this 
binding is complemented by palmitoylation on cysteine residues in the hypervariable region of 
the protein (the so-called ‘second signal’) to anchor the Ras proteins to the membrane. By 
contrast, K-RAS4B, the predominant splice variant (from now on as K-RAS), contains an 
alternative second signal composed by a polybasic stretch of lysine residues. In this case, 
membrane anchoring is mediated by the electropositive lysines that form ionic bonds to the 
electronegative lipid head groups of the inner leaflet of the plasma membrane (187). 	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3.2 SIGNALING DOWNSTREAM RAS  
 
 GTP–bound RAS, the active form, can interact productively with more than 20 effectors 
to regulate several cellular responses, including proliferation, differentiation and survival. The 
most important effectors include RAF, phosphatidylinositol 3-kinase (PI3K) and Ral guanine 
nucleotide dissociation stimulator (RALGDS) (53, 187) (Figure 2). 
The first mammalian effector to be characterized, and the most intensively studied, is 
the protein serine/threonine kinase RAF. GTP-bound RAS binds to, and contributes to the 
activation of, the three RAF proteins, A-RAF, RAF1 or C-RAF and B-RAF. This interaction 
causes RAF to be relocated to the plasma membrane, which seems to be crucial for its activation 
by serine/threonin phosphorylation (116, 134). Activated RAF subsequently activates by 
phosphorylation the Mitogen Activating Protein (MAP) kinase kinase 1 and 2 (MEK 1 and 
MEK 2), which afterward activates by phosphorylation the Extracellular signal-Regulated 
Kinases 1 and 2 (ERK1 and ERK2). Substrates for ERK1/2 include cytosolic and nuclear 
factors (such as transcription factors), reflecting that they can be transported into the nucleus 
after activation. One of this transcription factors is the ETS domain-containing transcription 
factor (ELK1), an E26 transformation-specific sequence (ETS) family member that forms part 
of the serum response factor that regulates FOS expression (242). ERK1/2 proteins can also 
phosphorylate and activate the transcription factor JUN. JUN and FOS proteins form the 
activator protein 1 (AP1) transcription factor. Activation of these transcriptional regulators can 
lead to the expression of proteins that control cell-cycle progression, such as cyclin D (161). 
Hence, RAF activation can promote cell cycle progression. For this reason, the RAF/MEK/ERK 
pathway is also known as the mitogen or proliferative pathway.  
 RAS–GTP also binds to the catalytic subunit of type I PI3Ks (156, 175), resulting in the 
translocation of PI3K to the plasma membrane and subsequent activation. PI3K phosphorylates 
phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-
triphosphate (PIP3), a second messenger that binds to a large number of proteins, for instance 
the kinases PDK1 (3-phosphoinositide-dependent protein kinase 1) and AKT (16), controlling 
their activity. PDK1 is important for the activation of a large number of protein kinases of the 
AGC family, including AKT, some PKCs, p70 S67K and RSK. AKT promotes survival by 
inactivation though phosphorylation pro-apoptotic proteins including BAD and Forkhead 
(FKHR) transcription factors (79, 227). PI3K-AKT signals also control several growth-
regulatory transcription factors, including FOXO proteins and nuclear factor-kB (NF-kB) (16). 
FOXO proteins control the pace of the cell cycle, as well as apoptosis, DNA repair and 
protection from oxidative damage (218, 228). AKT signaling works as a negative control of 
these proteins. Whereas FOXO is inactive by AKT, the transcription factor NF-kB is activated, 
which positively regulates cell survival, proliferation, chemoresistance, angiogenesis, cellular 
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invasion and oncogenesis (3, 96). The PI3K/PDK1/AKT pathway has a strong anti-apoptotic 
function and seems to be an important part of the survival signal generated by RAS. In addition 
PI3K activation leads to stimulation of RAC, a RHO family protein involved in the regulation 
of the actin cytoskeleton and the transcription factor, such as NF-kB (109, 131). 
 
  RALGDS is the third best-studied effector, an ubiquitous protein that present a large 
number of targets (59). RAL interacts with the phospholipase D1 and ARF mediating vesicle 
transport and membrane traffic (88, 125) and with SEC5, Filamin, RALBP1 and ZONAB 
regulating endocytosis, exocytosis, actin organization and controlling of gen expression (142, 
22, 58, 173). The RAS-GDS-RAL pathway has been shown to be involved in modulation of the 
activity of transcription factors, like the FOXO family proteins (50). 
 Although initial studies established a relatively minor role for RAS-RALGDS-RAL 
pathway in cell transformation (58, 169), recent studies indicated a crucial role (71). RALGDS 
was required for tumor formation in a mouse model of Ras-dependent skin carcinogenesis (63) 
and the activation of this pathway was necessary and sufficient to induce the growth of non-
metastatic prostate cancer cells promoting bone metastasis in xenograft models (240).  
  Many other effectors are directly coupled to RAS-GTP, several of which have known 
roles in regulating cellular responses: Phospholipase Cε, which promotes the hydrolysis of PIP2 
to diacylglycerol and inositol-1,4,5-triphosphate and the subsequence calcium mobilization and 
protein kinase C activation (98, 198, 202). RAC exchange factor TIAM1 (T-cell lymphoma 
invasion and metastasis 1) also binds directly to RAS-GTP, leading to increased levels of RAC 
and subsequent actin reorganization (109). Other RAS effectors include the RAS 
Figure 2. Ras signaling network. RAS proteins are signaling switch proteins that, in response to 
extracellular stimuli, induce a complex signaling network that control several cellular responses. Adapted 
from Karnoub et al., 2008 (97).   	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interaction/interference protein-1 (RIN1), ALL-1 fused gene on chromosome 6 protein (AF6) 
and the RAS association domain-containing family (RASSF) proteins (97).  
 RAS proteins control several important cellular functions by the interaction with many 
effectors. Therefore, the correct regulation of this complex signaling pathway is essential for the 
maintenance of cellular homeostasis.  
 
3.2.1 Aberrant signaling in human tumors 
 
Around 30% of human tumors present activating RAS mutations (35). The most 
frequently mutated isoform is K-RAS. These mutations are found in around 22% of tumors and 
preferentially in pancreatic ductal adenocarcinomas (90%), colorectal cancer (45%) and lung 
adenocarcinomas (35%) (60). By comparison, the rates of N-RAS and H-RAS oncogenic 
mutations are much lower (6% and 3%, respectively) and the tissue distribution is different to 
K-RAS mutations (Table 1 in Appendix I).  
 In most cases, these somatic missense mutations introduce amino acid substitutions at 
positions 12, 13 and 61, which impair the intrinsic GTPase activity and confer resistance to 
GAPs, thereby causing RAS to accumulate in the GTP-bound active form (24, 217). Three-
dimensional studies of the RAS structure indicate that oncogenic mutations of Q61 impair the 
GTP hydrolysis reaction by interfering with the coordination of a water molecule that is 
required for the nucleophilic attack on the γ-phosphate of GTP (31, 184). Similarly, oncogenic 
substitutions in residues G12 and G13 prevent the formation of van der Waals bonds between 
RAS and GAP through steric hindrance and so perturb the proper orientation of the catalytic 
glutamine (Q61) in RAS, which results in the pronounced attenuation of GTP hydrolysis (183).  
RAS can also be activated by alterations in other members of their activating pathway. 
For instance, in some tumors the activation of the protein is due to loss of GAPs. The most 
significant example is the NF1, a developmental disorder that is characterized by large number 
tumors. These tumors are induced by the elimination of both copies of NF1 that encodes the 
neurofibromin protein, one of the main GAPs of RAS, resulting in the activation of RAS 
pathway (see for more details the 2.3.1 section) (230).  
In some tumors, RAS is activated by the overexpression of the growth factor receptor 
tyrosine kinases. The most common examples are EGFR and ERBB (HER2/neu), which are 
frequently activated by their overexpression in breast, ovarian and stomach carcinomas (140). In 
other tumors like glioblastoma, EGFR is hyperactivated by the expression of a truncated 
receptor that lacks part of the extracellular domain. This modification promotes a ligand-
independent receptor activation and a constitutive activation of the pathway (106). EGFR-
family tyrosine kinases are also commonly activated in tumors of epithelial origin by the 
autocrine production of EGF-like factors such as TGF-α (106). 
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 The constitutive activation of the oncogenic RAS proteins deregulates downstream 
effector pathways to confer the abnormal functional properties of cancer cells: deregulated cell 
growth, survival and differentiation. Moreover, oncogenic RAS accelerates the metabolic 
reprogramming of cancer cells predominantly through the upregulation of hypoxia-inducible 
factor 1α (HIF1α), which stimulate a glycolytic shift (162) and induces non-cell-autonomous 
changes in the cellular microenvironment that have essential roles in tumor initiation and 
progression. One example is the induction of angiogenesis (162). The constitutive activation of 
the pathway also plays a role in the evasion of cancer cells to the immune system (42, 123) and 
contributes to the metastasis process by inducing alterations in cell–cell and cell– matrix 
interactions and the acquisition of a migratory phenotype (162). 
All these effects can be also induced by mutations or amplification of RAS effectors. B-
RAF is frequently activated in melanomas (~70%) and colon carcinoma (~15%) (53). The PI3K 
pathway is activated by the amplification of the p110α genes in a small proportion of ovarian 
tumors and by the amplification of its downstream target AKT2 in ovarian and breast cancer 
(19). However, the most significant activation of this pathway comes from the deletion of the 
negative regulator or the PI3K signaling, the tumor suppressor gene PTEN, which occurs in 
~30-40% of human tumors (16).  
 
3.3 RAS IN HUMAN DEVELOPMENTAL DISORDERS 
 
RAS proteins have been intensively studied for more than three decades, since its 
dysregulation is one of the primary causes of cancer (132). More recent, observations 
accumulated in the last decade have associated some inherited developmental disorders with 
germline mutations in RAS (H-RAS, N-RAS and K-RAS) or in other upstream (PTPN11 and 
SOS1) or downstream components (B-RAF, C-RAF, MEK1 and MEK2) of the RAS signaling 
pathway (Figure 3) (60, 187, 207, 215). Most of these loci (H-RAS, K-RAS, N-RAS, B-RAF, 
PTPN11 and NF1) are also found mutated in human tumors. However, in contrast to the 
somatic oncogenic mutation, these substitutions are germline mutations that encode less active 
proteins compared to the cancer-associated mutations, with the exception of H-RAS. H-RAS 
mutations that cause CS encode strong gain of function mutations ant it is therefore not 
surprising that affected individuals are predisposed to benign and malignant tumors (187). 
 The developmental disorders that result from germline mutations in members of the 
RAS signaling pathway are known as Neuro-Cardio-Facial-Cutaneous’ (NCFC) syndromes or 
‘RASopathies’. These syndromes share a variable degree of common alterations: facial 
abnormalities, heart defects, impaired growth, and, in some instances, cancer predisposition and 
neurocognitives alterations. Cardio-facio-cutaneous syndrome (CFC), Costello Syndrome (CS), 
LEOPARD Syndrome (LS), Neurofibromatosis type 1 (NF1) and Noonan Syndrome (NS) are 
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the best-known NCFC syndromes. Legius Syndrome (NF1-like), Noonan syndrome-like with 
loose anagen, Noonan-like/multiple giant cell lesion syndrome and Noonan-like syndrome have 
been recently described as complex disease that share some features with NS or NF1 (165). 
 
3.3.1 Neurofibromatosis type 1 (NF1) 
 
 Neurofibromatosis type 1 (NF1; OMIM 162200) was the first ‘RASopathy’ described 
(34). It is an autosomal dominant disorder affecting approximately 1 in 3000 newborns. Their 
clinical diagnosis is based on the presence of café-au-lait maculae, axillar or inguinal freckling, 
neurofibromas and plexiform neurofibromas, iris Lisch nodules, osseous dysplasia and optic 
pathway glioma. In addition, individuals may have “Noonan-like” faces, mild neurocognitive 
impairment and a predisposition to developing certain malignancies such as central nervous 
system tumors (gliomas and astrocytomas), neurofibrosarcomas and juvenile myelomonocytic 
leukemia (JMML). For this reason, NF1 patients normally have reduced life span (215). 
Inactivated genetic modification in the NF1 gene causes this disease. As mentioned before NF1 
encodes neurofibromin 1, a GAP that is a negative regulator of RAS (see 2.1.1 section). The 
NF1 missense mutations result in loss-of-function of the protein causing a reduction in RAS-
GTPase activity and therefore an increase of the active RAS form.  
Figure 3. Schematic diagram showing the RAS-MAPK signaling pathway and the components affected 
in the NCFC syndromes. Adapted from Tidyman et al., 2008 (215). 
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 In mouse, the expression of one copy of a null mutation of the NF1 locus is associated 
to an enhanced predisposition to specific tumors including phaeochromocytomas and myeloid 
leukaemias, tumors that are evident in human NF1 patients (84). However, the expression of 
two copies of the null mutation is incompatible with the embryonic development. Homozygous 
null embryos die at mid gestation. Mutant embryos exhibit globular and hypoplastic hearts with 
significant ventricular septal defects and display double outlet right ventricle (25, 84). Mutant 
embryos also display hyperplasia of neural crest-derived sympathetic ganglia (25). Besides 
hematopoietic cells derived from the liver of these embryos display hypersensitivity to 
Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF) (23,111) and are sufficient to 
induce a chronic myeloproliferative syndrome in bone marrow (BM) transplanted animals 
(111).  
 
3.3.2 Cardio-facio-cutaneus (CFC) syndrome 
 
 Cardio-facio-cutaneus syndrome (CFC; OMIM 115150) is a sporadic occurrence 
syndrome. Epidemiological studies that estimate the prevalence of the disease do not exist. 
Around 60 cases published and 100 unpublished cases are known to the CFC International 
association (170). This condition is characterized by failure to thrive, severe feeding problems, 
developmental delay, reduced growth, distinctive dysmorphic facial features, abnormalities of 
the skin, gastrointestinal tract and central nervous system (seizures are frequently observed), 
and cardiac defects [most commonly pulmonic stenosis, followed by hypertrophic 
cardiomyopathy (HCM) and septal defects] (170). CFC syndrome has considerable clinical 
overlap with NS and CS. In contrast to the other NCFC syndromes, CFC syndrome is believed 
to have no increased malignancy risk. However, the observation of acute lymphoblastoid 
leukemia (ALL) in one patient (151) raises questions about this matter. Four genes have been 
associated with this syndrome: K-RAS (rare), B-RAF (~75%), MEK1 and MEK2 (~25%) (151, 
174, 60). Due to the phenotypic overlap of CFC syndrome and NS the role of K-RAS in the CFC 
syndrome remains unclear because K-RAS mutations were also indentified in Noonan patients.  
 A genetic modified mouse model for CFC syndrome has been recently generated. This 
mouse model expresses low levels of expression of B-RafV600E from germline, a constitutively 
active mutation first identified in human melanoma. B-Raf+/LSLV600E mice are viable and display 
several of the characteristic CFC features: reduced life span, small size, facial dysmorphism, 
cardiomegaly and epileptic seizures. These mice also show up-regulation of catecholamines and 
cataracts, two features detected in a low percentage in CFC patients. In addition, B-Raf+/LSLV600E 
mice develop neuroendocrine tumors, a pathology not observed in CFC patients (223). 
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3.3.3 Costello syndrome (CS) 
 
 Costello syndrome (CS; OMIM 218040) is a rare developmental disorder, that affects a 
very few patients (~ 300 around the world) (67). Costello patients develop multiple anomalies, 
including prenatal overgrowth followed by postnatal feeding difficulties and severe failure to 
thrive, short stature, distinctive coarse facial features, cardiac defects (most commonly HCM, 
septal defects, valve thickening and/or dysplasia, and arrhythmias), musculoskeletal and 
ectodermal abnormalities and neurocognitive delay (164). CS patients have an increased risk of 
developing neoplasias, including rhabdomyosarcomas, neuroblastomas and bladder cancer. 
These solid tumors affect approximately to 15% of CS patients. Cutaneous papilloma is a 
distinctive and common feature of this disorder (66). CS is caused by germline missense 
mutation in H-RAS (12). The distribution frequency of mutations reveals that more than 80% of 
individuals have G12S substitution, followed by G12A (9%) and G13D (1.4%) (67). These 
substitutions disrupt guanine nucleotide binding and cause a reduction in intrinsic and GAP 
induced GTPase activity. As an exception with the rest of the syndromes, these mutations are 
frequently found in human tumors. In addition, less frequently observed mutations, such as 
K117R and A146T may result in an atypical phenotype (215). 
 Two independent knock-in mouse models involving the expression of the H-RasG12V 
mutation have been generated to analyze the molecular mechanisms responsible for the 
phenotypic defects of CS patients (40, 189). Schuhmacher and colleagues described in 2008 that 
germline expression of the oncogenic H-RasG12V allele phenocopies some of the abnormalities 
observed in CS patients, including facial dysmorphia and cardiomyopathies. These mice also 
display alterations in the homeostasis of the cardiovascular system, including development of 
systemic hypertension, extensive vascular remodeling and fibrosis in heart and kidneys. This 
phenotype is age dependent and is a consequence of the abnormal upregulation of the renin-Ang 
II system. The expression of the mutation results in hyperplasia of the mammary gland (189). 
However, development of tumors in these mice is rare. In 2009, Chen and colleagues described 
that the expression of the same mutation is associated with high perinatal mortality, abnormal 
cranial dimension, defective dental ameloblast and nasal septal deviation. In contrast to the first 
mouse model, mice also develop papillomas and angiosarcomas (40). The phenotype 
differences between these two mice carrying the same mutation, may be explained by gene 
modifiers, as has been suggested for human patients.  
 
3.3.4 Noonan syndrome (NS) 
 
 Noonan syndrome (NS; OMIM 163950) was described by the pediatric cardiologist 
Jacqueline Noonan 40 years ago. NS is one of the most common developmental disorders, with 
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estimated incidence of 1:1,000 to 1:2,500 live births, but mild cases may be even more common 
(141). The typical signs of NS include typical facial feature, chest and spinal deformities, short 
stature, characteristic heart defects, and learning disabilities with mild mental retardation (208). 
 The facial appearance of Noonan patients shows considerable change with age, being 
most striking in the newborn period and most subtle in the adulthood, some adults lack facial 
alterations (8). In general, NS patients are characterized by ptosis and wide-spaced eyes, low 
set, posteriorly rotated ears with fleshy helix, inverted triangular face which is broad at the 
temples and tapers to a small chin and long and broad or webbed neck (7).  
 The weight and length are also variable with the age. Although patients display normal 
size and weight at birth, the neonatal feeding problems and failure to thrive (63%) slows the 
proper development of the children. Even though feeding problems are solved spontaneously 
later in infancy, the pubertal growth is often attenuated or delayed, resulting in a final adult 
reduced height. Growth hormone (GH) deficiency and resistance and neurosecretory 
dysfunction have been described in these patients (171, 220, 224).  
 NS is the most common syndromic cause of congenital heart disease after the Down’s 
syndrome (OMIM 190685). The frequency of congenital heart disease is estimated between 
50% and 90%. The most common are pulmonary stenosis (often with dysplastic valves; 50–
60%), HCM (20%), and secundum atrial septal defect (6–10%). Subventricular septal defect, 
peripheral pulmonary stenosis, atrioventricular canal, aortic stenosis, mitral valve abnormalities, 
aortic coarctation, tetralogy of Fallot, and coronary artery anomalies are less common 
alterations. HCM can be mild or severe and can be present from the prenatal period to late 
childhood. Almost 25% of patients die because of heart failure in the first year (171, 193).  
 Most NS patients display skeletal abnormalities: chest deformities (90%), scoliosis 
(13%), various orthopedic defects, such as cubitus valgus (50%) and joint hyperextensibility 
(50%) (6, 192). Giant cell lesions of the jaw have been reported in several patients (149).  
Up to 80% of NS boys have cryptorchidism. Male gonadal dysfunction has been 
reported due to primary Sertoli cell dysfunction rather than cryptorchidism (135). In both sexes, 
pubertal development is delayed. But, in contrast to male patients, fertility in females is not 
impaired (171). Urinary tract malformations are also present in 10% of cases, mostly 
pyelouretic stenosis and/or hydronephrosis, although treatment is usually not need (192, 224). 
 Several coagulation defects have been described: factor VII, XI and XII deficiencies, 
thrombocytopaenia, Von Willebrand’s disease, and platelet dysfunction. These manifestations 
appear individually or in combination and affect about one of third of all individuals (138, 192).  
  Lymphatic vessels dysplasia, hypoplasia or aplasia (20%), abnormal pigmentation 
[naevi (25%), café-au-lait spots (10%) and lentigines (3%)], ophthalmic abnormalities, hearing 
loss and hepatosplenomegaly (25%) are other phenotypic features of NS (7, 171). 
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 Developmental delay and learning problems are less common than in CS and CFC. In 
most individuals the intelligence is normal and mild retardation, characterized by specific visual 
and verbal problems, is seen in one-third of patients (192). Prominent behavioral problems are 
clumsiness, eating problems, fidgety or stubborn spells, echolalia, irritability, social problems 
and attention deficit. In spite of this wide range of behavioral problems, NS children can be 
raised with parental support alone (236). Besides, 80% of diagnosed NS, graduated from high 
school, one-third attended college and 5% had a master degree (7).  
 
3.3.4.1 Molecular pathogenesis 
  
 PTPN11 was found mutated in NS ten years ago (211). The PTPN11 gene product, 
SHP-2, is a non-receptor tyrosine phosphatase that relays signals from activated growth factor 
receptors to RAS, SRC family kinases, and other molecules. SHP-2 generally plays a positive 
role in signal transduction and regulates cellular responses such as proliferation, differentiation, 
and migration (148, 155). This protein is composed to N-terminal and C-terminal SH2 domains 
and a catalytic protein tyrosine phosphatase (PTP) domain. Its catalytic function is auto-
inhibited through a blocking interaction between the N-SH2 and PTP domains. 50% of cases of 
NS are caused by missense, gain-of-function, mutations in this gene (171). These mutations 
cluster in and around the interacting portions of the N-terminal and the catalytic PTP domain, 
which are involved in switching the protein between its inactive and active conformations. 
Mutations typically perturb equilibrium, causing constitutive or prolonged activation of the 
protein. A number of mutations, however, affect residues that also participate in catalysis or in 
the control of substrate specificity (209, 210). PTPN11 gene has been recognized as an 
oncogene. Somatic mutations have been frequently identified in JMML	   and pediatric acute 
leukemia. These mutations occurred at the same residues as in NS, but with substitutions that 
result in a more active protein (213). Vertical transmission of the same mutations in a family is 
commonly associated with PTPN11 substitutions. PTPN11-associated NS is linked with a high 
incidence of pulmonary stenosis or atrial septal defects, bleeding diathesis, short stature, and 
JMML. In contrast the incidence of HCM and coarctation of the aorta is lower in patients with 
these mutations (171).  
 Currently, SOS1 mutations are the second most frequent cause of NS (10%). SOS1 
encodes a RAS-GEF. The majority of the reported mutations were located in residues that are 
responsible for the stability of the protein in an inhibited conformation. Therefore, these 
alterations reduce its autoinhibition activity, leading to constitutive activation of the protein 
with the subsequently constitutive activation of the RAS pathway (172, 212). SOS1-associated 
NS is characterized by a higher prevalence of ectodermal abnormalites generally associated 
with lower prevalence intellectual disability, short stature and atrial septal defects (171). 
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 Missense mutations in the RAF1 gene have also been found in 5-15% of NS patients 
(157, 168). These mutations are often clustered in two regions: the conserved region 2, flanking 
the residue S259; and the conserved region 3, in and surrounding the activation segments. In 
addition, two mutations in the C-terminal domain have also been reported (157, 168). HCM is 
associated to RAF1-NS (75 vs 20% overall NS patients with other mutated genes) and it seems 
to be associated with mutations in the Ser259 and Ser621 hotspots. Multiple naevi, lentigines of 
café-au-lait spots are reported in a third of patients, suggesting a predisposition to 
hyperpigmented cutaneous lesions (207).  
 Germline B-RAF mutations have been described in a small percentage of patients (<2%) 
(180, 154, 168). As mentioned before, B-RAF has been described as a major gene mutated in 
CFC syndrome patients. Interestingly, NS and CFC are associated with specific and different B-
RAF mutations, suggesting a genotype-phenotype correlation. B-RAF-associated NS is related 
to neonatal growth failure and feeding problems, mild to moderate cognitive deficits, hypotonia 
and a higher prevalence of multiple nevi and dark colored lentigines. B-RAF mutations produce 
a more severe adult phenotype than PTPN11 or SOS1 mutations (207).  
 K-RAS and N-RAS germline mutations account for less than 2% of the NS patients. This 
low number of cases makes impossible to establish a genotype-phenotype correlation. In an 
analysis of 917 individuals with NS or related disorders, four unrelated individuals (three de 
novo and one familial) had mutations in N-RAS (Cys149Thr or Gly179Ala) (41). K-RAS 
mutations have been described in a small percentage of NS patients, and are usually correlated 
with more severe symptoms (26, 33, 46, 99, 104, 115, 118, 122, 147, 153, 167, 188, 243). With 
the exception of a vertical transmission in a family presenting a novel K-RAS mutation (M72L) 
(26), all the cases are sporadic, likely reflecting the decreased reproductive fitness caused by the 
more frequent and severe intellectual disabilities of these patients. Therefore, several patients 
display an intermediate phenotype between NS and CFC syndrome (33, 243). Craniosynostosis, 
a rare finding, was described in four NS patients with K-RAS mutations (26, 104, 188).  
 14 different K-RAS mutations have been described in Noonan patients (Table 2 in 
Appendix I). These gain-of-function mutations result in milder activation of the K-RAS protein 
compared to the typical oncogenic forms and have not been identified in human tumors (187). 
The position of the mutated amino acid residues altered in NS suggests two distinct 
pathogenetic mechanisms: 
a) The first group of mutations includes the mutant proteins that affect the P-loop 
(V14I), the Switch I (P34L and P34Q) and II (T58I and G60S) domain or intermediated regions 
of the G domain (Q22R, M72L, N26I and N116S) (Figure 4). All these mutations have less 
GTPase activity, basally and after stimulation with a GAP protein, than wild type K-RAS but 
more than oncogenic G12D. Thus, these mutants reduced RAS inactivation, resulting in 
increased RAS signaling (65, 186, 188). Specifically, the intrinsic GTPase activities of the NS-
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associated V14I and T58I recombinant proteins are lower than wild type K-RAS, but less 
impaired that oncogenic G12D. Furthermore, both mutant proteins also show intermediate 
levels of GTP hydrolysis in response to the GAP-related domains of p120GAP and 
neurofibromin, compared to the wild type and K-RASG12D. A particular interesting feature of the 
T58I mutant protein is its differential responsiveness to p120GAP and neurofibromin. The 
intermediate phenotypes of NS-associated mutants V14I and T58I are also observed in 
functional assays. The dose-response curves for hematopoietic progenitor colony formation in 
response to GM-CSF or erythropoietin are left-shifted in murine fetal liver cells expressing both 
mutant proteins relative to wild type K-Ras, but these cells are less hypersensitive than cells 
expressing the G12D form. Macrophage progenitor cultures expressing T58I or G12D K-Ras 
displayed robust and prolonged activation of Ras and downstream effectors compared to 
cultures expressing wild type or V14I K-Ras. By contrast, COS-7 cells expressing K-Ras V14I 
demonstrated elevated basal and serum-starved levels of Ras-GTP and phospho-MEK compared 
to cells expressing wild type or T58I receptors to the nucleus. These studies show that these 
alleles are activated, and support the idea that cell context modulates their functional and 
biochemical effects since the same mutations in different cell types have a different outcome 
(188).  
b) The second group of mutations includes the mutant proteins that alter regions that 
reside far from the P-loop typically altered in cancer, specifically the α-5 helix of the K-RAS 
4B isoform (V152G, D153V and F156I) (Figure 4). Based on structural modeling, Carta and 
colleagues indicated that the V152G and D153V substitutions destabilize the conformation of 
the portions of the G domain that contributes extensively to the interactions of K-RAS with the 
GTP/GDP guanine ring. They predicted that the mutants will have normal GTPase function but 
reduced binding to GTP and GPD, permitting GEF-independent activation (33). Although depth 
biochemical analysis of the V152G and D153V K-RAS mutants has not yet been reported, an 
F156L substitution in H-RAS results in a rapid rate of nucleotide dissociation, modestly 
increases of Ras-GTP leves, and transform rodent fibroblast (186). Also, the Val152, Asp153 
and Phe156 are encoded by exon 4B, so the mutations only alter K-RAS 4B isoform, providing 
new evidence that this isoform plays a major role during development.  
 Finally, it have recently been identified nine missense mutations in RIT1, in 17 of 180 
NS patients (9%) without described causative mutation. Clinical manifestations of these 
individuals are consistent with those of NS, but present a high frequency of HCM (11). RIT1 is 
a RAS subfamily member involved in regulation of the p38 MAPK-dependent signaling 
cascade related to cellular stress (32, 196). This protein also cooperates with nerve growth 
factor to promote neuronal development and regeneration (83, 195). This study is the first 
evidence that other members of the RAS subfamily are implicated in developmental disorders.   
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 3.3.4.2 Cancer in Noonan syndrome  
 
 NS is associated with risk for benign and malignant proliferative disorders. 
Approximately 10% of NS children are affected by a mild myeloproliferative disorder (MPD), 
which is usually self-limiting. A smaller percentage of patients develop JMML and/or other 
hematological malignancies, such as myelogenous leukemia and B-cell acute lymphoblastic 
leukemia (91). There are no good epidemiological studies to establish if NS patients display 
tumor predisposition. The literature illustrates that 45 of 1,151 NS patients (mutations unkown) 
developed cancer (3.9%). These tumors include: neuroblastoma (8 patients), acute 
lymphoblastic leukemia (8 patients), glioma and rhabdomyosarcoma (8 patients), acute myeloid 
leukemias (3 patients), testicular cancer (3 patients), non-Hodgkin lymphomas (2 patients), and 
colon cancers (2 patients). Single reports of Wilms tumor, hepatoblastoma, Hodgkin disease, 
chronic myelomonocytic leukemia, chronic lymphocytic leukemia, breast cancer, malignant 
schwannoma, and bile duct cancer were also described. The ages of the patients at the time of 
cancer diagnosis were comparable to the expected for sporadic cancers (103). It has also been 
reported 40 cases of NS (or Noonan-like syndrome) associated with MPD with a benign course 
in 16 (40%) and an aggressive course in 6 (15%) cases. By the age of 20, the cumulative 
incidence of cancer in NS was approximately 4%, lower than the 15% for CS. Both syndromes 
had a cancer incidence peak in childhood (103). 
 Furthermore, Jongmans and colleagues published a study of a cohort of 297 Dutch 
patients with NS with PTPN11 mutations (mean age 18 years). Twelve patients developed 
cancer, providing a cumulative risk for developing cancer of 23% up to the age of 55 years (a 
3.5 times increased risk). Hematological malignancies were the most frequent neoplasm (4/12, 
33%). The non-hematological malignancies observed included three novel cancers in Noonan 
patients: a malignant epithelioid angiosarcoma, a colon cancer of the sigmoid and a basal cell 
carcinoma. In conclusion, this study provides the first evidence of an increase tumor risk in 
PTPN11-NS patients, compared to that in the general population (91). 
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Figure 4. Schematic representation of K-RAS showing the distribution of the amino acid substitution 
found in Noonan patients (above) and the three amino acids commonly mutated in human tumors 
(bellow). The P-loop, switch 1 (SwI), switch II (SwII) domains and the hypervariable region are also 
represented. The position of these domains is represented. Adapted from Schubbert et al., 2007 (186). 
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 This study provides evidence that NS patients present increased cancer predisposition. 
The information is limited, because this disorder is a pediatric disease and no follow up and 
registry of adult patients exists. Adult patients are healthy or display mild alterations that are 
treated for the required specialist. Therefore, the study of tumor risk in NS patients is very 
difficult. However, these studies would provide relevant information for prevention, early 
detection and treatment of the tumors that seems to have a higher incidence in NS patients.  
 
3.3.5 LEOPARD syndrome  
 
 LEOPARD syndrome (LS; OMIM 151100) is an acronym for the more characteristic 
features of this syndrome: multiple Lentigines, ECG abnormalities, Ocular hypertelorism, 
Pulmonary valve stenosis, Abnormalities of the genitalia, Retardation of growth and 
sensorineural Deafness. LS is a rare autosomal dominant disorder, about 200 patients have been 
reported worldwide but the real incidence of this syndrome has not been assessed and is 
typically associated with PTPN11 mutations (51, 181). LS, in contrast to the NS, is caused by 
PTPN11 mutations that results in reduced PTP activity. The mutant PTP is then thought to act 
in a dominant-negative fashion to inhibit SHP-2 expressed from the normal PTPN11 allele (51, 
62, 64, 74, 101). Interestingly, the dysregulated activation of the RAS-MAPK signaling 
pathway by mutations that have opposing effects upon SHP-2 activity result in the development 
of two syndromes (NS and LS) that share clinical features (54, 62). 
Homozygous Ptpn11-null mice die at day 10 of embryonic development due to 
defective gastrulation (182). However, the elimination of SHP-2 expression in multiple adult 
tissues results in severe skeletal abnormalities, impaired hematopoiesis, weight loss and 
lethality (18). Moreover, mice expressing the Ptpn11Y279C mutation, one of the most common in 
LS, recapitulates most of the features of LS. Ptpn11+/Y279C mice display short stature, 
craniofacial dysmorphia, skeletal and chest abnormalities, pathological HCM, abnormal 
genitalia and macrophage accumulation in the Corti, indicative of sensorineural defects. 
Biochemical analyses show an increase of the basal and agonist-induced Akt and mTOR 
activity. Interestingly, the cardiac defects were completely reversed by treatment with 
rapamycin, an inhibitor of mTOR (136). Similar results are obtained by the overexpression of 
Q510E, a dominant-negative loss-of-function mutation, in myocardial cells during gestation 
(under the β−myosin heavy chain promoter). Newborn mice display a heart hypertrophic 
associated with an impaired contractile function and hyperactivation of the Akt/mTOR pathway. 
As in the Ptpn11Y279C mice (136), the HCM is ameliorated by rapamycin treatment (185).  
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3.3.6 Legius syndrome 
 
 Legius syndrome (OMIM 611431), or neufibromatosis type 1-like syndrome, is an 
autosomal dominant disorder characterized by multiple axillary freckling, café-au-lait spots, 
macrocephaly, and a NS-like facial dysmorphism in some individuals. Some patients have 
learning difficulties and/or hyperactive behavior (207). This syndrome presents clinical 
overlapping with NF1 and NS. The estimated prevalence in the Orphanet webpage is <1 in 
1,000,000 newborns. Legius syndrome is caused by heterozygous mutations in SPRED1 (29).  
SPRED1 encodes SPRED1, which is a member of the SPROUTY/SPRED family. SPRED1 
functions as negative regulator of RAS by inhibiting RAF phosphorylation (229). SPRED1 
mutations associated with Legius syndrome cause truncation of the protein resulting in loss of 
SPRED1 function, thereby increasing the RAS/MAPK signaling. It is unclear whether 
individuals with SPRED1 germline mutations have an increased risk for developing cancer.  
 
3.3.7 Noonan syndrome-like with loose anagen hair (NS/LAH) 
  
 Although, Noonan syndrome-like with loose anagen hair (NS/LAH; OMIN 607721) 
shows reminiscent features of NS, the patients are distinguished due to the reduced growth 
linked to GH deficiency, cognitive deficits, hyperactive behavior and loose anagen hair. Most 
patients exhibit hairless and darkly pigmented skin with eczema or ichthyosis, and a tendency to 
pruritus. Ectodermal anomalies also include sparse eyebrows and dystrophic or thin nails. The 
voice is characteristically hoarse or hypernasal. Cardiac anomalies (dysplasia of the mitral valve 
and septal defects) are significantly over-represented compared to NS. Estimated prevalence in 
the Orphanet webpage is <1 in 1,000,000 newborns. NS/LAH is genetically homogeneous, 
since all patients display the same missense change (Ser2Gly) in SHOC2, a scaffold protein 
required for the efficient signaling transmission from RAS to the MAPK cascade (45, 139). 
 
3.3.8 Noonan-like/multiple giant cell lesion syndrome (NL/MGCLS) 
 
 Multiple giant cell lesions (MGCLs) of the jaw and/or other bone/soft tissues are rarely 
associated to NS. The presence of MGCLs in Noonan patients was originally known as 
Noonan-like/multiple giant cell lesion syndrome (NL/MGCLS) or Noonan syndrome with 
cherubism (OMIM 163955) (25). Now, it seems that MGCLs is an associated feature of NS, LS 
and CFC and that NL/MGCLS is not a separate disorder, since this feature has been 
documented to occur in different conditions and be caused by mutations affecting PTPN11, 
SOS1 and MEK1 genes previously reported mutated in those syndromes (207). 
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3.3.9 Noonan-like syndrome 
 
 It has been recently reported the presence of germline mutations in CBL gene in patients 
with features fitting or partially overlapping NS, characterized by an unusually variable 
phenotype (developmental delay and reduced growth, facial dysmorphism, café-au-lait spots 
and predisposition to JMML during childhood), with clinical features that might be quite subtle 
in some subjects (137, 150, 158). CBL is a member of a small family of E3 ubiquitin ligases 
that negatively regulate intracellular signaling downstream of receptor tyrosine kinases, but also 
contribute to signal traffic by its adaptor function (207).  
 
3.4 ANIMAL MODELS OF NOONAN SYNDROME 
 
 Several animal models have been generated to study the role of different mutations 
found in Noonan patients. Animal models help to better understand the molecular and cellular 
bases of the developmental and physiological defects associated with the NCFCS, as well as to 
determine their tumor predisposition and to evaluate preventative and therapeutic strategies. 
 Studies in zebrafish have demonstrated that K-RAS, RAF1 and PTPN11, genes mutated 
in NS, are necessary for the normal development of myocardial and craniofacial structures in 
the case of K-RAS. Zebrafish embryos with morpholino knock-down of these genes display 
heart malformation (167, 168). Moreover, the expression of the mRNA of Noonan mutant RIT1 
(11), N-RAS (177) and PTPN11 (92) into zebrafish embryos results in craniofacial and cardiac 
abnormalities, defects reminiscent of NS. Interestingly, MEK inhibitor treatment completely 
rescues these developmental defects in the embryos that express the mutant N-RAS (177) 
 Araki and colleagues developed the first NS knock-in mouse model in 2004, which 
expresses one of the most frequent NS-associated mutations, the Ptpn11D61G. The expression of 
one copy of this mutated allele results in high embryonic lethality (around 50%). Surviving 
Ptpn11+/D61G mice have short stature, craniofacial abnormalities and MPD. Severely affected 
Ptpn11+/D61G embryos have multiple cardiac defects: ventricular septal defects, double-outlet 
right ventricle (DORV) and enlarged valve primordial. These alterations are gene dose 
dependent since homozygosity results in embryonic lethality at mid-gestation. E13.5 
Ptpn11D16G/D61G embryos are hemorrhagic and edematous and show smaller and necrotic liver 
and severe cardiac defects (atrial, atrioventricular or ventricular septal defects, DORV and 
markedly enlarged outflow tract and atrioventricular valve primordial). Furthermore, 
Ptpn11+/D61G embryos present increased Erk activation in altered regions, such as the 
endocardial cushions. This hyperactivation is cell and pathway specific, suggesting that Ras-
MAPK pathway activation takes place in specific cell types responsible for the abnormalities 
(14). All these studies were developed in a mix 129S4/SvEv and C57BL6/J background. The 
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incomplete penetrance of the cardiac defects could reflect the presence of modifier alleles in 
these strains. To address this possibility Ptpn11+/D61G mice were backcrossed to 129S6/SvEv, 
Balb/c, and C57BL6/J pure backgrounds. No alterations were found in the Balb/c background, 
although only half of the Ptpn11+/D61G expected mice was obtained. On 129S6/SvEv, 
Ptpn11+/D61G mice display nearly normal viability. In contrast, C57BL6/J E13.5 embryos display 
severe cardiac defects incompatible with life, indicating that there are important strain-specific 
modifiers of the NS cardiac phenotype (13).  
 Further characterization of the myeloproliferative phenotype of this model suggests that 
Ptpn11D61G germline mutation accelerates hematopoietic stem cell (HSC) cycling, increases the 
stem cell pool, and elevates short-term and long-term repopulating capabilities. The later stage 
myeloid progenitors are also increased. MPD is reproduced in primary and secondary recipient 
mice suggestive of a stem cell origin. Interestingly, the MPD phenotype is ameliorated by the 
deletion of Gab2, an interacting protein target of Shp-2 in cell signaling. It indicates that Gab2 
is an important mediator for the pathogenic effects of Ptpn11 mutations (239).  
 In contrast to the Ptpn11D16G mice, heterozygous Ptpn11+/N308D mice, that express a low 
activated version of the Shp2, are viable and E13.5 embryos have no apparent cardiac defects. 
However, 50% of homozygous Ptpn11N308D/N308D embryos develop multiple cardiac defects 
incompatible with life. The other 50% have no apparent cardiac defects and survive, although 
display growth defects, typical facial appearance and hematologic abnormalities similar to those 
seen in surviving Ptpn11+/D61G mice (13, 14). The abnormalities of Ptpn11+/N308D mice are less 
severe (13). Interestingly, the expression of Ptpn11D61Y, other typical NS mutation, in 
endocardial cells recapitulates the alterations found in Ptpn11D16G/D61G mice (14). However, 
myocardial specific expression, using α myosin heavy chain (α-MHC) promoter, has no 
obvious cardiac consequences. The specific expression in neural crest produced facial defects 
similar to the previous reported in mice (13).  
 Transgenic mice overexpressing the Shp2 Q79R mutant protein (one of the most 
common NS mutations) under the α-MHC promoter, which allows the expression of the 
mutation only in myocardial cells after birth, do not display cardiac defects, similar to previous 
studies (13, 145). In contrast, transgenic mice overexpressing Shp2 Q79R in myocardial cells 
during the gestation [under the β−myosin heavy chain (β-MHC) promoter], show similar 
alterations than those reported in the Ptpn11D16G mouse model (145). These heart alterations 
persist postnatally and induce a cardiac hypofunction that ends in congestive heart failure.  
These studies indicate that the cardiac defects of NS came from the expression of the 
mutant protein in endothelia and myocardial cells during the development. The overexpression 
of the mutation in the same cells in completely developed heart has no effect. Interestingly, as in 
the Ptpn11D16G mice, overexpression of Shp2 Q79R selectively activates Erk1/2. This pathway 
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is necessary and sufficient to mediate the alterations, since incorporation of the null Erk1 mice 
(Erk1-/-) or the heterozygous Erk2 mice (Erk2+/-) completely recue the cardiac phenotype (145). 
 Mice that overexpress the Shp2 Q79R mutation in neural crest cells, by using the Wnt-1 
promoter, develop craniofacial alterations similar to the Ptpn11D16G mice (14, 146). These mice 
show lower body length and weight and typical craniofacial defects (smaller skull lengths, 
greater inner canthal distances, taller frontal bone heights and reduced mandibular bone length). 
Therefore, facial abnormalities in Noonan PTPN11-patients reflect aberrant Shp2 action in 
neural crest-derived cells. Treatment during pregnancy with U0126 (inhibitor of ERK1/2 
phosphorylation) abrogates the craniofacial abnormalities. This data illustrate the importance of 
the Erk1/2 signaling in the neural crest for the craniofacial development (146). 
 Mice overexpressing the Shp2 Q79R mutation only in the endothelial-derived cells die 
at embryonic day E14.5. Embryos at E13.5 are smaller than control littermates and show edema, 
smaller and necrotic liver and hemorrhage. The heart displays an increased endocardial cushion 
size, associated with Erk1/2 activation, suggesting that hyperactivation of this pathway may 
play a pathogenic role. Erk1 deletion rescues the endocardial phenotype, but embryos still die at 
E14.5. However, Erk2 deletion does not affect endocardial cushion size (105).  
 In 2010, Chen and colleagues generated a NS-associated Sos1E846K knock-in mouse 
model. Heterozygous mice were obtained at Mendelian ratios, whereas homozygous mice are 
born at significantly lower frequency (2.38%), due to severe cardiovascular problems. The few 
Sos1E846K/E846K mice born have a significant lower life span and display some of the typical NS 
features: smaller size, facial appearance and multiple cardiac defects; alterations also found in 
Sos1+/E846K mice. These mice also develop hematologic disorder characterized by splenomegaly, 
leukocytosis, myeloid expansion in BM and spleen and increased sensitivity to IL-3 and GM-
CSF. Prenatal treatment with the MEK inhibitor PD0325901 ameliorates embryonic lethality, 
cardiac defects, and NS features of the homozygous mutant mice, demonstrating that this 
signaling pathway might represent a promising therapeutic target for Noonan patients (39).  
 Same phenotype is found in the NS-associated Raf1L613V knock-in mice. Raf1+/L613V mice 
are obtained at Mendelian ratios in a 129S6 × C57BL/6 mixed background. However, similar to 
Ptpn11D16G mice (14), Raf1+/L613V mice cannot be backcrossed to C57BL/6 mice for more than 3 
generations. Heterozygous mice have short stature, craniofacial dysmorphia and hematologic 
abnormalities. Valvuloseptal development is normal, but Raf1+/L613V mice exhibit eccentric 
cardiac hypertrophy. Postnatal PD0325901 treatment reduces body length and normalizes the 
cardiac phenotype, whereas do not improve the facial dysmorphia (237).  
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 Noonan syndrome (NS) is one of the most common developmental disorders associated 
with mutations in members of the RAS-MAPK pathway. The broad spectrum of phenotypic 
alterations and mutations together with the low incidence of some of these mutations, make 
difficult to establish a good phenoype-genotype correlation. For instance, although K-RAS is 
mutated in a small percentage of patients (<2%), these mutations are associated with a more 
severe phenotype. However, the low number of patients make impossible to establish the typical 
spectrum of alterations associated with these mutations. 
 Moreover, since this disorder is caused by mutations in members of the RAS-MAPK 
pathway, a signaling pathway frequently mutated in human tumors, it is possible that Noonan 
patients present an increased risk of tumor development. However, this disorder is managed as a 
pediatric condition, thus the information about the adult patients is highly limited. For this 
reason, there is no reliable information about the tumor predisposition of these patients are also 
limited. Hence, the objectives of this thesis were the following: 
 
1. To generate and characterize a K-Ras knock-in mouse model by expressing the 
most common K-RAS mutation found in Noonan patients, the substitution V14I, in 
order to determine the phenotypic features associated with the expression of this 
mutation. 
 
2. To study whether germline expression of the K-RasV14I mutation results in an 
increased risk of tumor by itself or cooperating with loss of tumor suppressor genes 
such as p16Ink4a/p19Arf and Trp53.  
 
3. To determine whether some chronic conditions such as pancreatitis or some leading 
risk factor such as nicotine administration (tobacco smoking) increases tumor risk in 
mice that express the K-RasV14I mutation.  
 
4. To delineate the consequences of the postnatal expression of the K-RasV14I mutation 
in all cell types or in specific tissues such as lung or pancreas in order to compare 
the oncogenic properties of this mutation to the typical K-RasG12V oncogenic 
substitution. 
 
5. To determine whether MEK inhibitor treatment is a good therapeutic drug to 
prevent or ameliorate some of the NS-associated developmental features.  
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5.1 GENERATION OF THE CONDITIONAL K-RasLSLV14I KNOCK-IN MOUSE 
MODEL  
 
5.1.1 Generation of the targeting DNA vector to modify the endogenous locus of K-Ras 
 
 The first step in the modification of the endogenous locus of K-Ras in the 5’ region is 
the generation of a targeting vector that allow the incorporation of the V14I mutation and the 
cassette “LoxP-PGK-Hyg-STOP-LoxP” in the proper region by the homology recombination.  
 The genomic DNA of K-Ras was isolated from a 129Sv/J genomic DNA library 
(Stratagene) using as a probe a 400 bp Sacl-Stul fragment of pCMV-K-Ras DNA that contains 
the human noncoding exon 0 (117). To target the 5´ region of the K-ras locus, we mutagenized 
one nucleotide (underlined) corresponding to codon 14 (GTA [Val] to ATA [Ile]) in a plasmid 
containing the first K-Ras exon within a 700 bp EcoRI DNA fragment. This mutation introduces 
an isoleucine at the fourteen codon instead of the endogenous valine. The mutagenesis was 
performed using the QuikChange® single site mutagenesis kit (Stratagene) according to the 
manufacture’s instructions and the specific primers: AJ-KrasV14I-F1: 5’-
GTTGGAGCTGGTGGCATAGGCAAGAGCGCC-3’ and AJ-KrasV14I-R1: 5’- 
GGCGCTCTTGCCTATGCCACCAGCTCCAAC-3'. In the primer sequence, nucleotides in 
bold correspond to nucleotides which have been modified. 
 The next step was the introduction of the LSL cassette  (PGK-Hyg-STOP cassette 
flanked by loxP sites). This cassette was inserted with a 5 Kb NotI-EcoRV DNA fragment at an 
EcoRI site located 100 bp upstream of the mutagenized exon 1. Finally, we introduced the 
negative selection cassette (PGK-TK) in a KpnI site located at end of the left homology arm. 
These steps were performed by restriction endonucleases digestion followed by the ligation of 
the fragments.  
 During the process, selected clones were sequenced to ensure that only the desired 
mutations or fragments were introduced. The final targeting vector was called pAJ-34.  
 
5.1.2 Homology recombination in ES cells  
 
 The targeting vector was linearized with Eam1105I, an enzyme with a single cutting site 
in our vector. 20 µg of the vector were electroporated into 5.6x106 R1 ES cell, derived from 
129/Sv embryos (144) in a final volume of 0.8 ml at 240 V and 500 µF using the Genepulser 
(Biorad). This step was performed by the Transgenic Mice Unit of the CNIO. 
 After the electroporation, the ES cells were maintained in culture in Dulbecco’s 
Modified Eagle Medium (DMEM, Sigma-Aldrich) supplemented with 15% of heating 
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inactivated fetal bovine serum (FBS) and 103 U/ml of leukemia inhibitory factor (LIF). During 
this culture time the positive and negative selection was performed.   
 The targeting vector contains a hygromycin (Hyg) resistance gene whose expression is 
driven by the phosphoglycerate kinase (PGK) promoter. This gene encodes a kinase that 
inactivates the antibiotic by phosphorylation. Therefore only clones in which the targeting 
vector was introduced can inactivate the hygromycin and survive in a medium containing the 
antibiotic. This positive selection was performed by culturing the ES cells 7 days in a medium 
supplemented with 200 µg/ml of hygromycin. In this medium only the cells that have the 
targeting vector by recombination can survive. 
 The targeting vector also contains the thymidine kinase (TK) gene under the control of 
the PGK promoter located far from the homology recombination sites. The TK catalyzes the 
phosphorilation of deoxithymidine in a pathway leading to DNA synthesis. Gancyclovir is an 
analogous of nucleoside 2´deoxiguanosine. The TK can phosphorilate and transform this 
molecule in its bioactive form. This form is a competitive inhibitor of DNA polymerase and 
competes with the deoxiguanosine triphosphate (dGTP) for the active site of the enzyme, 
blocking its activity and thereby the cell replication. Therefore, clones in which the targeting 
vector was introduced randomly, not by the homology recombination, will have all the 
construction, including the TK gene, and die in a medium that contain gancyclovir. This 
negative selection was performed by growing the ES cells 7 days in a medium supplemented 
with 2 µM of gancyclovir.  
 Positive and negative selection was performed at the same time by culturing the ES cell 
in a medium with hygromycin and gancyclovir. Hence only the clones in which the targeting 
vector was introduced in the proper place by the homology recombination event can survive. 
DNA from the double resistant clones was isolated and submitted to Southern blot analysis to 
ensure that the LSL cassette and the V14I mutation were introduced.  
 
5.1.3 Identification of the homologous recombinant clones by Southern blot 
 
5.1.3.1 Genomic DNA isolation 
  
 To isolate the DNA from the double resistance clones, cells were incubated in a lysis 
buffer (pH8.0) that contains 1M Tris-HCl, 5M NaCl, 10% Sodium Dodecyl Sulfate (SDS), 
0.5M Ethylenediaminetetraacetic acid (EDTA) and 400 µg/ml of K proteinase at 55ºC over 
night. Next, a NaCl saturated water solution was added to each sample, which after short ice 
incubation and centrifugation at maximum speed allows precipitation of proteins and cell 
debris, leaving the DNA in the supernatant. This supernatant was transferred to a fresh tube and 
DNA was precipitated adding an equal volume of isopropanol. Pellet was washed twice with 
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70% ethanol, dried and finally resuspended in TE (10 mM Tris-HCl pH 8.0 and 1mM EDTA 
pH 8.0). 
 
5.1.3.2 Genomic analysis by Southern blot  
 
 20 µg of genomic DNA was digested with a specific restriction enzyme during 12 hours 
at 37ºC. XbaI was the restriction enzyme chosen according to the Southern blot strategy. After 
XbaI incubation, DNA restriction fragments were loaded onto a 0.7% agarose (Seckem LE) gel 
and the fragments were separated by electrophoresis according to size. 1X Tris-Acetate-EDTA 
(TAE) was the buffer used for the agarose gel electrophoresis and etidium bromide was the dye 
used for the DNA detection.  
 A radioactively labeled nucleic acid probe was previously designed to complementary 
bind to a specific DNA region. This region differs in size depending on the presence or not of 
the construction with the LSL cassette and the V14I mutation. In our strategy, the external 
probe (probe a) recognized a specific EcoRV-XbaI DNA fragment located in the 3´region of K-
Ras locus. The expected size will be 5 Kbp for the ES cell clones carrying the wild type (WT) 
allele and 3.5 Kbp for the clones carrying the recombinant allele (LSLV14I) (Figure 5).  
 
 
  
  
  
  
 
 
 
 The nucleic acid probe is a DNA fragment with a sequence complementary to a specific 
region of the locus. Therefore it is necessary that both, the probe and the genomic DNA 
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Figure 5. Gene targeting strategy. (A) Homologous recombination at the 5´region of the K-Ras locus. White 
box represents the K-Ras noncoding exon 0; black box, K-Ras coding exon 1; checkered box, PGK-Hygromycin 
(Hyg) resistance cassette; octagonal box (STOP), transcriptional inhibitory sequences; triangle, loxP sites; 
asterisk, mutation in codon 14 (V14I). The position of the external probes used in the Southern blot analysis is 
indicated. Representative restriction enzyme cleavage sites are in indicated (X, XbaI; E, EcoRI; V, EcoRV; N, 
NotI). (B) Southern blot analysis of DNA isolated from recombinant ES cells clones carrying the wild type (WT) 
allele and the expected homologous recombinant event (+/LSLV14I) after digestion with XbaI. The size of the 
wild type (5 Kbp) and targeted (3.5 Kpb) alleles is indicated. 
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fragments were denatured, in a single-stranded DNA to the complementary binding. For this 
reason, the DNA gel was placed into an alkaline solution (1.5M NaCl and 0.5N NaOH) for 20 
minutes at room temperature (RT) to denature the double-stranded DNA. For DNA fragments 
larger than 15 Kbp, prior to denaturalization, the gel must be treated with an acid solution to 
depurinate the DNA fragments, breaking the DNA into smaller pieces that are easily transfered 
from the gel to the membrane. To this aim agarose gel was treated with an acid solution (0.25N 
HCl) for 15 minutes at RT. Finally, since the transfer needs a pH lower than 9, the gel was 
incubated in a neutralizing solution (0.5M Tris HCl pH 7.4 and 1.5M NaCl) during 30 minutes 
at RT to equilibrate the pH. All these steps were performed on a rotary platform.  
 After the gel treatment, the DNA fragments were transferred to nylon membrane 
(Hybond-N+, Amershand) by capillary action using 10X Saline Sodium Citrate (SSC) as a 
buffer transfer from 12 to 24 hours. Ion exchange interactions bind the DNA to the membrane 
due to the negative charge of the DNA and the positive charge of the membrane. Then the 
membrane was exposed to 1.2x105 µJ of ultraviolet radiation using a UV Stratalinker 1800 
(Strategene) to permanently attach the DNA to the membrane by covalent interactions.  
 After that, the DNA within the membrane was exposed to hybridization with the 
specific probe. Before that, the membrane was blocked during 4 hours with the hybridization 
solution that contains salmon sperm DNA, formamide and detergents such as SDS to reduce 
non-specific binding of the probe and the probe was radioactively labeled. 20 µg of purified 
probe was denatured by heat (5 minutes boiling) and labeled with 50 µCi of α32P-CTP 
according to the manufacture’s instructions (Amersham Rediprime II Random primer). The 
membrane was incubated with labeled probe in the hybridization buffer (5mM 
Polyvinylpyrrolidone, 2mM Ficoll, 0.1M Dextran Sulfate, 25mM Na2HPO4, 20mM NaH2PO4, 
0,9M NaCl, 35mM SDS, 2.5M EDTA pH 8, 10 mg/ml of salmon sperm DNA, 13M formamide 
and water) for 24 hours at 42ºC. 
 After hybridization, excess probe was washed from the membrane using first 2X 
SSC/0.1% SDS, second 1X SSC/0.1% SDS and third 0.1X SSC/0.1% SDS incubations for 20 
minutes at 42ºC.  
 Finally, the pattern of hybridization was visualized by exposing the membrane to the 
Phosphoimager screen for 24 hours and scanning the screen afterward (Molecular Dynamics).   
 
5.1.4 Generation of chimeric mice 
 
 ES clones carrying the homologous recombination event were submitted to cytogenetic 
analysis and two of them among those exhibiting normal morphology, growing, karyotype and 
absence of mycoplasm were used to generate chimeric mice by microinjection into C57BL/6J 
blastocysts. This step was performed by the Transgenic Mice Unit of the CNIO.  
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 Tissues from the chimeric mice have been developed from the injected ES cells 
(129/Sv) and the recipient blastocyst cells (C57BL/6J). This mixture of starter cells is shown in 
the mouse’s coat, which exhibits patches of coat color from the host embryo (black) and patches 
from the injected ES clones (agouti). Coat color percentage was determined, and male with 50% 
or higher ES cell contribution (agouti) were backcrossed to C57BL/6J females to test for 
germline transmission of the targeted allele. To check for germline transmission, the tail DNA 
from the agouti offspring was analyzed by Southern blot, following the same strategy explained 
before (see 3.1.3.2 section). Moreover, the exon 1 of the K-Ras allele was amplified from tail 
genomic DNA by PCR. The PCR product was sequenced to verify the presence of G→A 
transition (Figure 6). Mice born from the chimeras that display germline transmission of the 
homologous recombinant event were called K-Ras+/LSLV14I mice. 
 
 
 
 
 
 
 
 
5.1.5 Germline K-RasV14I expression 
 
 K-Ras+/LSLV14I mice were crossed with the transgenic mice EIIaCre (108) that express 
the Cre recombinase at the zygote stages to allow the efficient cleavage of the LSL cassette in 
the germline. The tail DNA from the offspring was analyzed by Southern blot to test the 
cleavage of the LSL cassette. For this aim, an external probe was designed to recognized an 
XbaI-EcoRI fragment located upstream of the LSL cassette. The expected size will is of 5 Kbp 
for wild type mice and 1.9 Kbp for the mice that express the K-RasV14I mutation (V14) after 
XbaI digestion (Figure 7). Mice in which the STOP cassette is eliminated will express the 
mutant allele but still maintain one of the loxP. These mice were called K-Ras+/LV14I, for 
simplicity, were called only K-Ras+/V14I.  
 
K-Ras+/+! K-Ras+/LSLV14I!
Figure 6. Detection of the V14I mutation. Sequencing of exon 1 of the K-Ras allele from tail genomic DNA of 
the K-Ras+/+ (left) and K-Ras+/LSLV14I (right) agouti animals. Black arrow points to the modified nucleotide 
transversion G → A. G (guanine) in black and A (adenine) in green.  
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 Mice that express the mutation in all the cells, including germline cells, were crossed to 
C57BL/6J.OlaHsd to eliminate the EIIaCre transgene. The offspring of these crosses presented 
a mixed C57BL/6J.OlaHsd;129S2/SvPasCrl background (from now on C57BL;129S2/Sv).  
 
5.2 MICE: MAINTENANCE AND GENOTYPING  
 
5.2.1 Maintenance of mice 
 
 Animals were maintained in the animal facility of the CNIO (Centro Nacional de 
Investigaciones Oncológicas) according with the animal care standards established by the 
European Union. All the experiments were reviewed and approved by the Animal Care 
Committee of the Institute of Health Carlos III and the University of Salamanca. In the CNIO’s 
animal facility the animals were subjected to cycles of light and dark of 12 hours each with the 
temperature and humidity of the rooms controlled.  
 Mice were maintained in a mixed C57BL/6J;129S2/Sv background (from now on 
B6/129) or were backcrossed up to seven generation into 129S2/Sv (from now on 129S2/Sv) or 
C57BL/6J (from now on C57BL/6J) background. Other strains of mice used in this study 
include the p16Ink4a/p19Arf–/– (191), Trp53–/– (52), α myosin heavy chain (α–MHC)-Cre (2), 
Rosa26LSLLacZ (133), Mx1-Cre (107), Elas-tTA/tetO-Cre (70), K-Ras+/- mice (developed by 
Carmen Guerra in our laboratory), RERTn (69) and Pi3kcaLmgLH1047R (provided by the 
Experimental Therapeutic Unit of the CNIO).  
 
Figure 7. Excision of the LSL cassette strategy. (A) K-RasV14I allele results from crossing K-Ras+/LSLV14I mice 
to EIIaCre transgenic animals to excise the LSL cassette. White box represents the K-Ras noncoding exon 0; 
black box, K-Ras coding exon 1; checkered box, PGK-Hygromycin (Hyg) resistance cassette; octagonal box 
(STOP), transcriptional inhibitory sequences; triangle, loxP sites; asterisk, mutation in codon 14 (V14I). The 
position of the external probes used in the Southern blot analysis is indicated. Representative restriction enzyme 
cleavage sites are indicated (X, XbaI; E, EcoRI; V, EcoRV; N, NotI). (B) Southern blot analysis of DNA isolated 
from tails of mice carrying the wild type (+/+) and K-RasV14I (+/LV14I) allele after digestion with XbaI. Size of 
the wild type (5 Kbp) and K-RasV14I (1.9 Kbp) alleles is indicated. 
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5.2.2 PCR genotyping 
 
 For routine genotyping of K-RasLSLV14I and K-RasV14I alleles, tail DNA was extracted as 
explained before (see 3.1.3.1 section). We submitted tail DNA to PCR analysis at 94ºC for 5 
min, followed by 30 cycles of 94ºC denaturing for 1 min, 60ºC annealing for 1 min, and 72ºC 
extension for 1 min, followed by an elongation cycle of 72ºC for 10 min with the following 
primers: 5´forward primer (5IO_2: 5’-TACCGCAAGGGTAGGTGTTGG-3’, reverse wild type 
primer (3Ex1_2: 5’-ACCAGCTCCAACCACCACAAG-3’) and reverse mutant primer (130rev-
2: 5’-CTGCTCTTTACTGAAGGCTC-3’). The sizes of the diagnostic PCR products are 403 bp 
for the K-Ras wild type allele and 621 bp for the targeted K-RasLSLV14I allele. Samples in which 
the floxed STOP cassette was excised, primers 5I0 and 3Ex1 yield a DNA fragment of 669 bp. 
 
5.3 BODY WEIGHT AND SIZE ANALYSIS 
 
 For growth curves, body length and body weight were measured every fifteen days. 
Mice were anesthetized with continuous flow of 1% to 3% isoflurane/oxygen mixture and the 
anal-nasal length was determined using a digital caliber.  
 
5.4 BLOOD EXTRACTION AND NECROPSY 
 
5.4.1 Blood extraction and analysis 
 
 To obtain blood from living animals, mice were anesthetized with continuous flow of 
1% to 3% isoflurane/oxygen mixture and around 100 µl of blood was collected from the orbital 
sinus. Blood collection from the renal vein was used like a terminal method of blood extraction 
during the necropsy. In both cases, the blood was obtained using EDTA-tubes and blood 
populations were quantified using a blood analyzer (Abacus Junior Vet).  
 
5.4.2 Necropsy 
 
 For the necropsy of adult animals, mice were sacrificed in CO2 chamber and several 
tissue samples were collected including bone (femur), brain, heart, kidney, large intestine, liver, 
lung, pituitary gland, sex organs, skin, small intestine, spleen, stomach, thymus and urinary 
bladder. All the tissues samples were fixed in formalin and processed by the Comparative 
Pathology Unit at CNIO. Embryos at the different analyzed time points (E13.5 and E18.5) were 
extracted from the uterus of the mother, fixed in formalin and processed by the Comparative 
Pathology Unit at CNIO.  
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5.5 HISTOPATHOLOGY AND IMMUNOHISTOCHEMISTRY 
 
5.5.1 Histopathology 
 
 Embryos and tissues were fixed in 10% buffered formalin and embedded in paraffin. 
Embryos, pancreata and lungs were serially sectioned (3 µm) and every 10 sections stained with 
hematoxylin and eosin (H&E). Sections (3 µm) of bone marrow (femur), brain, heart, kidney, 
large intestine, liver, lung, pituitary gland, sex organs, skin, small intestine, spleen, stomach, 
thymus and urinary bladder were stained with H&E for histopathological examination.  
 
5.5.2 Blood smear preparation and staining 
 
 Blood smears were prepared using the Wedge technique. A small drop of blood about 3 
mm of diameter was placed at one end of a glass slide. A second slide (pusher slide) was hold in 
front of the drop at a 30-45º angle to the smear slide. The pusher slide was pulled back into the 
blood drop and hold in that position until the blood spread across the width of the slide. It was 
then quickly and smoothly pushed forward to the end of the smear slide, creating a wedge 
smear. The slides were air-dried for 20 minutes and stained using May-Grünwald/Giemsa. 
Blood smears were covered with May-Grünwald solution (Merck) and incubated for 1 minute. 
After this time, the solution was washed carefully by adding destilled water and the slides were 
covered and incubated for 20 minutes with 1:10 Giemsa (Merk). Finally, the Giemsa solution 
was washing using destilled water and the blood smears were air-dried.  
 
5.5.3 X-Gal staining on cryosections 
 
 X-Gal staining provides a visual assay of LacZ activity. LacZ gene encodes the β-
galactosidase enzyme. This enzyme cleaves X-Gal into galactose and 5-bromo-4-chloro-3-
hydroxyndole. This second compound is then oxidized into 5, 5-dibromo-4,4-dichloro-indigo. 
As its name suggests, this final product has a blue color.  
 To detect β-galactosidase activity, hearts were included in O.C.TTM (Sakura) and frozen 
at -80ºC. The samples were cut in 10 µm sections using a cryostat (Vacutomer, Dako) and X-
Gal staining was performed as described (Hogan et al., 1994). Sections were stored at 4ºC over 
night or 1 hour at RT. Next, they were fixed using a fixation solution that contains 0.2% 
glutaraldehyde (Sigma-Aldrich), 2mM MgCl2, 5mM Ethylene Glycol Tetraacetic acid (EGTA) 
and 0.1M phosphate buffer pH 7.2 for 15 minutes at RT. The fixation solution was washed 3 
times, 20 minutes, with a washing solution that contains 2mM MgCl2, 0.02% NP40, 0.01% 
sodium deoxycolate (Sigma-Aldrich) and 0.1M phosphate buffer pH 7.2. After the washes, the 
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sections were incubated in a staining solution (0.1M pH 7.2, 2mM MgCl2, 0.02% NP40, 0.01% 
sodium deoxycolate, 5mM K3Fe(CN)6, 5mM K4Fe(CN)6 and 1mg/ml X-Gal) at 37ºC over night. 
The following day, the sections were washed 3 times with the washing solution previously 
described, and thereafter rinsed once with 1X PBS and after with water. Finally, the 
counterstaining was performed with Nuclear Fast Red (NFR). The sections were stained with 
NFR for 1 minute. This staining was stopped with H2O and after that the sections were 
dehydratated. To this aim, sections were washed for 2 minutes with 70% Ethanol, then 2 
minutes with 100% Ethanol and were rinsed with Xilol (Merck) for 1 minute. Finally the 
sections were mounted with the mounting media (DAKO).   
 
5.5.4 Immunohistochemistry 
 
 The immunohistochemistry was performed by the Comparative Pathology Unit of the 
CNIO using standard procedures. Antibodies used for immunohistochemistry analysis included 
goat polyclonal anti-CD3 antibody (1:250; M-20; Santa Cruz 1127), rabbit polyclonal anti-
CD31 (1:50: ABCAM), rat monoclonal anti-F4/80  (1:10; D10; Monoclonal Antibodies CNIO 
core unit), prediluted rabbit monoclonal Ki67 (SP6; Master Diagnóstica 000311OQD), goat 
polyclonal anti-Pax5 (1:500; Santa Cruz 1974) and rabbit polyclonal anti-pErk (1:15; 9101, Cell 
signaling Technology) 
 
5.5.5 Ki67 and cardiomyocyte quantification 
 
 The number of Ki67 positive cells was quantified using Axiovision Release 4.8.2 
software. Cardiomyocyte area and relative cardiomyocyte numbers were quantified in heart 
H&E stained sections using Metamorph-Metaview software (Universal Imaging). 
 
5.6 MOLECULAR ANALYSIS OF THE K-RasV14I MUTATION 
 
5.6.1 Protein extraction 
  
 To extract proteins, small pieces of tissues (heart, lung and spleen) and pellets of mouse 
embryonic fibroblasts (MEFs) were incubated in an extraction buffer solution that contains 
50mM Tris-HCl (pH 7.4), 150mM NaCl and 0.5% NP-40. To avoid the possible degradation of 
protein and to maintain the phosphate groups during the process, a cocktail of proteases 
inhibitors (Complete Mini, Roche) and phosphatase inhibitors (Sigma-Aldrich) were added to 
the extraction solution. In this solution, the tissues were homogenized on ice using a mini-
homogenizer. After that, cells debris and chromosomal DNA were removed by 30 minutes 
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centrifugation at maximum speed (13,500 rpm). Finally, the supernatant was transferred to a 
fresh tube.  
 
5.6.2 Protein quantification 
 
 Total protein amount in tissues and cells extract was determined using the Bradford 
protein quantification method. The Bradford assay is a colorimetric protein assay based on the 
formation of a complex between the dye, Coomassie Brilliant Blue G-250, and proteins under 
acidic conditions. The protein-dye complex causes a shift in the absorption maximum of the dye 
from 465 to 595 nm. The amount of absorption at 595 nm is proportional to the to the amount of 
proteins present in the sample. 1 µl of the protein sample was added to 1 ml of 1X Bradford 
solution (Bio-Rad) and the 595 nm absorbance was read on a spectrophotometer (Amersham 
Biosciences). A protein standard (growing concentration of Bovine Serum Albumin, BSA) was 
used to calculate the protein concentration on each sample.  	  
5.6.3 Western blot: identification of Ras proteins and members of the Ras signaling 
pathway 
 
 Western blot method was used to determine the levels of expression of Ras proteins and 
its downstream effectors. The Western blot is an analytic technique used to identify proteins 
separated by electrophoresis and transfered to a membrane, using specific antibodies. 40 µg 
protein extracts obtained from E13.5 embryo, heart, lung, MEFs and spleen were separated 
using gel electrophoresis by molecular weight. The proteins were resolved by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE). Therefore, the samples were separated using 
4-12% Bis-Tris polyacrilamide gels (Criterion XT Precast gel, Bio-Rad) and loaded with 1X XT 
Sample buffer (Bio-Rad) and 1X XT Reducing agent (Bio-Rad). The second buffer provided 
SDS and Tris-(2-Carboxyethyl)-phosphine (TCEP) as reducing agent. The SDS is an anionic 
detergent that maintains polypeptides in a denatured state and imparts a negative charge to the 
proteins. Heat treatment of the proteins in the presence of SDS and reducing agent (TCEP) 
effectively linearized the proteins. Thus, negative charged proteins in their denatured state 
moved to the positively charged electrode through the polyacrylamide mesh of the gel. In these 
conditions the proteins were separated by electrophoresis according to size. 1X MES (Bio-Rad) 
was the buffer used for the electrophoresis.  
 Then, the proteins were transferred to a nitrocellulose membrane (GE Healthcare) by 
semi-dry transfer method using 1X Tris-Glycine/20% methanol as buffer transfer at 0.35 mA 
for 45 minutes. The efficiency of the transfer was checked by staining the membrane with 
Ponceau solution (Sigma-Aldrich-Aldrich). Ponceau staining was completely removed by 
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continued water washing. After that, the membrane was incubated in 5% BSA in 1X Tris-
Buffered Saline (TBS) solution with a 0.1% of Tween-20 at RT during 1 hour to block non-
specific bindings. Subsequently the membrane was blotted with antibodies against Akt (1:1000; 
Cell Signaling Technology), phosphorylated Akt (1:1000; phosphoresidues Ser473; Cell 
Signaling Technology), Erk1 (1:1000; G262-118, BD Pharmigen), Erk2 (1:2000; 33, BD 
Pharmigen), phosphorylated Erk1/2 (1:500; phosphoresidues Thr202 and Tyr204; Cell 
Signaling Technology), Mek 1 (1:1000; C-18; Santa Cruz Biotechnology Inc.), phosphorylated 
Mek1 (1:500; phosphoresidues Ser217 and Ser211; Cell Signaling Technology), Pan-Ras 
(1:250; Ab-3, Calbiochem) and GAPDH (1:20000; Sigma-Aldrich-Aldrich) for loading control. 
The antibodies were diluted in 5% BSA/1X TBS/0.1% Tween-20 or 5% non-fat milk/1X 
TBS/0.1% Tween-20 according to the manufacture’s protocols. The incubations were 
performed at 4ºC over-night.  
 After the incubation, unbound primary antibodies were washed from the membrane 
using four incubations of 10 minutes each with 1X TBS/0.1% Tween-20 at RT. Finally the 
membrane was incubated with the corresponding polyclonal goat horseradish peroxidase-linked 
secondary antibody against mouse or rabbit IgG for 1 hour at RT. These secondary antibodies 
were diluted at 1:1000 in 5% non-fat milk/1X TBS/0.1% Tween-20 and after four washes of 10 
minutes each in 1X TBS/0.1% Tween-20 were visualized with an enhanced chemiluminescent 
system (ECL Plus, Amersham Bioseciences). Horseradish peroxidase catalyzes the oxidation of 
a cheminescent agent (luminol) in 3-aminophthalate, in a reaction that produces luminescence in 
proportion to the amount of protein. Therefore, exposure of the membrane to a sensitive 
photographic film and exposing it to the light of the reaction, we obtained an image 
corresponding to the band recognized by the primary antibody. 
 
5.6.4 Determination of the Ras activation levels   
 
 To measure active GTP-bound K-Ras protein, 4 mg of protein extract from E13.5 
embryos and MEFs were incubated with the Raf1 RBD agarose beads at 4ºC for 1 hour with 
gentle agitation according to manufacture’s instruction (Ras activation assay kit, Cell Biolabs). 
Pulled-down K-Ras protein was detected by Western blot analysis, using the Pan-Ras antibody 
described above (see 3.6.3 section).  
 
5.7 RNA ISOLATION AND QUANTITATIVE REAL TIME RT-PCR 
 
 Total RNA was isolated from hearts using trizol (Qiagen). Complementary DNA 
(cDNA) was synthesized using the NCode VILO microRNA cDNA synthesis kit (Invitrogen). 
The quantitative real time RT-PCR (qPCR) for microRNA-100 was performed using Express 
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SYBR GreenER Supermix with premixed ROX (Invitrogen). The Ct (Cycle threshold) values 
were normalized to SNOR95 (dCt) and relative expression was calculated using the 2-dCt 
method. Primers for microRNA qPCR for mir-100 were purchased from abm and miScript 
primer assay (Qiagen) for SNOR95. For quantification of MKK6, Nanog and Smarca 5 
expression, TaqMan probes were used according to the manufacturer’s protocol (Applied 
Biosystem) and Ct were normalized to 18S rRNA (dCt).  
 
5.8 MEFS ISOLATION AND IMMORTALIZATION 
 
 MEFs were isolated from E13.5 embryos and cultured in DMEM supplemented with 
2mM glutamine, 1% penicillin/streptomycin and 10% fetal calf serum (FCS). Immortalization 
assay were performed using a classical 3T3 protocol (216).   
 
5.9 IN-VIVO IMAGING METHODS 
 
5.9.1 Micro X-ray computed tomography (micro-CT) 
 
 The CT acquisition was performed by the Molecular Imaging Unit at the CNIO, with an 
eXplore Vista PET CT (GE Healthcare) using an amperage of 200 µA and a voltage of 35 kV. 
Four-month old mice were anesthetized with a continuous flow of 1% to 3% isoflurane/oxygen 
mixture. 3D images of the skeleton were generated and analyzed with MMWS/Vista Software 
(GE Healthcare). Six measurements were taken using micro-CT images: skull length, skull 
width, skull height, inner canthal distance, and jaw length and width. The measures were 
established using anatomical references according to Jackson Laboratory standards protocols 
and procedures (http://craniofacial.jax.org/standard_protocols.html) (Figure 8). The skull 
volume was determined using 3D images.  
 
5.9.2 PIXImus Densitometry 
 
 The densitometry acquisition was performed using PIXImus scans (PIXImus, LUNAR, 
Madison, WI). This scan provided skeletal and body composition data such as Bone Mineral 
Density (BMD, g/cm2), Bone Mineral Content (BMC, g), body mass (g), lean content (g), fat 
content (g) and percentage of fat content. The PIXImus small animal densitometer (DEXA) had 
a resolution of 0.18 x 0.18 mm pixels and was equipped with software version 1.46. Mice were 
anesthetized with a continuous flow of 1% to 3% isoflurane/oxygen mixture.  
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5.9.3 Magnetic Resonance Imaging (MRI) study 
 
 MRI studies were performed at the ‘Gregorio Marañón’ hospital. Mice were 
anaesthetized with a continuous flow of 2% Sevoflurane. MRI was acquired using a 
intraGateFLASH sequence from the aorta to the heart apex with slice thickness of 0.75 mm, 
repetition time (TR) 8 ms, echo time (TE) 2.691 ms, field of view (FOV) 6 x 4.13 cm and 
matrix size 465 x 256 cm. Left-ventricular functionality was evaluated on images in diastole 
and systole (Segment v1.9, R2354 software). Left ventricular epicardial and endocardial borders 
were manually delineated on the short-axis of each slide in order to measure the end-diastolic 
volume (EDV), end-systolic volume (ESV), ejection fraction (EF), left ventricle mass (LVM) 
and cardiac output (CO). The wall thickness in diastole (WTd) and systole (WTs), systolic wall 
thickening (WTn) and fractional shortening (FS) were measured in one slide at 3 mm from the 
apex. 
 
5.10 ANALYSIS OF HEARING PARAMETERS 
 
 The analysis of the hearing parameters was performed by the ‘Servicio de Evaluación 
Neurofuncional no Invasiva at the Instituto Biomédicas Alberto Sols CSIC-UAM. Servicio de 
Evaluación Funcional de Animales de Laboratorio, CIBERER, ISCIII’. 4-months-old mice were 
anesthetized with an intraperitoneal injection (i.p) of ketamine (75mg/kg)/xilacyne (5mg/kg) 
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Figure 8. Representation of the anatomical landmarks used for the skull characterization. Four difference 
CT images were used to determine the six skull parameters analyzed. Each parameter was represented using 
colored lines and numbers. Yellow represents the skull length (1), orange the skull width (2), green the skull 
height (3), purple the jaw width (4), red the inner canthal distance (5) and blue the jaw length (6).  
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mixture. Mice were exposed to a ‘click’, a mixture of sounds with different unknown 
frequencies to determine the hearing threshold, and a pure sounds of 8, 16, 28 and 40 kHz to 
determine the audiogram. The stimuli response was recording using electrodes placed in a 
standard position.  
 
5.11 HEMODYNAMIC STUDY  
 
 Mean blood pressure was recorded in conscious mice at 4, 5 and 6 months of age with a 
non-invasive tail-cuff method (CODA, Kent Scientific). Blood pressure was measured in the tail 
of the mouse using a Volume Pressure Recording (VPR) sensor and an occlusion tail-cuff. Mice 
were accustomed to procedure for one week before accepting the recorded parameters. 
 
5.12 FLOW CYTOMETRY ANALYSIS 
 
5.12.1 Flow cytometry analysis: spleen 
 
 Single-cell suspensions were obtained from spleens using standard procedures. Mice 
were sacrificed by CO2 inhalation and spleens were dissected. Splenocytes were obtained by 
mechanical dissociation of the organ in RPMI 1640 (BioWhittaker, Lonza) and filtration using 
40 µm cell strainers. Erythrocytes were lysed after 30 seconds incubations in ACK lysis buffer 
(BioWhittaker, Lonza) and cells were resuspended in 1X PBS (BioWhittaker, Lonza) 
containing 0.5% BSA (Sigma-Aldrich-Aldrich) and 2 mM EDTA. Prior to analysis, cells were 
pre-incubated with purified anti-mouse CD16/32 antibody (1:200; BD Pharmigen, San Jose, 
CA) for 15 minutes on ice to block nonspecific Fc receptor-mediated binding. Aliquots of 5x106 
cells were stained for 30 minutes to 1 hour at RT in the dark with the following monoclonal 
antibodies from BD Pharmigen, San Jose, CA: APC rat anti-mouse CD19 (1:200; clone 1D3), 
APC hamster anti-mouse CD3e (1:200; clone 145-2C11), FITC rat anti-mouse CD11b (1:200; 
clone M1/70), PerCP-Cy5.5 rat anti-mouse CD11b (1:200; clone M1/70), PE-Cy7 rat anti-
mouse CD8a (1:200; clone 53-6.7), PE-Cy7 rat anti-mouse Ly-6G and Ly6C (Gr1) (1:100; 
clone RB6-8C5), PerCP-Cy5.5 rat anti-mouse CD4 (1:200; clone RM 4-5) and PerCP-Cy5.5 
mouse anti-mouse CD45.2 (1:100; clone 104). 4’,6-diamidino-2-phenylindole (DAPI) was used 
to discriminate dead cells. Single stained controls were used for the signal compensation in the 
different channels and flourescense minus one (FMO) was used for setting the gating on control 
samples. The FMO control contains all the flourochromes in a panel, except the one that is 
being measured. The absence of signal of this flourochrome allows the setting of the 
corresponding gating for this color. Samples were processed on FACS CANTO II analyzer (BD 
Pharmigen, San Jose, CA). A minimum of 10,000 events was acquired. Data was analyzed 
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using FlowJo (Treestar, Ahskand, OR).  
 
5.12.2 Flow cytometry analysis: bone marrow 
 
 Mice were sacrificed by CO2 inhalation and femur and tibia were dissected. BM cells 
were freshly harvested by flushing femur and tibias with RPMI 1640 medium (BioWhittaker, 
Lonza). The end of the bones was cut, the tip of a needle with RPMI 1640 medium was inserted 
into the BM cavity and the BM was flushed into a tube. Erythrocytes were lysed with 30 
seconds ACK lysis buffer (BioWhittaker, Lonza) incubation and Fc receptors were blocked by 
30 minutes incubation with 3% BSA (Sigma-Aldrich-Aldrich) on ice.  
 HSCs were identified as Lin- IL7Rα- c-Kit+ Sca1+; CLPs as Lin- IL7Rα+ c-Kitlow 
Sca1low; CMPs as Lin- IL7Rα- c-Kit+ Sca1+ FcγRlow CD34+; GMPs Lin- IL7Rα- c-Kit+ Sca1+ 
FcγRhigh CD34+; and MEPs as Lin- IL7Rα- c-Kit+ Sca1+ FcγRlow CD34-. 5x106 BM cells were 
stained at RT for 1 hour in the dark with alexa-flour-488 rat anti-mouse CD127 
(IL7Rα) (1:200; clone A7R34; eBioscience), APC mouse lineage antibody cocktail (1:100; BD 
Pharmigen, San Jose, CA), APC-H7 rat anti-mouse CD117 (c-Kit) (1:200; clone 2B8; BD 
Pharmigen, San Jose, CA), PE rat anti-mouse CD34 (1:250; clone RAM 34; BD Pharmigen, 
San Jose, CA), PE-Cy7 rat anti-mouse CD16/32 (FcγR) (1:400; clone 93; eBioscience) and 
PerCP-Cy5.5 rat anti-mouse Ly-6A/E (Sca1) (1:400, clone D7; eBioscience). DAPI was used to 
discriminate dead cells. Single stained controls were used for the signal compensation and 
FMOs were used for setting the gating on control tube. Samples were processed on FACS 
CANTO II analyzer (BD Pharmigen, San Jose, CA). A minimum of 50,000 events was 
acquired. Data was analyzed using FlowJo (Treestar, Ahskand, OR).  
 
5.12.3 Flow cytometry analysis: blood 
 
 Blood was collected as mentioned before (see 3.4.1 section). Erythrocytes were lysed 
with 15 minutes Erythrocyte Lysis Buffer (10 ml, Qiagen) incubation on ice and after 10 
minutes centrifugation at 1200 rpm, cells were resuspended in 1X PBS/0,5% BSA/2 mM 
EDTA. Non-specific bindings were blocked using 15 minutes purified anti-mouse CD16/32 
antibody (1:200; BD Pharmigen, San Jose, CA) incubation on ice. Aliquots of 5x106 cells were 
stained for 30 minutes to 1 hour at RT in the dark with the following monoclonal antibodies 
from BD Pharmigen, San Jose, CA: APC rat anti-mouse CD19 (1:200; clone 1D3), APC 
hamster anti-mouse CD3e (1:200; clone 145-2C11), PerCP-Cy5.5 rat anti-mouse CD11b 
(1:200; clone M1/70), PE-Cy7 rat anti-mouse CD8a (1:200; clone 53-6.7), PE-Cy7 rat anti-
mouse Ly-6G and Ly6C (Gr1) (1:100; clone RB6-8C5), PerCP-Cy5.5 rat anti-mouse CD4 
(1:200; clone RM 4-5) and PerCP-Cy5.5 mouse anti-mouse CD45.2 (1:100; clone 104). DAPI 
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was used to discriminate dead cells. Single stained controls were used for the signal 
compensation and FMOs were used for setting the gating on control samples. Samples were 
processed on FACS CANTO II analyzer (BD Pharmigen, San Jose, CA). A minimum of 50,000 
events was acquired. Data was analyzed using FlowJo (Treestar, Ahskand, OR).  
 
5.12.4 Flow cytometric analysis and sorting: heart 
 
 Hearts were homogenized with Collagenase P (1mg/ml; Roche) for 20 minutes at 37º C 
and filtered through 40 µm cell strainers to obtain a single cell suspension. Then, cells were 
stained for 15 minutes on ice with APC rat anti-mouse Ly-6A/E (Sca1) (1:200; clone D7; BD 
Pharmigen, San Jose, CA), FITC rat anti-mouse CD31 (PECAM-1) (1:50; clone MEC 13.3; BD 
Pharmigen, San Jose, CA) and PE rat anti-mouse PDGFRα (CD140α) (1:100; clone APA5; 
eBioscience). Samples were sorted using a BD influx cell sorter (BD Pharmigen, San Jose, CA). 
DAPI was used to discriminate dead cells. Data was analyzed using FlowJo (Treestar, Ahskand, 
OR). 
 
5.12.5 Apoptosis assay 
 
 Single bone marrow cell suspension was obtained as mentioned in the 3.12.2 section. 5 
x 106 cells were stained with APC lineage antibody cocktail (1:100; BD Pharmigen, San Jose, 
CA), APC-H7 rat anti-mouse CD117 (c-Kit) (1:200; clone 2B8; BD Pharmigen, San Jose, CA) 
and PerCP-Cy5.5 rat anti-mouse Ly-6A/E (Sca1) (1:400; clone D7; eBioscience). Cells were 
subsequently stained with 5 µl of PE rat anti-mouse Annexin V and DAPI in the dark during 15 
minutes at RT using the 1x Annexin V binding buffer [0.1M Hepes/ NaOH (pH 7.4)/ 1.4M 
NaCl/ 25mM CaCl2] from the BD annexin V-PE apoptosis detection kit I (BD Pharmigen, San 
Jose, CA).  Annexin V is a marker of early apoptotic cells. In apoptotic cells, the membrane 
phospholipid phosphatidylserine (PS) is translocated from the inner to the outer leaflet of the 
plasma membrane. Annexin V is a Ca2+-dependent phospholipid-binding protein that has a high 
affinity for PS and binds to cells with exposed PS. Therefore, Annexin V staining identifies the 
early apopototic cells. This staining is used in combination with the vital dye DAPI, then viable 
cells are Annexin V and DAPI negative, cells that are in a early apoptosis are Annexin V 
positive and DAPI negative, and cells that are in late apoptosis are both Annexin V and DAPI 
positive. Apoptosis was analyzed by quantification of the Annexin V positive/ DAPI negative 
cell population by FACs.  
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5.12.6 Proliferation assay 
 
 For the proliferative assay, mice received 150 mg/kg of BrdU (5-bromo-2-
deoxyuridine) (BD Pharmigen, San Jose, CA) by intraperitoneal injection 12 hours before 
euthanasia. BrdU is a synthetic nucleoside that is an analog of thymidine. It is incorporated into 
the newly synthesized DNA of replicating cells, substituting for thymidine during DNA 
replication. Using antibodies against this analog, cells that were actively replicating their DNA 
can be detected. To detect the proliferative HSC, lineage negative fraction was separated using 
magnetic mouse hematopoietic enrichment method and then cells were incubated with a specific 
antibody for BrdU. 
 First, single BM cells suspension was obtained as mentioned in the 3.12.2 section. Cells 
were enriched in hematopoietic progenitor by lineage depletion using BD IMagTM-streptavidin-
conjugated magnetic beads (Mouse Hematopoietic Progenitor (Stem) Cell Enrichment-Set, BD 
Pharmigen, San Jose, CA). For this aim, BM cells were incubated with the Biotinylated Mouse 
Lineage Depletion Cocktail (5µl per 1x106 cells) on ice for 15 minutes. This cocktail contains 
biotinylated monoclonal antibodies against mouse CD3e (CD3 ε chain), CD11b (Integrin αM 
chain), CD45R/B220, Ly6G and Ly6C (Gr-1) and TER-119/erythoroid cells (Ly-76). Therefore, 
this cocktail reacts with cells from the major hematopoietic cell lineages: T-lymphocytes, B-
lymphocytes, monocytes/macrophages, granulocytes and erythrocytes. After washing with a 1X 
BD IMagTM buffer, cells were incubated with the BD IMagTM Streptavidin Particles Plus-DM 
(5µl per 1x106 cells) for 30 minutes at 6ºC-12ºC. These particles bind the cells bearing the 
biotinylated antibodies and provide a magnetic bead. The tube containing this labeled cell 
suspension was then placed within the magnetic field of the BD IMagnetTM. Labeled cells 
(mature hematopoietic cells) migrate toward the magnet, leaving the unlabeled cells (lineage 
cells) in suspension. The supernatant, with the unlabeled cells (depleted fraction), were 
aspirated and placed in a new tube. Additional selections were performed to optimize the 
process. Finally, the total cell suspension with the depleted fraction was stained with APC rat 
anti-mouse CD117 (c-Kit) (1:200; clone 2B8; BD Pharmigen, San Jose, CA) and PE rat anti-
mouse Ly-6A/E (Sca1) (1:200; clone D7; BD Pharmigen, San Jose, CA).  
 Cells were subsequently incubated with FITC anti-BrdU (FITC BrdU Flow kit, BD 
Pharmigen, San Jose, CA). This staining is an intracellular staining, therefore required a 
permeabilization step to allow the entrance of the antibody inside the cell. Also required the 
DNA denaturalization to allow the antibody access to the incorporated BrdU residues. For this 
aim, cells were incubated with BD Cytofix/Cytoperm buffer for 15 minutes at RT. This buffer 
contains a mixture of the fixative paraformaldehyde and the detergent saponine, hence it 
preserves the cell morphology, fixes the cellular proteins and permeabilizes the cells. After the 
incubation, cells were washed with 1 ml of 1X BD Perm/Wash buffer, centrifuged 10 minutes at 
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300g and the supernatant was discarded. This supernatant was resuspended in with 100 µl of 
BD Cytoperm Plus buffer for 10 minutes on ice. This buffer is used as a staining enhancer and 
secondary permeabilization reagent. A re-fixation step was performed by 5 minutes incubation 
at RT with 100 µl of BD Cytofix/Cytoperm buffer. After washing with 1 ml of 1X BD 
Perm/Wash buffer, cells were treated with DNase for 1 hour at 37ºC to expose the incorporated 
BrdU. Then, cells were washed and stained with FITC anti-BrdU antibody (1:50, FITC BrdU 
Flow kit, BD Pharmigen, San Jose, CA) in 1X BD Perm/Wash buffer for 20 minutes in the dark 
at RT. Finally, cells were washed and stained with Hoechst for cell cycle analysis. Samples 
were processed on LSRII/Fortesa analyzer (BD Pharmigen, San Jose, CA). A minimum of 
50,000 events was acquired. Data was analyzed using FlowJo (Treestar, Ahskand, OR).  
 
5.13 COLONY FORMING ASSAY 
 
5.13.1 BM colony assay 
 
 In the bone marrow, the HSCs produce the hematopoietic progenitors. These 
progenitors proliferate and differentiate resulting in the generation of the variety of mature 
blood cells. In vitro assay systems have been developed to quantify these progenitors. When 
cultured in a semi-solid media, such as methylcellulose, supplemented with the proper nutrients 
and cytokines, individual progenitors called colony-forming cells (CFCs), proliferate to form 
discrete cell clusters or colonies. Each progenitor forms a type of colonies easily identified 
based on their different morphology. In our case, BM cells (2x104) were cultured in the 
methylcellulose-base media Methocult M3234 (StemCell Technologies) in absence of cytokines 
or containing recombinant murine GM-CSF (PeproTech) or IL-3 (PeproTech) at growing 
concentrations to promote the formation of the CFC-granulocyte macrophage (CFU-GM). 
Methocult M3234 medium contains 1% Methycellulose, 15% FBS, 1% BSA, 10 µg/ml of 
insulin, 200 µg/ml of human transferrin (iron-saturated), 10-4M 2-Mercaptoethanol and was 
supplemented with Iscove´s MDM medium (IMDM, StemCell Technologies), 2 mM glutamine 
and 1% penicillin/streptomycin.  
 Single BM cell suspension was obtained as mentioned in the 3.12.2 section. A ten-fold 
higher concentration of cellular suspension (2x105 cells/ml) was prepared in IMDM (StemCell 
Technologies) and 300 µl of this suspension was added to 3 ml of Methocult M3234 containing 
the proper amount of cytokines (0.001, 0.01, 0.1, 1 and 10 ng/ml of IL3 or 0.001, 0.01, 0.1, 1 
ng/ml of GM-CSF) or in absence of cytokines. After vortex the mixture and let stand for 2-5 
minutes to dissipate the bubbles, 1.1 ml of cells plus Methocult mixture was dispensed using a 
syringe attached to 18 gauge needle to each of two 35 mm dishes (StemCell Technologies) for 
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duplicate experiments. The duplicated dishes were placed into a 100 mm culture plate with an 
uncovered extra 35 mm dish containing 3-4 ml of sterile water to maintain the humidity. Cells 
were incubated at 37ºC, 5% CO2 and 95% humidity for 9-12 days. Colonies were counted on 
day 9 using an inverted microscope.  
 
5.13.2 CFU-F colony assay of cardiac stem cells 
 
 For colony forming units-fibroblast (CFU-F) assay, 5,000 Sca-1+/PDGFRα+/CD31- 
cells were plated on chamber slides (Ibidi) and cultured in αMEM (GIBSO) plus 20% of Fetal 
Calf Serum (FCS) for two weeks.  
 
5.14 BONE MARROW TRANSPLANTATION 
 
 BM cells from K-Ras+/+ and heterozygous K-Ras+/V14I mice backcrossed to the 
C57BL/6J background for four generations were harvested from femurs and tibias. After 
eritrocytes lysis, a ten-fold higher concentration of cellular suspension (107 cells/ml) was 
prepared in 1X PBS (BioWhittaker, Lonza). 100 µl of this suspension (106 cells) was injected 
into the lateral tail vein of lethally irradiated (two doses of 550 cGy in a three hours interval) 
C57BL/6J host mice. A small group of mice was injected only with 1X PBS (BioWhittaker, 
Lonza) like an irradiation control. Mice were maintained with 2.5 mg/100 ml of Enrofloxacine 
(broad spectrum antibiotic) in drinking water until the end of the experiment.  
 
5.15 MICE PROTOCOLS TO CONTROL THE CRE RECOMBINASE ACTIVITY 
 
5.15.1 Polyinosinic-polycytidylic acid (pI-pC) treatment 
 
 For induction of interferon-inducible Cre (Mx1-Cre) expression, K-Ras+/+; Mx1-Cre+/T 
and K-Ras+/LSLV14I; Mx1-Cre+/T 4- to 5-week-old mice were injected intraperitoneally (i.p) with 
10 µg/g body weight of Polyinosinic-polycytidylic acid (pI-pC, Sigma-Aldrich) in 1X PBS 
every other day for three doses.  
 
5.15.2 Tamoxifen diet treatment 
 
To activate the expression of the K-Ras+/LSLV14I and Pi3kca+/H1047R in somatic cells in a 
temporally controlled manner we used the RERTnert/ert strain that express a CreERT2 
recombinase which activity is driven by tamoxifen. K-Ras+/LSLV14I; RERTnert/ert and the K-
Ras+/LSLV14I; RERTnert/ert; Pi3kca+/H1047R mice were submitted to a tamoxifen diet (Tekland CRD 
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Tam400/CreER) ad libitum. This treatment resulted in the activation of the inducible Cre-ERT2 
recombinase, leading the expression of both mutations. The standard diet (28018S, Tekland) 
contains genistein, a phytoestrogen that belongs to the category of the isoflavones. The 
genistein has been shown to interact with animal and human estrogen receptors. To avoid the 
competition between genistein and tamoxifen to bind to the estrogen receptor, 10 days before 
the TAM-diet administration, mice were maintained with a wash out diet (2019S, Tekland). 
This diet does not contain alfalfa or soybean meal, thus minimizing the occurrence of natural 
phytoestrogens. The active metabolite of tamoxifen, 4-hydroxy-tamoxifen (4OHT), was 
produced in the organism by hydroxylation.  
 
5.15.3 Adenovirus intratracheal infection 
 
 Eight-week-old mice were treated once by intratracheal adeno-Cre instillation with 
3x108 plaque forming units (pfu)/mouse of virus after anesthesia via i.p injection of ketamine 
(75mg/kg, Imalgene®) and xylazyne (12 mg/kg, Rompum®) solution. The virus was introduced 
directly in the trachea through a cannula (200). After inoculation mice were maintained during 
10-15 minutes under a heat lamp.  
 
5.16 INDUCTION OF PANCREATITIS BY CAERULEIN TREATMENT 
 
 Chronic pancreatitis was induced by treatment with caerulein (Sigma-Aldrich), a 
cholecystokinin analog (133, 241). Caerulein was administered as a 0.1 ml single daily i.p 
injection of 50 mg/ml solution in saline, 5 days per week during the time of the study (70). 
 
5.17 NICOTINE TREATMENT 
 
 Nicotine at a concentration of 100 µg/ml (Sigma-Aldrich) was provided ad libitum in 
the drinking water with sucrose (2% water/volume) to 4 week-old-mice for 1 year (203). 
 
5.18 MEK INHIBITOR TREATMENT 
 
 To determine whether the MEK inhibitor PD0325901 (Wuhan Sunrise Technology 
Development Company Limited, China) treatment could prevent or ameliorate some of the 
defects associated with the expression of the K-RasV14I mutation we performed three different 
treatment protocols (Figure 9):    
1. Prenatal treatment: MEK inhibitor PD0325901 was resuspended in 0.5% 
hydroxypropylmethylcellulose (Sigma-Aldrich) with 0.2% Tween80 (Sigma-Aldrich) 
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and injected i.p (1 mg/kg of body weight) into pregnant female daily, beginning on 
gestational day 7.5 (E7.5) until P9. Vehicle-injected mice were used as a control. At 
P10, PD0325901 or vehicle was injected i.p (1mg/kg of body weight) directly into the 
pups every other day, until 4 weeks after birth. 
2. Postnatal treatment: PD0325901 was dissolved in DMSO (Sigma-Aldrich), and then 
resuspended in 0.5% hydroxypropylmethylcellulose with 0.2% Tween80 (in a 
proportion of 1% DMSO/99% hydroxypropylmethylcellulose; Tween80) and daily 
injected (i.p, 5 mg/kg of body weight) at P21 for 6 weeks. Control mice were injected 
only with vehicle. 
3. Adult treatment: PD0325901 was dissolved in DMSO (Sigma-Aldrich), and then 
resuspended in 0.5% hydroxypropylmethylcellulose with 0.2% Tween80 (in a 
proportion of 1% DMSO/99% hydroxypropylmethylcellulose; Tween80) and daily 
injected (i.p, 5 mg/kg of body weight) into 4-month-old mice 1 month. Control mice 
were injected only with vehicle. 
 
 
 
 
 
  
 
 
  
 
5.19 STATISTICS 
 
 Results were expressed as mean ± SD. K-Ras+/V14I and K-RasV14I/V14I mice were 
compared to K-Ras+/+ mice using 2-tailed Student´s test. A P value less than 0.05 was 
considered significant. U Mann Whitney test was used in the experiments of the cardiac stem 
cells. Long rank (Mantel-Cox) test was used to compare the survival curve of mice treated 
either with the vehicle or with the PD0325901. A P value less than 0.05 was considered 
significant.  
 
 
1!
E0! E7.5! P0! P21! 2 months! 4 months! 5 months!P10!
2!
3!
Figure 9. Treatment protocols. Arrows indicate the duration of the treatments. Pink arrows: prenatal 
treatment or treatment 1, green arrow: postnatal treatment or treatment 2, purple arrow: adult treatment or 
treatment 3. 
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6.1 GENERATION OF A CONDITIONAL K-RAS KNOCK-IN MOUSE MODEL FOR 
NOONAN SYNDROME  
 
 To better understand the developmental and physiological defects associated with the 
expression of germline K-RAS mutations we have generated a knock-in mouse model that 
expresses the most common K-RAS mutations found in Noonan patients, the substitution V14I 
(122). Furthermore, this mouse model allows to evaluate the tumor predisposition of K-RAS-
Noonan patients and to test preventative and therapeutic strategies that can prevent or 
ameliorate the alterations associated with the expression of these activated mutations.  
 
6.1.1 Conditional K-RasLSLV14I knock-in mouse model  
 
 To generate a mouse model for Noonan Syndrome (NS), we knocked-in a G→A 
transition in the first base of the 14th codon of the K-Ras locus, a strategy that led to the 
replacement of the normal GTA sequence (valine) by ATA (isoleucine), the most frequent K-
RAS mutation observed in NS patients (122). To control the expression of this mutation we 
introduced a transcriptional STOP sequence upstream of the mutagenized exon flanked by loxP 
sites (108). The loxP sites are 34 bp of DNA sequences that are specifically recognized by the 
Cre recombinase, an enzyme that catalyses a recombination event between the two loxP sites. In 
our strategy, the orientation of the loxP sites allows the elimination of the transcriptional STOP 
sequence and consequently the expression of the mutations by the recombination event driven 
by the Cre recombinase. Together with the STOP cassette we also introduced a hygromicin 
resistant gene (Hyg) whose expression is driven by the phosphoglycerate kinase (PGK) 
promoter. Therefore, the resistance sequence can be removed together with the STOP cassette, 
avoiding interferences with the expression of the mutated allele (see section 5.1 Material  and 
Methods for detail description) 
 The allele that includes all the modifications was called K-RasLSLV14I where “LSL” 
indicated “LoxP-STOP-LoxP” cassette, a short name for the cassette “LoxP-PGK-Hyg-STOP-
LoxP” and V14I indicated the mutation. 
 Mice lacking the K-Ras gene die from E12.5 to E15 (89, 100). Therefore, since the 
STOP sequence prevents the expression of the K-Ras mutated allele; mice homozygous for the 
LSLV14I sequence are not viable. 
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6.2 K-RasV14I EXPRESSION IS COMPATIBLE WITH EMBRYO AND POSTNATAL 
STAGES 
 
 Prenatal widespread expression of oncogenic K-Ras mutations (G12V or G12D) was 
not tolerated during the embryonic development and embryos died from E9.5 to E11.5 due to 
placental, cardiovascular and hematopoietic defects (69, 193, 221).  
 To address if expression of the K-RasV14I mutation is compatible with embryonic and 
postnatal development, K-Ras+/LSLV14I mice were crossed with the transgenic mice EIIaCre 
(108). In this mouse, the adenovirus EIIa promoter drives the expression of the Cre recombinase 
selectively to pre-implantation embryos, at one-cell zygote stage of embryonic development. 
Promoting, in our mouse model, the expression of the mutation in all cell populations, including 
gemline cells. Mice carrying the K-RasV14I allele in all the cells were identified by Southern blot 
(see 5.1.5 section in Materials and Methods) and crossed with C57BL/6J mice to eliminate the 
EIIaCre transgene. The resulting K-Ras+/V14I mice express the K-RasV14I allele in heterozygosity 
in all the cells. These mice were in a mixed C57BL/6J;129S2/Sv background (from now on 
B6/129). All the studies described in this manuscript were carried out with these mice, unless 
otherwise indicated.  
 K-Ras+/V14I mice were born at the expected Mendelian ratio and reached adulthood. In 
contrast, homozygous K-RasV14I/V14I mice displayed high perinatal lethality due to 
cardiovascular problems (see bellow). 10% of homozygous K-RasV14I/V14I animals, obtained 
from crosses between heterozygous mice, overcame these problems, survived and reached 
adulthood. Although, K-Ras+/V14I and K-RasV14I/V14I mice presented reduced life span with a 
half-life of 62 and 36 weeks, respectively (Figure 10).  
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Figure 10. K-RasV4I mice displayed reduced life span. Survival curve of wild type (n=25; open circles), K-
Ras+/V14I (n=68; gray circles), and K-RasV14I/V14I (n=30; solid circles) mice in mixed B6/129 genetic background.  
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 K-Ras+/V14I mice were fertile. Both K-RasV14I/V14I females and males were also fertile, 
since crosses with K-Ras+/V14I and wild type mice succeeded. However, the offspring from 
crosses with heterozygous K-Ras+/V14I mice was smaller (3 to 4 pups) compared to the average 
litter size (7 pups). Moreover, no mating between K-RasV14I/V14I mice worked. Thus, all these 
findings suggest that K-RasV14I/V14I mice have some fertility problems.  
 Male gonadal dysfunction is reported in Noonan patients. In contrast, fertility in females 
is not affected (100, 171). Therefore, the breeding inefficiency between K-RasV14I/V14I mice 
could reflect some of the alterations found in NS patients.  
   
6.2.1 Perinatal lethality of K-RasV14I/V14I mice  
 
 Analysis of embryos and newborns at different stages revealed that K-RasV14I/V14I mice 
died early just after birth. At embryonic days E13.5 and E18.5, the number of homozygous 
embryos appeared as expected and were comparable, in size and morphology, to their wild type 
littermates. However, daily control of the matings (pregnant females, date of birth, offspring 
number and genotyped of the death pups) illustrated that high percentage of K-RasV14I/V14I mice 
were born dead or died shortly after birth (Table 1).  
 
 
 
 
 
 
 
 
 
 Heart characterization revealed that K-RasV14I/V14I neonatal mice showed an enlarged 
heart already evident at midgestation (E13.5) (Figure 11A). Although K-RasV14I/V14I mice found 
dead at P0 were similar in size and morphology to the wild type littermates, careful histological 
analysis of these homozygous mice (n=5) revealed focal necrosis areas in tissues such as liver 
and muscle, a result consistent with defects associated to a cardiovascular etiology (Figure 
11B). All together, these results suggest that homozygous mice die at perinatal stages due to 
cardio-respiratory problems.  
Table 1. Viable progeny from matings between K-Ras+/V14I mice.  
Stage n K-Ras+/+ K-Ras+/V14I K-RasV14I 
        
E13.5 68 16 (23%) 38 (56%) 14 (21%) 
E18.5 46 12 (26%) 21 (46%) 13 (28%) 
P0 25 7 (28%) 13 (52%) 5 (20%) 
P21 416 159 (38%) 214 (52%) 43 (10%) ! Number and the corresponding percentage of embryos and mice at different stages are shown.  
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6.3 MOLECULAR ANALYSIS OF THE K-RasV14I MUTATION AND THE K-Ras 
SIGNALING PATHWAY 
 
 6.3.1 Molecular analysis of the K-RasV14I mutation 
 
 K-RASV14I mutation is located in the P-loop of the protein and interferes with the 
guanine nucleotide exchange factor site. Biochemical analysis suggested that this change 
induces a reduced GTPase activity, basally or after stimulation with GAP proteins, compared to 
the wild type form of the protein but more than the oncogenic form G12D (see more detail in 
2.3.4.1 section). Therefore this modification induces an intermediate increase of the active RAS 
status compared to the wild type and oncogenic protein (65, 186, 188). 
 RAS, in their active conformation, can interact with more than 20 effectors to regulate 
several cellular responses (53, 187). One of these effectors is the RAF protein. GTP-active RAS 
binds to the RAS-binding domain (RBD) of this protein to control downstream signaling 
cascade. To quantify the RAS activation of, the GTP-bound status of the protein, we used 
RAF1-RBD agarose beads. These beads selectively bind to the RAS-GTP allowing its isolation 
by a pull-down assay.  
 To this aim, we obtained protein extracts from E13.5 embryos. As expected, the amount 
of K-Ras-GTP was more abundant in K-Ras+/V14I and K-RasV14I/V14I embryos than in wild type 
littermates. However, the total GTP bound K-RasV14I protein, even in homozygous embryos, 
was lower that the amount bound to the oncogenic K-RasG12V isoform (Figure 12). This result 
Figure 11. K-RasV4I/V14I mice display perinatal lethality. (A). Top: H&E stained paraffin transverse section of 
E13.5 wild type (+/+) and K-RasV14I/V14I (V14I/V14I) embryos. Scale bar, 500 µm. Bottom: H&E stained 
paraffin transverse section of neonate (P0) wild type (+/+) and K-RasV14I/V14I (V14I/V14I) pups. Scale bar, 1000 
µm), showing the heart morphology at these stages. (B). H&E stained paraffin sections from liver (top) and 
muscle (bottom) from a representative K-RasV14I/V14I sick P0 mouse. Asterisk indicates the necrotic area in liver. 
Solid arrowhead points to necrotic area in muscle. Scale bar, 100 µm. 
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confirms that the activation levels of the K-RasV14I protein are higher than those of the wild type 
protein, but lower than those of the oncogenic form. Therefore, the K-RasV14I protein has 
attenuated biochemical phenotype compatible with embryo and postnatal development.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3.2 Molecular analysis of the K-Ras signaling pathway  
  
 To analyze if the enhanced level of GTP-bound K-Ras protein in K-Ras+/V14I and K-
RasV14I/V14I embryos is associated with an increased signaling activation, we characterized two 
of the most important signaling pathways (the RAF and the PI3K pathway) by Western blot.  
 
 
 
 
 
Figure 12. Molecular analysis of the activation status of the K-RasV14I mutation. Western blot of protein 
extracts (4 mg) obtained from K-Ras+/+ (+/+), K-Ras+/V14I (+/V14I) and K-RasV14I/V14I (V14/V14I) E13.5 
embryos and K-Ras-/- (-/-) and K-Ras+/G12V (+/G12V) MEFs incubated with the Ras binding domain (RBD) of c-
Raf. The resulting complexes, as well as 40 µg of unprocessed protein extracts were resolved by SDS-PAGE, 
transferred to a nitrocellulose membrane and blotted with a Pan-Ras antibody. GAPDH was used as a loading 
control. The migration of the RBD-bound Ras proteins, as well as of the individual K-Ras, H-Ras and N-Ras 
proteins is indicated by arrowheads. 
GAPDH!
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Figure 13. Functional characterization of the K-Ras signaling. Proteins extracts (40 µg) obtained from E13.5 
embryos and spleens and hearts of 4-month-old K-Ras+/+ (+/+), K-Ras+/V14I (+/V14I) and K-RasV14I/V14I 
(V14I/V14I) mice were resolved by SDS-PAGE, transferred to a nitrocellulose membrane and blotted with 
antibodies against nonphosphorylated and phosphorylated forms of Erk1/2, Mek1 and Akt. GAPDH was used as 
a loading control. The migration of the corresponding proteins is indicated by arrowheads. 
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 In spite of the accumulation of the K-RasV14I mutation in the active form, the 
phosphorylation levels of the Mek, Erk1/2 and Akt downstream kinases were comparable in 
wild type and mutant E13.5 embryos (Figure 13). Same results were obtained in adult tissues 
such as spleen and heart, two of the organs most affected by the expression of the K-RasV14I 
isoform (see bellow). According to this result, the total levels of the Erk1, Erk2, Mek1 and Akt 
protein effectors were similar in wild type and mutant E13.5 embryos and in the studied adult 
tissues, heart and spleen (Figure 13). These observations are reminiscent of those previously 
observed in H-RasG12V Costello mouse model (189), thus suggesting the existence of negative 
feedback mechanisms that control the levels of Ras signaling. This negative feedback signaling 
has been previously suggested for K-RasG12D signaling during embryo development (194). 
Alternatively, it is possible that Western-blot analysis of phosphorylated downstream effectors 
may not be sensitive enough to detect subtle differences in the amount of Ras signaling 
generated in tissues expressing constitutively active K-RasV14I proteins. In fact, significant 
levels of pErk were detected by immunohistochemistry in heart of K-RasV14I/V14I embryos and 
neonate, one of the most affected tissues in these mice (Figure 14). Similar results were 
described for other NS mouse models (14). 
 
 
 
 
 
 
 
 
 
6.4 ROLE OF K-RasV14I IN PROLIFERATIVE SENESCENCE 
 
 Primary mouse embryonic fibroblast (MEFs) expressing the K-RasG12V or K-RasG12D 
oncogenes do not undergo proliferative senescence and proliferate as immortal cells (69, 221).  
 To address if MEFs expressing the K-RasV14I mutation became immortalized with the 
same kinetics of those that express the oncogenic mutations, MEFs were extracted from E13.5 
embryos and were immortalized by the standard 3T3 protocol. Unlike K-Ras oncogenes, the 
endogenous expression of the K-RasV14I mutation did not prevent the proliferative senescence. 
After few passages in culture, K-Ras+/V14I (n=6) and K-RasV14I/V14I (n=5) MEFs underwent 
 +/+ !  V14I/V14I!
Figure 14. Enhanced Erk activation in heart embryos. pErk1/2 immunostaining in hearts of E18.5 wild type 
(+/+) and K-RasV14I/V14I (V14I/V14I) embryos. Scale bar, 50 µm.  
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proliferative senescence, as well as wild type cells (n=5). However, upon continuous passages, 
K-RasV14I/V14I MEFs overcame the crisis and became immortal (around passage 14th) faster than 
wild type MEFs. This process was gene dose dependent since K-Ras+/V14I MEFs displayed an 
intermediate phenotype, overcoming the crisis around passage 17th  (Figure 15).  
 
 
  
 
  
 
 This observation indicates that although the expression of the K-RasV14I mutation is not 
associated with a hyperproliferative phenotype, the expression of this mutation induces a 
stronger proliferative response, at least in MEFs.  
 
6.4.1 Molecular analysis of the K-RasV14I mutation in MEFs 
 
 We determined the Ras-GTP levels in MEFs following the approach described in 
section 6.3.1. As observed in E13.5 embryos, primary K-Ras+/V14I and K-RasV14I/V14I MEFs 
showed higher levels of activate GTP-bound Ras, than the wild type MEFs. Again, this 
activation was lower compared to MEFs that express the G12V oncogenic form (Figure 16A).  
 We also determined the activation status of the RAS signaling pathway in primary 
MEFs by Western blot. Like E13.5 embryos and adult tissues, K-Ras+/V14I and K-RasV14I/V14I 
MEFs contained equal phosphorylation and total levels of Mek, Erk1/2 and Akt downstream 
effectors, compared to the wild type cells (Figure 16B). Therefore, primary K-RasV14I-
expressing MEFs displayed comparable signaling response in their downstream mitogenic 
(Raf/Mek/Erk) and survival (PI3K/Pdk/Akt) pathways to wild type MEFs.  
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Figure 15. Immortalization properties 
of MEFs expressing the K-RasV14I 
mutation. Immortalization of wild type 
(n=5; open circles), K-Ras+/V14I (n=6; 
gray circles) and K-RasV14I/V14I (n=5; 
solid circles) MEFs following the 3T3 
protocol. Error bars indicate the SD.  
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6.5 K-RasV14I DISPLAYED REDUCED BODY SIZE  
 
 Noonan patients display normal size and weight at birth. However, adults present 
smaller height due to a reduction of the pubertal growth (171, 220, 224). This feature was 
reproduced in all the Noonan mouse models previously generated (13, 14, 39, 237). 
 As Noonan patients, K-Ras+/V14I and K-RasV14I/V14I mice displayed similar weight and 
body size to wild type animals at birth (data not shown). Nevertheless, K-RasV14I/V14I mice were 
significantly smaller at weaning. At 4 weeks of age, the body weight of K-RasV14I/V14I male was 
significantly reduced [11.7±2.22 g (n=18) vs. 16.3±3.97 g (n=24)] and the mutant mice were 
shorter than the controls [(7.1±4.26 cm (n=7) vs. 8.2±2.27 cm (n=6)]. These differences became 
ameliorated with age, mostly in the case of the body weight. At 3 months of age, the body 
length remains reduced [(9.5±3.14 cm (n=7) vs. 10.0±1.45 cm (n=6)]. These differences are 
gene dose dependent, since K-Ras+/V14I displayed smaller size and length only at weaning and 
these parameters were normalized along the time (Figure 17A and B).  
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Figure 16. Molecular analysis of the K-
RasV14I mutation in MEFs. (A). Western blot 
analysis of protein extracts (4 mg) obtained 
from K-Ras-/- (-/-), K-Ras+/+ (+/+), K-Ras+/V14I 
(+/V14I) and K-RasV14I/V14I (V14/V14I) and K-
Ras+/G12V (+/G12V) MEFs incubated with the 
Ras binding domain (RBD) of c-Raf. The 
resulting complexes, as well as 40 µg of 
unprocessed protein extracts were resolved by 
SDS-PAGE, transferred to a nitrocellulose 
membrane and blotted with a Pan-Ras antibody. 
GAPDH was used as a loading control. The 
migration of the RBD-bound Ras proteins as 
well as the individual K-Ras, H-Ras and N-Ras 
proteins is indicated by arrowheads. (B). Protein 
extracts (40 µg), from K-Ras+/+ (+/+), K-
Ras+/V14I (+/V14I) and K-RasV14I/V14I 
(V14I/V14I) MEFs, were resolved by SDS-
PAGE, transferred to a nitrocellulose membrane 
and blotted with antibodies against 
nonphosphorylated and phosphorylated forms 
of Erk1/2, Mek1 and Akt. GAPDH was used as 
a loading control. The migration of the 
corresponding proteins is indicated by 
arrowheads. 
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 We analyzed lean and fat content by densitometer to find an explanation of these 
differences. At 4 weeks of age, K-RasV14I/V14I male (n=5) presented less lean content than the 
control mice (n=4). This difference became ameliorated with age, being the lean content 
comparable at 4 months of age. In the case of fat content, 4-weeks-old K-RasV14I/V14I male (n=5) 
displayed a small reduction compared to wild type littermates (n=4). This difference 
disappeared one month later, but increased exponentially at 3 and 4 months of age. No 
differences were found in K-Ras+/V14I mice (n=10) (Table 3 in Appendix I).  
 These observations indicate that K-RasV14I mice displayed smaller body weight due to a 
reduction of lean and fat content at weaning. However, reduction in lean content as well as body 
weight became ameliorated with age. In contrast, the fat content still remained reduced at 3 and 
4 months of age. K-RasV14I mice displayed MPD around 4 months of age (see bellow, 6.9 
section), thus this loss of the fat content could be an indicative of the illness of the mice.  
 
6.6 K-RasV14I MICE DISPLAYED FACIAL DYSMORPHIA AND NO SKELETAL 
ABNORMALITIES  
 
6.6.1 K-RasV14I mice displayed normal skeleton 
 
 Most Noonan patients develop skeletal alterations such as thoracic deformities and 
spine abnormalities (6, 192). Using micro X-ray computed tomography (micro-CT) we 
analyzed the entire skeleton of K-Ras+/V14I and K-RasV14I/V14I mice at different ages to determine 
the presence of alterations. However, as the other Noonan mouse models (13, 14, 39, 237) no 
abnormalities were found in any of the scanned mice (data not shown). 
Figure 17. NS-like developmental defects in K-RasV14I mice. (A) Growth curves of male mice. Top: Body 
weight of wild type (n=24; open circles), K-Ras+/V14I (n=36; gray circles) and K-RasV14I/V14I (n=18; solid circles) 
mice. Bottom: Body length of wild type (n=6; open circles), K-Ras+/V14I (n=14; gray circles) and K-RasV14I/V14I 
(n=7; solid circles) mice. Error bars indicate SD. *P < 0.05; **P < 0.01; ***P < 0.001. (B) Representative image 
of 4-month-old male wild type (+/+), K-Ras+/V14I (+/V14I) and K-RasV14I/V14I (V14I/V14I) mice.	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 A small percentage of Noonan patients develop osteopenia and/or osteoporosis (204). 
We determined the bone status in our mouse model analyzing the bone mineral density (BMD) 
and bone mineral content (BMC) at different ages (1, 2, 3, 4 months) by densitometer (Table 3 
in Appendix I). No alterations were found in K-Ras+/V14I mice (n=10). However, at 4 weeks of 
age, BMC of K-RasV14I/V14I mice (n=5) was significantly reduced compared to wild type mice 
(n=4). Interestingly, these differences disappeared with age. In addition, no significant 
differences were found in the BMD of K-RasV14I/V14I mice (n=5) and wild type littermates (n=4). 
Besides, no bone histological alterations were found in 4-months old and aging mice (data not 
shown). All these findings together revealed that the K-RasV14I mice displayed normal skeletal 
structure and normal bone physiology.  
 
 
6.6.2 K-RasV14I mice displayed facial dysmorphia 
  
 Noonan patients display typical facial dysmorphia characterized by ptosis and wide-
spaced eyes, low set, posteriorly rotated ears, inverted triangular face and broad or webbed neck 
(7). Noonan mouse model that express Ptpn11, Raf1 or Sos1 mutations has a “triangular” facial 
appearance reminiscence of the facial abnormalities seen in NS patients (13, 14, 39,146, 237). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
+/+ ! +/V14I ! V14I/V14I!A!
B!
Figure 18. Craniofacial dysmorphia of K-RasV14I mice. (A) Representative micro-CT scans of skulls of 4- 
month-old wild type (+/+), K-Ras+/V14I (+/V14I) and K-RasV14I/V14I (V14I/V14I) male mice in mixed B6/129 
genetic background. (B) Morphometric measurements of 4-month-old wild type, K-Ras+/V14I and K-RasV14I/V14I 
male mice. Numbers shown indicate the media ± SD. Statistical significance was assessed by two-tailed 
Student’s test. *P < 0.05; **P < 0.01; NS: no significant. 	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 K-RasV14I/V14I mice exhibited facial dysmorphia characterized by a more pronounced 
triangular facial appearance with a shorter distance between the ears and the nose, blunter snout 
and wider separation between the eyes (Figure 18A). Analysis of 4-month-old males (n=6) by 
micro-CT revealed increased skull width and height along with reduced length resulting in a 
more round skull with bigger volume. Consistent with a gene dose effect, these alterations were 
less pronounced in heterozygous mice (n=7) (Figure 18A and B). These features are 
reminiscent of the facial phenotype of the other NS mouse models (13, 14, 39,146, 237) as well 
as of NS patients (7).  
 
6.7 K-RasV14I MICE DISPLAYED NORMAL AUDITORY PARAMETERS 
 
 Hearing loss is found in 10-40% of NS patients due to otitis media complication (15-
40%) or sensorineural defects (10-25%) (224). The auditory parameters of 4-months-old K-
RasV14I mice were analyzed by ABR (Auditory Brainstem Response) by the “Servicio de 
Evaluación Neurofuncional no Invasiva. Instituto Biomédicas Alberto Sols CSIC-UAM. 
Servicio de Evaluación Funcional de Animales de Laboratorio, CIBERER, ISCIII”.  
 The ABR is a neurophysiological technique that measures the brainstem function in 
response to auditory stimuli. This technique is based on auditory stimulation using known 
characteristic sounds and the subsequent recording of the electrical activity generated by the 
auditory neurons using electrodes placed in standard positions. The ABR system allows 
determining the hearing threshold for click stimulation and for pure tones (audiograms). 
 K-Ras+/V14I (n=7) and K-RasV14I/V14I mice (n=4) displayed similar hearing threshold for 
click stimulation to the control mice (n=8) (Table 5 in Appendix I). The values of the three 
analyzed genotypes were found in the reference values of normal audition. No differences were 
found in the analysis of the hearing threshold for pure tones (8, 16, 28 and 40 kHz). Moreover, 
the audiogram of the control mice (n=8) had the typical shape of mice with normal audition [all 
the hearing thresholds were lower than 45dB SPL (decibel Sound Pressure Levels) and the best 
values were obtained at the frequency of 16 kHz] and was comparable to the audiogram 
obtained in mix B6/129 cohort of mice. K-Ras+/V14I (n=7) and K-RasV14I/V14I mice (n=4) 
displayed an audiogram similar to the wild type mice (Figure 19).  
 These results indicate that 4-month-old K-RasV14I mice display normal audition. 
Therefore, the expression of this mutation in mice is not associated with hearing defects under 
normal conditions. An evaluation in extreme conditions (aging or noisy environment) might be 
needed to highlight the presence of these defects.  
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6.8 K-RasV14I MICE DEVELOPED HEART ABNORMALITIES 
 
 One of the most common alterations of Noonan patients is the congenital heart disease 
(50-90%) that includes pulmonary stenosis, hypertrophic cardiomiopathy (HCM) and secundum 
atrial septal defects (171, 193). These cardiac alterations have been reproduced in all the mouse 
models that express mutations found in NS patients, being in many cases incompatible with life 
(13, 14, 39, 237). 
 K-RasV14I mice displayed substantially larger hearts already evident in midgestation 
(E13.5) embryos and neonatal animals. Histological analysis revealed that K-RasV14I embryos 
and neonatal animals displayed a significant bigger heart, with a significant increase in the size 
of all chambers (Figure 11). At 4 months of age, cardiac abnormality was characterized by a 
significant increase in heart weight and heart/body weight ratio (Figure 20A).  Histological 
analysis revealed a substantial thickening of all chambers. We did not observe gross alterations 
in the histological structure of auricles or ventricles or tissue fibrosis. However, the aortic 
valves were thicker in the mutant mice. Heterozygous animals displayed similar, albeit less 
pronounced, alterations (Figure 20B). 
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Figure 20. Heart defects in K-RasV14I mice. (A) Top: Heart weight and Bottom: heart/body weight ratio of 
4-month-old wild type (n=22) (+/+, open bars), K-Ras+/V14I (n=30) (+/V14I, gray bars) and K-RasV14I/V14I 
(n=13) (V14I/V14I, solid bars) male mice. Error bars indicate SD. **P < 0.01; ***P < 0.001. (B) Top: 
Formalin-fixed hearts. Scale bar, 0.5 cm. Middle: H&E stained heart ventricular sections. Interventricular wall 
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valves. Solid arrowheads point to aortic valves. Scale bar, 50 µm.	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 The enlargement of an organ size could be due to an increase in the number of cells 
(hyperplasia) or an increase in cells size (hypertrophy). We quantified the number of 
cardiomyocytes and determined the cardiomyocyte size in H&E hearts slides of 4-month-old 
animals. The cardiomyocyte area was comparable in mutant and control hearts. By contrast, the 
K-Ras+/V14I (n=12) and K-RasV14I/V14I mice (n=3) displayed a significant increase number of 
cardiomyocytes. This change is gene dose dependent, since K-Ras+/V14I mice presented an 
intermediate phenotype (Figure 21A). We studied if the increased number of cardiomyocytes 
was due to an elevated proliferation rate. Hence, we measured the cardiomyocyte proliferation 
by Ki67 immunostaining. Ki67 positive cells were more abundant in K-RasV14I/V14I hearts 
compared to control (Figure 21B and C). Therefore, these results suggest that K-RasV14I mice 
displayed a heart hyperplasia due to an enhanced proliferation rate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.8.1 K-RasV14I mice displayed an expansion of the cardiac stem cells 
 
 The longstanding dogma that mammalian heart is postmitotic organ with limited 
regenerative capacities has been challenged by the discovered of a number of multipotent stem 
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cell like population and their likely contribution to new cardiomyocytes and vascular lineages 
after injury (9, 20, 94, 163). Since we found an increase of cycling cardiomyocytes in K-RasV14I 
mice, we questioned whether the expression of the K-RasV14I might induce also an expansion of 
the cardiac stem cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. K-RasV14I hearts displayed increased pluripotency and expansion of cardiac stem cell at P10-
P14 (A) Relative expression of Nanog in hearts from wild type (n=4) (+/+, open bars) and K-Ras+/V14I (n=4) 
(+/V14I, gray bars) pups. (B) Percentage of Sca-1+/PDGFRα+/CD31- cells in hearts from wild type (n=4) 
(+/+, open bars) and K-Ras+/V14I (n=8) (+/V14I, gray bars) pups. (C)	  Number of CFU-F colonies derived from 
of Sca-1+/PDGFRα+/CD31- cells of wild type (n=4) (+/+, open bars) and K-Ras+/V14I (n=6) (+/V14I, gray 
bars) pups. (D) Representative pictures of DAPI (blue) and Phalloidin (red) of CFU-F coloines derived from 
of Sca-1+/PDGFRα+/CD31- cells of wild type (+/+) and K-Ras+/V14I (+/V14I) pups. (E) Relative expression of 
microRNA-100 in hearts from wild type (n=4) (+/+, open bars) and K-Ras+/V14I (n=4) (+/V14I, gray bars) 
pups. (F) Relative expression of MKK6 in hearts from wild type (n=4) (+/+, open bars) and K-Ras+/V14I (n=4) 
(+/V14I, gray bars) pups. (G) Relative expression of Smarca5 in hearts from wild type (n=4) (+/+, open bars) 
and K-Ras+/V14I (n=4) (+/V14I, gray bars) pups. Error bars indicate SD. *P < 0.05. 
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 We observed that Nanog expression, a pluripotency-associated gene, was significantly 
up-regulated in hearts from K-Ras+/V14I mice sacrificed from postnatal day 10 to 14 compared to 
wild type littermates (Figure 22A). Next, we analyzed the number of Mesenchymal Stem Cells 
(MSC)-like Sca-1+/PDGFRα+/CD31- cardiac stem cells in hearts from K-Ras+/V14I and wild type 
mice sacrificed at P10-14 and the capacity of these cells to produce colony forming units- 
fibroblast (CFU-Fs). Thus, we observed that in hearts from P10-14 K-Ras+/V14I mice the number 
of Sca-1+/PDGFRα+/CD31- cardiac stem cells was increased compared to control mice (Figure 
22B) and the number of CFU-Fs colonies derived from these mutant cardiac stem cell was 
bigger than those derived from wild type cells (Figure 22C and D).  
 Finally, we analyzed the expression of the microRNA-100. This microRNA-100 is 
required for proper differentiation of mouse embryonic stem cells and is repressed in 
undifferentiated embryonic stem cells (206). Moreover, down-regulation of this microRNA is 
essential for the initiation of the dedifferentiation/proliferation process after heart injury in mice 
(unpublished data from Aguirre A., Izpisua-Belmonte JC. and Sánchez-Martinez I.). In line with 
these, we observed a down-regulation of the microRNA-100 (Figure 22E), which results in an 
up-regulation of two of its targets, MKK6 (Figure 22F) and Smarca5 (Figure 22G), in hearts 
from P10-14 K-Ras+/V14I compared to control hearts.  
 
6.8.2 Hemodynamic study, cardiac morphology and function analysis 
 
 Non-invasive hemodynamics studies established that mean arterial pressure measured at 
4, 5 and 6 months of age was comparable in mutant and control mice (Figure 23). The absence 
of hypertension in these mice is in agreement with the lack of heart fibrosis and cardiovascular 
remodeling (data not shown). 
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 To analyze cardiac morphology and function, we performed Magnetic Resonance 
Imaging (MRI) studies on 4-month-old mice in collaboration with the ‘Instituto de 
Investigación Sanitaria Gregorio Marañón’. As expected, wall thickness in systole (WTs), 
systolic wall thickening (WTn) and left ventricle mass (LVM) were significantly increased in 
K-RasV14I/V14I mice (n=3) compared to wild type littermates (n=5). These results were in 
agreement with the larger heart characteristic of these mutant mice. Accordingly, K-RasV14I/V14I 
hearts showed enhanced end diastolic volume (EDV), the volume of blood in the left ventricle 
at the end of diastole, before the contraction. This increase was also in concordance with the 
bigger heart of mutant mice. Since K-RasV14I/V14I mice displayed enlarged heart, the volume of 
blood inside of the ventricle was also bigger. Moreover, end systolic volume (ESV), the volume 
of blood in the left ventricle at the end of the contraction, remained normal indicating preserved 
or enhanced function. Although the heart of K-RasV14I/V14I mice is larger and the volume of 
blood inside the heart is bigger, the contractibility function is able to pump all the blood out. 
Therefore, no volume change was found in K-RasV14I/V14I mice compared to control mice at the 
end of the systole. Consistent with this interpretation, fractional shortening (FS) and cardiac 
output (CO) is enhanced in K-RasV14I/V14I mice. The FS is the degree of shortening of the left 
ventricle diameter between end diastole and end systole and estimates the myocardial 
contractibility of the left ventricle. Hence, an increase in FS suggests enhanced myocardial 
contractibility. The CO is the volume of blood being pumped out by the left ventricle per 
minute. In K-RasV14I/V14I mice the volume of blood inside of the heart is bigger. However, due to 
the enhanced heart function, the heart is able to pump all the blood out. Therefore, the CO is 
also bigger (Table 6 in Appendix I). 
 Other parameters such as wall thickening in diastole (WTd), ejection fraction (EF) and 
heart rate (HR) were comparable in mutant and control mice.  
 These results suggest that K-RasV14I mice display an enlarged heart, but the increase of 
the heart size is not pathological. The cardiac function of K-RasV14I mice is preserved or 
enhanced and allows the correct function of this bigger heart. 
 
6.8.3 Myocardial expression of the K-RasV14I mutation 
 
 To determine if the postnatal expression of the K-RasV14I mutation in myocardial cells 
have an impact in the heart function, we crossed the conditional K-Ras+/LSLV14I mouse model 
with mice that express the Cre recombinase under the control of the α myosin heavy chain (α–
MHC) promoter. This promoter allows the expression of the mutation only in myocardial cells 
after birth. This strain also carried the Rosa26LSLLacZ allele to monitor the efficiency of the 
deletion of the “STOP” cassette by determining the number of LacZ expressing cells.  
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 X-Gal staining revealed an efficient deletion of the “STOP” cassette in myocardial cells. 
However, the pattern of Β-Gal positive cells in mutant mice was comparable to the wild type 
littermates at 4 months of age (Figure 24A). Interestingly, the expression of the K-RasV14I 
mutation in myocardial cells after birth had no obvious consequences. The size and the 
histology of mutant hearts were similar to the wild type littermates (Figure 24A and B). These 
results suggest that the expression of the mutant protein in myocardial cells of completely 
developed hearts is not associated to cardiac alterations. Therefore, the expression of the 
mutation during the development and/or in other cell types (for example: endothelial cells) is 
essential for the development of the heart abnormalities. 
 These observations are reminiscent of those previously reported in mouse models that 
express the Ptpn11D61Y (13) and K-RasG12D mutation (47) or overexpress the Ptpn11Q79R (145) 
mutation in myocardial cells, using the same promoter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
6.9 HEMATOLOGICAL DEFECTS OF K-RasV14I MICE  
 
 Individuals with NS display hepatoesplenomegaly (25%) and have predisposition to 
proliferative disorders, being the most common the MPD (10%) (10, 75). Noonan mouse 
models that express Ptpn11D61G, Raf1L613K or Sos1E846K mutations, developed hematological 
Figure 24. Postnatal myocardial expression of the K-RasV14I mutation does not cause cardiac 
alterations. (A) Top: X-Gal stained transverse section from 4-month-old K-Ras+/+; αMHC-Cre+/T; 
Rosa26+/LSLLacZ (+/+, +/Cre, +/Rosa26) and K-Ras+/LSLV14I; αMHC-Cre+/T; Rosa26+/LSLLacZ (+/V14I, +/Cre, 
+/Rosa26) mice. Bottom: H&E stained transverse section from 4-month-old K-Ras+/+; αMH -Cre+/T; 
Rosa26+/LSLLacZ (+/+, +/Cre, +/Rosa26) and K-Ras+/LSLV14I; αMHC-Cre+/T; Rosa26+/LSLLacZ (+/V14I, +/Cre, 
+/Rosa26) mice. (B) Heart weight (top) and heart/body weight (bottom) of 4-month-old K-Ras+/+; αMHC-
Cre+/T (+/+, +/Cre) and K-Ras+/LSLV14I; αMHC-Cre+/T (+/V14I, +/Cre) mice. Error bars indicate SD.  
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disorders characterized by splenomegaly, leukocytosis, myeloid expansion and increased IL-3 
and GM-CSF sensitivity, reminiscence of the alterations found in NS patients (14, 39, 237).  
 At 4 months of age, K-RasV14I/V14I animals (n=10) showed leukocytosis in peripheral 
blood, mainly due to expansion of neutrophil, eosinophil and basophil population. Mutant mice 
were also anemic and suffered from thrombocytopenia, a reduction of the platelet count (Table 
7 in Appendix I). Blood smear analysis showed the presence of high number of granulocyte 
immature cells. Heterozygous mice displayed intermediate phenotype. At this time, K-
RasV14I/V14I mice (n=12) displayed severe splenomegaly. Heterozygous K-Ras+/V14I mice (n=22) 
also had enlarged spleens albeit to a more limited extent (Figure 25A and B). H&E staining of 
spleen sections showed marked congestion and increased extramedullary hematopoiesis with 
loss of splenic architecture and expansion of the red pulp compartment. Histopathological 
analysis also revealed perivascular lymphoid and myeloid infiltrates in a variety of organs 
including liver, kidney and lung (Figure 25C).  
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Figure 25. Hematological disorders in 4-month-old K-RasV14I mice. (A) Spleen/body weight ratio in wild 
type (n=13) (+/+, open bars), K-Ras+/V14I (n=22) (+/V14I, gray bars) and K-RasV14I/V14I (n=12) (V14I/V14I, 
solid bars) mice. (B) Representative spleens of wild type (+/+), K-Ras+/V14I (+/V14I) and K-RasV14I/V14I (V14I) 
mice. Scale bar, 5 mm. (C) H&E stained paraffin sections of spleen, liver, lung, kidney and peripheral blood 
smears stained with May-Grünwald/Giemsa of wild type (+/+) and K-RasV14I/V14I (V14I) mice. Spleen, 
asterisks and arrowheads indicate the white and red pulp, respectively. Solid asterisks indicate 
immunoinfiltrates.  Scale bars, 100 µm for spleen, liver, kidney and lung and 20 µm for blood smears. 
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 Flow cytometry analysis revealed significant expansion of myeloid cells in the spleen of 
K-RasV14I/V14I (n=14) and K-Ras+/V14I (n=18) mutant mice with increased levels of both 
Gr1+/CD11b+ double positive and CD11b+ single positive cells (Figure 26A and B). The 
expansion of myeloid cells was associated with a concomitant decrease in the percentage of 
CD3+ T-cells, due to a significant decrease of CD8+ T-cells. However, the percentage of CD19+ 
B-cells and CD4+ T-cells in mutant mice was comparable to wild type littermates (Figure 26C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.9.1 Cytokines response of bone marrow progenitors 
 
 The proliferative capacity of bone marrow (BM) progenitors was assayed in 
methylcellulose cultures in presence of IL-3 and GM-CSF. BM cells of K-Ras+/V14I and K-
RasV14I/V14I mice, but not those of wild type animals, formed significant number of colonies in 
absence of exogenous cytokines. These colonies were of smaller size and less differentiated 
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Figure 26. Four month-old K-RasV14I mice display expansion of the myeloid lineage, concomitant with a 
decrease in the CD8 single-positive cells. (A). Flow cytometry analysis of Gr1+ and CD11b+ cells in spleens 
of wild type (+/+) and K-RasV14I/V14I (V14I/V14I) mice. (B) Percentages of CD11b+ and Gr1+/CD11b+ 
myeloid cells in spleens of wild type (n=12) (+/+, open bars), K-Ras+/V14I (n=18) (+/V14I, gray bars) and K-
RasV14I/V14I (n=14) (V14I/V14I, solid bars) mice. (B) Percentages of CD19+ B-cells and CD3+, CD4+ and 
CD8+ T-cells in spleens of wild type (n=12) (+/+, open bars), K-Ras+/V14I (n=18) (+/V14I, gray bars) and K-
RasV14I/V14I (n=14) (V14I/V14I, solid bars) mice. Error bars indicate SD. *P < 0.05; **P < 0.01. 
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than colonies that grew in the presence of cytokines. BM progenitors of mutant mice also 
demonstrated hypersensitivity to GM-CSF and IL-3 (Figure 27A). In presence of these 
cytokines, cells of K-Ras+/V14I and K-RasV14I/V14I mice form more and bigger colonies than the 
wild types (Figure 27B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The phenotype of the methylcellulose colonies was determined by microscopic 
visualization of May-Grünwald Giemsa-stained cytospin preparation of colonies after 12 days 
in culture. The cell morphology of the K-RasV14I/V14I and the wild type colonies was similar. In 
both cases, the cell appearance resembles granulocyte/macrophages; therefore most of the 
colonies are CFU-GM (colony forming unit-granulocyte macrophage) colonies (Figure 28).
 In conclusion, K-RasV14I developed a hematological disorder characterized by 
splenomegaly, leukocytosis, myeloid expansion and increased sensitivity to IL-3 and GM-CSF 
similar to MPD.  
 
 
Figure 27. Cytokine response of K-RasV14I BM progenitors (A). Number of colonies formed by BM cells 
obtained from 4-month-old wild type (n=3) (open circles), K-Ras+/V14I (n=3) (gray circles) and K-RasV14I/V14I 
(n=3) (solid circles) mice in the absence or presence of the indicated concentrations of IL3 and GM-CSF. 
Error bars indicate the SD. (B) Representative pictures of individual colonies formed by BM cells from 4-
month-old wild type (+/+), K-Ras+/V14I (+/V14I) and K-RasV14I/V14I (V14I/V14I) mice in the presence of 10 
ng/ml of IL3 (upper panel) and 1 ng/ml of GM-CSF (lower panel).  
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6.9.2 Germline K-RasV14I mutation increased HSC and lineage progenitor population 
 
 To investigate the mechanism by which expression of the K-RasV14I protein induced 
MPD, we analyzed the BM of 4-month-old K-RasV14I mice for the presence of Lineage–/Sca-
1+/c-Kit+ (LSK) cells, a population known to be enriched for hematopoietic stem cells (HSCs). 
As illustrated in Figure 29, K-RasV14I/V14I (n=9) and K-Ras+/V14I (n=15) mice displayed a 
significant increase in the frequency and absolute number of LSK cells in bone marrow.  
 To delineate the mechanism by which K-RasV14I mutation caused HSC expansion, 
proliferation and apoptosis status of LSK cells of K-RasV14I mice were analyzed and compared 
with those cells of control mice. The mutant LSK cells had a similar proliferation index, based 
on BrdU uptake, to that observed in cells obtained from control littermates (Figure 30A and B). 
However, the mutant LSK cells had reduced levels of Appendyxin V, a marker for apoptotic 
cells (Figure 30C and D). These results indicate that the expansion of HSC population in K-
RasV14I mice is due to a decreased programmed cell death rather than to an enhanced cell 
proliferation.  
 
 
 
 
 
 
 
 
 
Figure 28. GM-CSF colonies 
formed by K-RasV14I BM cells. May-
Grünwald Giemsa-stained cytospin of 
individual methylcellulose colonies 
formed by BM cells obtained from 4-
month-old wild type (+/+) and K-
RasV14I/V14I (V14I/V14I) mice in 
presence of 10 ng/ml of IL3 (upper 
panel) or 1 ng/ml of GM-CSF (lower 
panel).  	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Figure 29. K-RasV14I mice displayed an expansion of HSCs. (A) Flow cytometry analysis of freshly 
harvested BM cells of 4-month-old wild type (+/+) and K-RasV14I/V14I (V14I/V14I) mice using antibodies 
against c-Kit and Sca-1. The percentage of Lineage–/Sca-1+/c-Kit+ (LSK) cells is indicated. (B) Percentage 
of LSK cells in the BM of 4-month-old wild type (n=11) (+/+, open bars), K-Ras+/V14I (n=15) (+/V14I, 
gray bars) and K-RasV14I/V14I (n=9) (V14I/V14I, solid bars) mice. Error bars indicate SD. *P < 0.05. 
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 Using multiparameter flow cytometry analysis, we defined the effects of K-RasV14I 
mutation on hematopoietic cell development by quantification of the committed progenitors, 
including common myeloid progenitors (CMPs), common lymphoid progenitors (CLP), 
granulocyte-macrophage progenitors (GMPs) and megakaryocyte-erythroid progenitors 
(MEPs). This analysis revealed a significant increase in the absolute numbers of CMPs and 
GMPs, as well as a slight increase in CLPs. However, the absolute numbers of MEPs did not 
display significant alterations (Figure 31A and B). 
 These observations suggest that the expression of the K-RasV14I protein promotes 
expansion of the both HSCs and committed precursor of the myeloid lineage.   
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Figure 30. Expansion of LSK cells in BM of 4-month-old K-RasV14I mice. (A) Flow cytometry analysis 
of BrdU+ cells in LSK cells of wild type (+/+) and K-RasV14I/V14I (V14I/V14I) mice. (B) Percentage of 
LSK BrdU+ cells in BM of wild type (n=6) (+/+, open bars), K-Ras+/V14I (n=5) (+/V14I, gray bars) and K-
RasV14I/V14I (n=5) (V14I/V14I, solid bars) mice. Error bars indicate SD. (C) Flow cytometry analysis of 
Annexin V+ DAPI- cells in LSK cells of wild type (+/+) and K-RasV14I/V14I (V14I/V14I) mice. (D) 
Percentage of LSK apoptotic cells (Annexin V+ DAPI- cells) in BM of wild type (n=5) (+/+, open bars), K-
Ras+/V14I (n=8) (+/V14I, gray bars) and K-RasV14I/V14I (n=8) (V14I/V14I, solid bars) mice. Error bars 
indicate SD. **P < 0.01.  
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6.9.3 Stem cell origin of K-RasV14I-driven MPD 
 
 To determine whether the MPD displayed by K-RasV14I mice was due to the observed 
expansion of HSCs, we transplanted BM cells from wild type K-Ras+/+ (n=20) and K-Ras+/V14I 
(n=14) mice, backcrossed to the C57BL/6J background for four generations, into lethally 
irradiated C57BL/6J recipients. In mice, there are two different CD45 alleles: CD45.1 (Ly5.1) 
and CD45.2 (Ly5.2). The C57BL/6J.OlaHsd strain that we used, expresses the CD45.2 (Ly5.2) 
isotype. More than 99% of blood cells obtained from K-Ras+/V14I mice backcrossed for four 
generations, expressed the CD45.2 (Ly5.2) allele similar to the original strain (data not shown). 
For this reason, we chose this generation for the transplantation experiments.  
 Peripheral blood of recipient mice was analyzed at various intervals after transplantation 
(2 to 34 weeks). The bone marrow cells, regardless of whether they were obtained from wild 
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Figure 31. Aberrant hematopoietic cell development in 4-month-old K-RasV14I mice. Staining for LSK 
cells, common lymphoid progenitors (CLP), common myeloid progenitors (CMP), granulocyte-
macrophage progenitors (GMP), and megakaryocyte-erythroid progenitors (MEP) in the BM of wild type 
(+/+) and K-RasV14I/V14I (V14I/V14I) mice using antibodies against Lin, c-Kit, Sca-1, CD34, FcγR 
(CD16/32) and IL-7R (CD127). (D) Frequencies of CLP, CMP, MEP and GMP populations in BM cells 
were quantified in wild type (n=11) (+/+, open bars), K-Ras+/V14I (n=15) (+/V14I, gray bars) and K-
RasV14I/V14I (n=9) (V14I/V14I, solid bars) mice. Error bars indicate SD. *P < 0.05. 
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type or K-Ras+/V14I mice efficiently reconstituted the entire hematopoietic system in the recipient 
mice. At 2 weeks after transplantation, all the hematopoietic populations were detected at 
normal levels in both types of transplanted mice (data not shown). In contrast, mice inoculated 
only with PBS were defective for blood cells and died between 2 to 4 weeks after irradiation. 
This is indicative of the efficiency of the irradiation and tail vain inoculation of BM cells.  
 
 
 
 
  
 
 Regardless of the genotype, the BM cells reconstituted the hematopoietic system. 
However, only those animals transplanted with cells derived from K-Ras+/V14I mice developed 
MPD between 30 to 34 weeks after transplantation. The presence of the K-RasV14I mutation in 
the spleen of sacrificed mice was determined by PCR. As expected, spleens of mice inoculated 
with BM cells derived from K-Ras+/V14I mice carried in heterozygosity the K-RasV14I mutation 
(Figure 32). In these mice, white blood cell (WBC) counts in their peripheral blood were 
increased mainly due to expansion of neutrophils, eosinophils and basophils (Table 8 in 
Appendix I). Spleens of mice reconstituted with BM cells carrying the K-RasV14I mutation were 
enlarged (Figure 33A and B). Histopathological analysis revealed perivascular lymphoid and 
myeloid infiltrates in liver, kidney and lung (Figure 33C). Flow cytometry analysis showed an 
expansion of the myeloid cells CD11b+ and Gr1+/CD11b+ in spleen (Figure 33D and E). 
Finally, the percentage of LSK cells, as well as of CMP and GMP progenitors was also 
significantly increased in the BM of the reconstituted mice (Figure 34). 
 We can conclude that the MPD phenotype was reproduced in primary recipient mice 
transplanted with K-Ras+/V14I BM cells. Therefore, the pathogenic effect of the K-RasV14I 
mutation initiates at stem cell level. 
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Figure 32. Spleens of reconstituted mice carry the K-RasV14I mutated allele. PCR genotyping for the K-
RasV14I allele. Lanes 1-4: DNA isolated from spleen of mice transplanted with BM cells from K-Ras+/V14I 
mice sacrificed 30-34 weeks after transplantation. Lanes 5-6: DNA isolated from spleen of mice 
transplanted with BM cells from wild type mice sacrificed 30-34 weeks after transplantation. Lane 7: DNA 
isolated from control wild type MEFs. Lane 8: DNA isolated from control K-Ras+/V14I MEFs; Lane 9: water. 
Size of the wild type (WT, 430 bp) and K-RasV14I (V14I, 669 bp) alleles is indicated by arrowheads.  
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6.9.4 Activation of K-RasV14I mutation in hematopoietic cells 
 
 N-RAS and K-RAS mutations are present in approximately 30% of acute myeloid 
leukemias (AML), MPD and myelodysplastic syndromes (MDS) (24). In mice, the expression 
of the K-RasG12D mutation in the hematopoietic system, using the interferon (IFN)-inducible Cre 
(Mx1-Cre) rapidly induced a fatal MPD (27, 37). However, mice that expressed the N-RasG12D 
mutation in the hematopoietic compartment by the same approach developed an indolent MPD, 
and die due to a diverse spectrum of hematologic alterations that included MPD, a disorder that 
was reminiscence of human MDS, lymphoid expansion and histiocytic sarcoma (120). 
Figure 33. MPD in mice transplanted with BM from K-Ras+/V14I mice. (A) Spleens of mice transplanted 
with BM cells from wild type (+/+) and K-Ras+/V14I (+/V14I) mice sacrificed 30-34 weeks after transplantation. 
Scale bar, 5 mm. (B) Spleen/body weight ratio of mice transplanted with BM cells obtained from wild type 
(n=20) (+/+, open bars) and K-Ras+/V14I (n=14) (+/V14I, gray bars) mice sacrificed 30-34 weeks after 
transplantation. (C) H&E stained paraffin section of lung, liver and kidney of mice transplanted with BM cells 
obtained from wild type (+/+) and K-Ras+/V14I (+/V14I) mice sacrificed 30-34 weeks after transplantation. 
Solid asterisk indicate immunoinfiltrates. Scale bar, 500 µm. (D) Flow cytometry analysis of Gr1+ and CD11b+ 
cells in spleens obtained from mice transplanted with BM cells obtained from wild type (+/+) and K-Ras+/V14I 
(+/V14I) mice sacrificed 30-34 weeks after transplantation. (E) Frequencies of donor cell-derived myeloid 
CD11b+ and Gr1+/CD11b+ cells in mice transplanted with BM cells obtained from wild type (n=20) (+/+, open 
bars) and K-Ras+/V14I (n=14) (+/V14I, gray bars) mice sacrificed 30-34 weeks after transplantation. Error bars 
indicate SD. **P < 0.01; ***P < 0.001. 
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 To characterize the biological consequences of expressing the K-RasV14I mutation in 
hematopoietic cells we crossed the conditional K-Ras+/LSLV14I mice with the interferon-inducible 
Cre (Mx1-Cre) line. We performed the same study with the K-Ras+/LSLG12V mice in order to 
compare both mutations. The Mx1-Cre transgene directs efficient recombination in BM and in 
hematopoietic cells with high repopulating potential (107). The Mx1 promoter can be activated 
by administration of IFNα,  IFN-β or the synthetic double-stranded RNA [polyinosinic-
polycydilic acid (pIpC)], an INF inducer (107).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Four to five-weeks-old K-Ras+/+;Mx1-Cre+/T (n=7) and K-Ras+/LSLV14I;Mx1-Cre+/T (n=10) 
mice were treated with pIpC to induce expression of the Cre recombinase and the subsequent 
expression of the K-RasV14I allele after excision of the floxed STOP cassette. K-RasV14I mutant 
and wild type control mice were sacrificed at 9 months (n=4) and 15 months (n=5 and n=3 
respectively) of age. One of the K-Ras+/LSLV14I;Mx1-Cre+/T mice succumbed before reaching 15 
months of age due to hematological alterations. At the analyzed time points (9 and 15 months) 
mutant mice developed progressive leukocytosis due to an expansion in the lymphoid, 
neutrophils, eosinophils and basophils population (data not shown). Mutant 9-month-old mice 
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Figure 34. Aberrant hematopoiesis in mice transplanted with BM from K-Ras+/V14I mice. (A) 
Flow cytometry analysis of BM cells obtained from mice transplanted with BM cells of wild type (+/+) 
and K-Ras+/V14I (+/V14I) mice sacrificed between 30 to 34 weeks after transplantation, using 
antibodies against c-Kit and Sca-1. The percentage of LSK cells is indicated. (B) Percentage of LSK 
donor-derived cells in mice transplanted with BM cells obtained from wild type (n=20) (+/+, open bar) 
and K-Ras+/V14I (n=14) (+/V14I, gray bar). (C) Percentage of CLP, CMP, MEP, and GMP cells in mice 
transplanted with BM cells obtained from wild type (n=20) (+/+, open bars) and K-Ras+/V14I (n=14) 
(+/V14I, gray bars) mice. Error bars indicate SD. **P < 0.01; ***P < 0.001. 
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displayed a slight increase in the spleen/body weight ratio compared to control mice (Figure 
35A and B). Histological analysis revealed the presence of small perivascular immunoinfiltrates 
in all tissues analyzed, such as kidney, liver and lung. The progression of the hematological 
alteration was evident at 15 months of age since spleen of mutant mice was significantly bigger, 
as well as the area of tissues affected by the immunoinfiltrates, being the lung the more affected  
(Figure 35). Similar results we obtained with the oncogenic K-RasG12V mutation, but in this 
case the development of the disease was faster (data not shown). Most of the mice were 
sacrificed at humane end point between 6 to 12 months old.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Therefore, we can conclude that the expression of the K-RasV14I mutation in 
hematopoietic cells is associated with the development of a hematological disorder similar to 
the MPD induced by the K-RasV14I germline expression and by the expression in the 
hematopoietic compartment of the oncogenic K-Ras isoforms, K-RasG12D and N-RasG12D (27, 
37, 120). However, the progression of the disease is slower in the K-RasLSLV14I;Mx1-Cre+/T mice 
than in the K-RasLSLG12D;Mx1-Cre+/T mice, since most of the K-Ras+/LSLV14I;Mx1-Cre+/T mice 
Figure 35. K-RasV14I expression induces the development of a hematological disorder. (A) Spleen 
weight of K-Ras+/+; Mx1-Cre+/T (+/+; +/Cre, gray bar) and K-Ras+/LSLV14I; Mx1-Cre+/T (+/V14I; +/Cre, solid 
bar) mice at 9 (n=4 and n=4, respectively) and 15 (n=3 and n=5, respectively) months of age. (B) 
Spleen/body weight of K-Ras+/+; Mx1-Cre+/T (+/+; +/Cre, gray bar) and K-Ras+/LSLV14I; Mx1-Cre+/T (+/V14I; 
+/Cre, solid bar) mice at 9 (n=4 and n=4, respectively) and 15 (n=3 and n=5, respectively) months of age. 
Error bars indicate SD. *P < 0.05. (C) H&E stained paraffin section of spleen, lung, liver and kidney of K-
Ras+/+; Mx1-Cre+/T (+/+; +/Cre) and K-Ras+/LSLV14I; Mx1-Cre+/T (+/V14I; +/Cre) mice sacrificed at 15 
months of age. Solid asterisks indicate immunoinfiltrates.  
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were alive at 15 months of age (83%; 5/6 mice), a time at which most of the K-
Ras+/LSLG12D;Mx1-Cre+/T (27, 37) and K-Ras+/LSLG12V;Mx1-Cre+/T mice succumbed by the 
progression of the disease. 
 
6.10 EFFECT OF MODIFIER ALLELES: GENETIC BACKGROUND AFFECTS NS 
PHENOTYPE 
 
 K-RasV14I/V14I mice in a mixed B6/129 background displayed significant perinatal 
lethally due to cardiovascular problems. However, 10% of these mice obtained from crosses 
between heterozygous mice, overcame these problems and survived. The incomplete penetrance 
of this perinatal lethality could reflect modifier alleles in one or the other strain or stochastic 
events. To distinguish between these possibilities, we backcrossed K-RasV14I mice to C57BL/6J 
and 129S2/Sv backgrounds. Heterozygous mice were viable and were obtained as expected 
Mendelian ratios in both genetic backgrounds for at least seven generations. However, 
homozygous mice were no viable when we intercrossed heterozygous mice backcrossed to the 
C57BL/6J background for five generations. At embryonic days E13.5 and E18.5, homozygous 
C57BL/6J mice appeared at the expected Mendelian ratio (data not shown). However, no 
C57BL/6J K-RasV14I/V14I mice were found at P0. In contrast, backcrosses to the 129S2/Sv 
resulted in a significant perinatal lethality at the fifth generation, similar to the mix B6/129 
background. Around 13% of the 129S2/Sv homozygous mice obtained from crosses between 
heterozygous mice, were born and reached adulthood (Table 9 in Appendix 1). 
 Therefore, we can conclude that the phenotypic consequences of the C57BL/6J 
background might be more aggressive, at least during embryonic and/or perinatal development, 
than those of 129S2/Sv background.  
 
6.10.1 Phenotypic consequences of the genetic backgrounds on the body size and facial 
dysmorphia 
 
 To determine the effect of modifier alleles on mice development, we followed up the 
body weight and body length of mutant and control mice backcrossed to the C57BL/6J or 
129S2/Sv backgrounds for five generations.  
 The weight and body size of C57BL/6J K-Ras+/V14I mice (n=25) was comparable to wild 
type animals (n=30). Similar to the C57BL/6J background, no differences were found between 
129S2/Sv heterozygous (n=21) and control mice (n=14). However, 129S2/Sv K-RasV14I/V14I 
mice (n=8) displayed significant reduced body size and body length compared to the wild type 
littermates. These differences persisted for at least 3 months (Figure 36).  
  Results 
	   	   	  101	  
 We also studied the effect of modifier alleles on the craniofacial alteration. We analyzed 
the different skull parameters by micro-CT in 4-month-old mice for five generations to 
C57BL/6J or 129S2/Sv genetic backgrounds.  The skull alterations (increased skull width and 
height, reduced length and bigger skull volume) were less pronounced in heterozygous mice of 
pure C57BL/6J and 129S2/Sv genetic backgrounds. However, 129S2/Sv homozygous mice 
displayed more evident skull alterations than the B6/129 homozygous mice (Table 10 in 
Appendix I). 
 
 
 
 
 
 These results suggest that the growth and the facial appearance phenotype of 
heterozygous mice became ameliorated or disappeared in the C57BL/6J or 129S2/Sv pure 
genetic backgrounds compared to the mix background. However, the phenotype of 129S2/Sv 
homozygous mice was similar or more dramatic than in the mix B6/129 homozygous mice.  
 
6.10.2 Phenotypic consequences of the genetic backgrounds on cardiac and hematopoietic 
alterations 
 
 To determine the effect of modifier alleles on the cardiac and hematopoietic phenotype, 
we sacrificed 4 month-old mutant and control mice after the fifth-generation backcross onto 
C57BL/6J or 129S2/Sv backgrounds.  
 Heart weight and heart/body weight ratio of C57BL/6J and 129S2/Sv heterozygous 
mice were bigger compared to the wild type littermates. This increase was similar in both 
genetic backgrounds and was comparable to the mix B6/129. The heart of K-Ras+/V14I mice was 
24% heavier in the C57BL/6J background (n=14), 26% in the 129S2/Sv background (n=10) and 
16% in the B6/129 mix background (n=30) than control mice. In contrast, cardiac phenotype of 
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Figure 36. Phenotypic consequences 
of the genetic backgrounds on the 
body size. Growth curves of male mice 
backcrossed for five generations to 
C57BL/6J and 129S2/Sv genetic 
backgrounds.. Body weight (Top) and 
body length (bottom) of wild type 
(n=30 and 14, respectively) (open 
circles), K-Ras+/V14I (n=25 and 21, 
respectively) (gray circles) and K-
RasV14I/V14I (n=8) (solid circles) male 
mice. Error bars indicate SD. *P < 0.05; 
**P < 0.01; ***P < 0.001.  
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homozygous mice was ameliorated in 129S2/Sv compared to the B6/129 mix background. The 
heart of 129S2/Sv K-RasV14I/V14I mice (n=5) was 32% heavier than control mice, while heart of 
homozygous B6/129 mice (n=13) was 57% heavier than the wild type littermates (Figure 37A).   
 In the context of the hematopoietic alterations, this phenotype was more dramatic in the 
C57BL/6J background. Mutant mice showed an increase in the number of leukocytes in 
peripheral blood, mainly due to expansion of neutrophils, eosinophils and basophils population. 
They were also anemic and suffered from thrombocytopenia (Table 11 in Appendix I). The 
spleen of C57BL/6J heterozygous mice (n=14) was 3 times bigger than the control mice (n=9), 
while the spleen of B6/129 heterozygous mice (n=22) was only 2 times bigger than the control 
mice (n=13). Similar results were obtained when we compared the spleen/body weight ratio 
(Figure 37B). However, the life span of C57BL/6J heterozygous mice was similar to the 
B6/129 heterozygous mice (half-life of 64 weeks vs 62 weeks) (Figure 36).  
 
 
 
  
 
  
 
 In contrast, this phenotype became ameliorated in the 129S2/Sv genetic background. 
Homozygous and heterozygous mice displayed a significant increase in spleen weight and 
spleen/body weight ratio. However, while spleen of B6/129 homozygous mice (n=12) was 5 
times bigger than the control mice (n=13), the spleen of 129S2/Sv homozygous mice (n=5) was 
only 3 times bigger that the wild type mice (n=10). In contrast, the spleen of B6/129 (n=22) and 
129S2/Sv (n=10) heterozygous mice was 2 times bigger than their corresponding controls. 
Similar results were obtained when we compared the spleen/body weight ratio of homozygous 
and heterozygous mice of both genetic backgrounds (Figure 37B). Blood count analysis also 
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Figure 37. Phenotypic consequences 
of the genetic backgrounds on cardiac 
and hematopoietic phenotype. (A) 
Right: Heart/body weight ratio of 4- 
month-old wild type (n=9) (+/+, open 
bars) and K-Ras+/V14I (n=14) (+/V14I, 
gray bars) C57BL/6J male mice. Left: 
Heart/body weight ratio of 4-month-old 
wild type (n=10) (+/+, open bars), K-
Ras+/V14I (n=10) (+/V14I, gray bars) and 
K-RasV14I/V14I (n=5) (V24I/V14I, solid 
bars) 129S2/Sv male mice. (B) Right: 
Spleen/body weight ratio of 4-month-old 
wild type (n=9) (+/+, open bars) and K-
Ras+/V14I (n=14) (+/V14I, gray bars) 
C57BL/6J male mice. Left: Spleen/body 
weight ratio of 4-month-old wild type 
(n=10) (+/+, open bars), K-Ras+/V14I 
(n=10) (+/V14I, gray bars) and K-
RasV14I/V14I (n=5) (V14I/V14I, solid 
bars) 129S2/Sv male mice. Error bars 
indicate SD. **P < 0.01; ***P < 0.001.  
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confirmed that the MPD is ameliorated in the 129S2/Sv background, at least in homozygous 
mice. No blood alterations were found at 4 months of age in heterozygous mice and 
homozygous mice only displayed leukocytosis (Table 11 in Appendix I). All together resulted 
in longer life span with a half-life of 82 weeks in K-Ras+/V14I mice (a 32% increase in the life 
span compared to B6/129 heterozygous mice) and of 57 weeks in K-RasV14I/V14I mice (a 58% 
increase in the life span compared to B6/129 homozygous mice) (Figure 38). 
 
 
 
 
 
 
 
 
 
   
 Together these results suggest no effect of modifier alleles on the cardiac alterations, 
since the phenotype observed in the three different backgrounds was similar However, the 
hematopoietic phenotype is sensitive to the presence of modifier alleles of these genetic 
backgrounds, being these alterations more remarkable in the C57BL/6J genetic background.  
 
6.11 CANCER RISK IN K-RasV14I mice 
 
 Patients with NS have high predisposition for benign and malignant proliferative 
disorders (91). This study, performed in a large cohort of patients with NS carrying the PTPN11 
mutation, describes that these patients have increased tumor risk (91). Regardless of this study, 
data on the incidence of malignancies in NS is incomplete, since there is no follow up in the 
adulthood and there are no studies about the tumor risk of different NS-associated mutations.  
 Our objective was to estimate the cancer risk and tumor spectrum of K-RasV14I mutant 
mice. Considering the universal role of RAS-MAPK signaling in oncogenesis, we hypothesized 
that the K-RasV14I gain of function mutation might confer an increased risk for developing a 
broad range of malignancies, including tumors in which K-RAS is preferentially mutated: 
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Figure 38. Phenotypic consequences of the genetic backgrounds on the survival rate. Left: survival 
curve of wild type (n=5; open circles) and K-Ras+/V14I (n=22; gray circles) C57BL/6J mice. Right: survival 
of wild type (n=9; open circles), K-Ras+/V14I (n=15; gray circles) and K-RasV14I/V14I (n=9; solid circles) 
129S2/Sv mice.  
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pancreatic ductal adenocarcinomas, colorectal cancer and lung adenocarcinomas (60).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 As described above, K-Ras+/V14I and K-RasV14I/V14I mice presented reduced life span with 
a half-life of 62 and 36 weeks, respectively (Figure 10) due to the development of 
Table 2. Summary of pathological alterations found in K-Ras+/V14I and K-RasV14I/V14I mice sacrificed at humane 
end point   
Numbers in parentheses indicate tumor incidence. Total percentage > 100% due to the fact that some mice 
developed more than one tumor type. See table 12 in Appendix I for more details. 
 
Neoplastic malignancies K-Ras+/V14I (n=26) K-RasV14I/V14I (n=12) 
Lymphoma 16  (61%) 8  (67%) 
       B-cell lymphoma 3  (11%) 0    (0%) 
       Lymphoblastic lymphoma 1    (4%) 0    (0%) 
Histiocytic sarcoma 5  (19%) 3  (25%) 
Myeloid leukemia 2    (8%) 0    (0%) 
Angiosarcoma 1    (4%) 0    (0%) 
Adenocarcinoma 4  (12%) 1    (8%) 
       Lung 2    (8%) 0    (0%) 
       Liver 2    (8%) 0    (0%) 
       Adenohypophysis 0    (0%) 1    (8%) 
Adenoma 6  (23%) 0    (0%) 
       Lung 1    (4%) 0    (0%) 
       Liver 1    (4%) 0    (0%) 
       Intestine 3  (11%) 0    (0%) 
       Epipidymis 1    (4%) 0    (0%) 
   
Other pathological alteration K-Ras+/V14I (n=26) K-RasV14I/V14I (n=12) 
Kidney alterations  2    (8%) 8  (67%) 
       Hydronephrosis  1    (4%) 3  (25%) 
       Glomerulonephritis 1    (4%) 1    (8%) 
       Pyelonephritis 0    (0%) 5  (42%) 
Vasculitis 3  (11%) 0    (0%) 
Infarctation area in heart 2    (8%) 1    (8%) !
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hematopoietic alterations characterized by splenomegaly, leukocytosis and anemia (Table 12 in 
Appendix I). Complete histological evaluation of K-Ras+/V14I (n=26) and K-RasV14I/V14I mice 
(n=12) sacrificed at humane end point, revealed the presence of multiple malignancies including 
lymphomas, sarcomas and carcinomas. Tumor development was slightly more prevalent in K-
Ras+/V14I (24/26, 92%) than in K-RasV14I/V14I mice (9/12, 75%) possibly due to their longer 
survival. Among the observed tumors, lymphomas were most frequent followed by sarcomas, 
preferentially histiocytic sarcomas and adenocarcinomas. Two K-Ras+/V14I animals also 
developed leukemia. Other pathologies included kidney alterations (hydronephrosis, 
glomerulonephritis and pyelonephritis), possibly as a consequence of the hematological 
disorders, vasculitis and areas of heart infarctation (Table 2 and Table 12 in Appendix I). 
 All these results suggest that K-RasV14I mice develop a MPD that in combination with a 
diverse spectrum of hematological disorders including lymphomas, histiocytic sarcomas and 
leukemia ultimately result in the death of the mice. Moreover, germline expression of the K-
RasV14I mutation induces the development of some adenomas and adenocarcinomas.  
 
6.11.1 Role of K-RasV14I in lung tumor development 
  
 Mutations of the K-RAS oncogene are found in 35% of human lung adenocarcinomas 
(60). In mice, the postnatal/adult expression of one allele of the oncogenic K-RasG12D or K-
RasG12V mutation in adults induces the appearance of lung adenomas/adenocarcinomas and 
pancreatic tumors (69, 86, 221).  
 The K-RasV14I mutation is a gain of function mutation that results in milder activation of 
the protein compared to the somatic oncogenic form. This mutation is compatible with embryo 
development and does not induce the appearance of pancreatic tumors. Moreover, only 8% 
(2/26) of K-Ras+/V14I mice developed lung adenocarcinomas and no lesions were found in K-
RasV14I/V14I mice. This mutation, in contrast to the oncogenic ones, is present throughout 
development in all the cells in the organism. Thus, the cells may have been adapted to these 
levels of activation, assuming them as normal in some tissues. It is also possible that the mice 
die of hematologic malignancies without having time to develop other pathologies. 
 To test this possibility, we used the conditional K-Ras+/LSLV14I strain to achieve the 
induction of the expression of the K-RasV14I mutation in adult stages in lung. We performed an 
intratracheal infection of two-month old conditional K-Ras+/LSLV14I mice with adenoviral vectors 
expressing the Cre recombinase (21). This strain also carried the Rosa26LSLLacZ reporter allele to 
monitor the efficiency of the infection by determining the number of LacZ expressing cells. In 
parallel, we infected K-Ras+/LSLVG12Vgeo mice as control for tumor development.  
  X-Gal staining of lungs of K-Ras+/LSLV14I;Rosa26LSLLacZ or K-Ras+/+;Rosa26LSLLacZ 
infected mice at 5 months of age (n=3) revealed the presence of similar percentages of LacZ 
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positive cells, indicative of the efficiency of the infection (Figure 39). However, expression of 
the K-RasV14I allele in adult lungs did not induce any lesions in K-RasV14I mice at 18 months of 
age (n=12) (Figure 39), a time when, as expected (21), all the K-Ras+/LSLVG12Vgeo animals had 
died due to the presence of numerous lung tumors (data not shown). These observations indicate 
that the K-RasV14I mutation does not have enough oncogenic properties to elicit lung tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
6.11.2 Role of K-RasV14I in pancreatic tumor development 
 
 We interrogated whether the K-RasV14I mutation may increase tumor risk in the context 
of chronic pancreatitis, a condition that has been shown to cooperate with oncogenic K-Ras 
mutations to induce pancreatic ductal adenocarcinomas (PDAC) (69, 70), one of the human 
tumors with worst prognosis (199).  
 
 
 
 
 
 
 
 
Figure 40. K-RasV14I expression induced PanIN lesions in pancreatitis context. (A) K-RasV14I mice were 
exposed to caerulein (gray box) for 6 months. The open box indicates the time of the K-RasV14I expression. 
The number of animals positive for low-grade PanIN1 and high-grade PanIN2/3 lesions is indicated for 
each time point. (B) H&E stained paraffin sections of pancreas of wild type (+/+) and K-RasV14I/V14I 
(V14I/V14I) mice treated with caerulein during 6 months and sacrificed just after the end of the treatment. 
Asterisk indicates a PanIN3 lesion.  
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Figure 39. Expression of the K-RasV14I mutation in lung does not induce tumor development. 
Left: X-Gal stained section from 5-month-old K-Ras+/LSLV14I; Rosa26+/LSLLacZ infected intratracheally 
with adeno-Cre. Right: H&E stained section from 18-month-old K-Ras+/LSLV14I; Rosa26+/LSLLacZ 
infected intratracheally with adeno-Cre illustrating the absence of lesions.  
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 Two-month-old K-Ras+/V14I (n=15) and K-RasV14I/V14I (n=13) mice were treated with 
caerulein for six months and sacrificed either at the end of the treatment or three months later 
for pathology inspection (Figure 40A). Just after caerulein treatment, 5 out of 8 K-Ras+/V14I 
mice (62%) and 7 out of 8 K-RasV14I/V14I mice (87%) displayed low-grade pancreatic 
intraepithelial neoplasias (PanIN1), the early lesions observed during PDAC development. 
Moreover, 3 out of 8 K-Ras+/V14I mice (37%) and 7 out of 8 K-RasV14I/V14I mice (87%) also 
developed high-grade PanIN2 and PanIN3 lesions (Figure 40A), the later also called “in situ” 
carcinomas, the direct PDAC precursors. Yet, no bona fide PDAC tumors were identified in K-
RasV14I mice. Three months after the caerulein treatment PanIN lesions were also found. 60% 
(3/5) of K-RasV14I/V14I mice displayed low-grade PanIN lesions and high-grade PanIN lesions 
could be found in 3 out of 5 mice (60%). Only one mouse out of seven K-Ras+/V14I mice 
displayed low and high-grade PanINs. Again, no bona fide PDAC tumors were identified at this 
time. As expected no lesions were found in wild type animals either just after caerulein 
treatment (n=3) (Figure 40B) or three months after the treatment (n=4). Furthermore, the 
caerulein treatment induced a tissue remodeling at the stroma level and acinar atrophy (Figure 
40B) similar to that observed in K-RasLSLG12Vgeo ;Elas-tTA/tetO-Cre mice (70). 
 These observations indicate that K-RasV14I protein has oncogenic potential in the 
context of pancreatic tumor development but at a significant reduced level compared to the 
bona fide oncoproteins K-RasG12D and K-RasG12V (70, 80). 
 Trp53 deficiency cooperated with the oncogenic K-RasG12V mutation to induce 
metastatic PDAC (70). A small group of K-Ras+/V14I;Trp53-/- mice was used to study 
cooperation between K-RasV14I expression and Trp53 loss in PanIN and PDAC development 
(n=4) in the context of caerulein treatment. These mice were sacrificed at humane end point due 
to lymphoma and sarcoma development (see 6.11.5 section), during the course of caerulein 
treatment (around three months after the beginning of the treatment at P30). Pancreata of these 
mice were removed for pathology inspection. Three out of four mice displayed low and high-
grade PanIN lesions and no bona fide PDAC tumors were found, similar to the results obtained 
in K-Ras+/V14I mice with wild type Trp53 (data not shown). These results indicate that loss of 
Trp53 did not cooperate with K-RasV14I mutation to induce pancreatic tumor development, in 
contrast to the K-RasG12V mice. However, K-Ras+/V14I;Trp53-/- mice died around three months 
after the beginning of the treatment. Therefore, it is possible that the length of the study might 
not be enough to rule out a possible cooperation. Experiments with heterozygous Trp53+/- mice 
treated with caerulein for six months might help to unveil this issue. 
 Finally, we generated a K-Ras+/LSLV14I;Elas-tTA/tetO-Cre mice in order to perform a 
comparative study to the pancreatic tumor model developed in the laboratory, K-RasLSLG12Vgeo 
;Elas-tTA/tetO-Cre mice (70). Both conditional compound mice carry a bitransgenic strain that 
expresses the Cre recombinase in acinar cells under the control of the rat Elastase promoter 
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using a tet-off strategy (Tetracycline-controlled transcriptional activation). By this conditional 
strategy the transcription of the Cre recombinase is activated in the absence of the antibiotic 
tetracycline or doxycycline (one of its derivates), leading to its expression in acinar cells. 
 Two-month-old K-Ras+/LSLV14I;Elas-tTA/tetO-Cre mice (n=10), maintained in absence 
of doxycycline, were treated with caerulein for six months and sacrificed just after treatment for 
histological analysis. This analysis revealed that only three mice (30%) displayed low-grade 
PanIN lesions. High-grade PanIN lesions were found only in one of them (Figure 41). 
Moreover, a group of ten K-Ras+/LSLV14I;Elas-tTA/tetO-Cre mice was sacrificed 6 months after 
the end of the caerulein treatment. In this cohort of mice, only one mouse displayed high-grade 
PanIN lesions and no mice displayed low-grade PanIN lesions (Figure 41). Furthermore, one 
mouse was sacrificed only 4 months after caerulein treatment due to humane end point. This 
mouse developed a high-grade PanIN3, similar to PDAC.  
 
 
 
 
 
 
 
 
 
 
 The number of lesions and the number of K-Ras+/LSLV14I;Elas-tTA/tetO-Cre affected 
mice was much lower than in the case of the K-RasLSLG12Vgeo ;Elas-tTA/tetO-Cre mice (68, 70). 
Furthermore, these results suggest that the expression of the K-RasV14I mutation only in acinar 
cells induces lower incidence of PanIN lesions than the germline expression of this mutation. In 
the K-Ras+/LSLV14I;Elas-tTA/tetO-Cre conditional mice, expression of the K-Ras activated 
mutation takes place in around 30% of acinar cells starting at E16.5 of embryo development. It 
is a low percentage compared to the K-RasV14I Noonan model in which the expression takes 
place in all cells since germline. The low transforming capacity of the K-RasV14I mutation and 
the low percentage of cells expressing the mutation in this model might explain the small 
number of PanIN lesions found in the K-Ras+/LSLV14I;Elas-tTA/tetO-Cre mice.  
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Figure 41. K-RasV14I expression in acinar cells induced low number of PanIN lesions in the context of 
pancreatitis. K-Ras+/LSLV14I;Elas-tTA/tetO-Cre mice were exposed to caerulein (gray box) for 6 months. 
The open box indicates the time of the K-RasV14I expression. The number of animals positive for low-grade 
PanIN1 and high-grade PanIN2/3 lesions is indicated for each time point.  
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6.11.3 Nicotine increases tumor risk of K-RasV14I expressing mice 
 
 Smoking is the most important risk factor for lung cancer, since 85-90% of the cases 
can be attributed to tobacco smoking in men (219). Moreover, smoking has been identified as a 
leading risk factor for PDAC development. Almost one fourth of deaths in patients with PDAC 
are linked to tobacco use (130) and smoking a pack of cigarettes or more a day is associated 
with a five-to six-fold increased risk of developing pancreatic cancer (127). Among the 
thousands of substances contained in tobacco smoke, nicotine has been the most widely studied 
due to its addictive properties. Several in vitro studies using cancer cell lines have demonstrated 
that nicotine increases cell proliferation, migration and survival by activating components of the 
MAPK, PI3K and Src pathway (48, 232). Moreover, nicotine administration promotes tumor 
growth in lung and pancreatic cancer mouse models (49, 77, 143).  
 We interrogated whether nicotine administration may increase tumor risk of K-RasV14I 
mice. To this aim, we exposed mutant and wild type mice at 2 months of age to continuous 
treatment of nicotine in the drinking water. K-RasV14/V14I mice were sacrificed at humane end 
point due to development of hematological disorders (see 6.11 section) after 4 months (n=1) and 
10 months (n=2) of nicotine treatment. Pancreata and lungs of these mice were histologically 
analyzed. Two out of three mice displayed adenocarcinomas in lung and one out of three 
displayed a sarcomatoid PDAC (Figure 1 in Appendix I). Interestingly, these lesions appeared 
independently of the length of nicotine treatment (Figure 42). In contrast, no lesions were found 
in wild type mice exposed to nicotine for 12 months (n=3). Although nicotine treatment 
promoted tumor development in K-RasV14/V14I mice, the effect was less aggressive than in the 
case of K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre mice, which pancreas were severely affected by 
high numbers of PanIN lesions (Hermann PC and Heeschen Ch, unpublished data).  
 
 
 
 
 
 
  
 These preliminary studies suggest that nicotine administration enhanced the oncogenic 
properties of the K-RasV14I mutation. Therefore, tobacco smoking in patients that express K-
Ras-NS-associated mutation might increase the risk of lung and pancreatic tumor development.  
Figure 42. Nicotine increases tumor risk in K-RasV14I mice. K-RasV14I mice were exposed at 2 months of 
age to continuous nicotine administration (gray box). The number of mice affected by lung 
adenocarcinomas and PDAC lesions and the sacrifice time point are indicated. 
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6.11.4 Loss of heterozygosity (LOH)  
 
 Loss of heterozygosity (LOH) or deletion of the wild type allele is a common secondary 
event detected in advanced tumors. In mice, loss of one wild type K-Ras allele increases lung 
tumor development by carcinogens (244). Furthermore, data of our laboratory also indicates that 
the elimination of the wild type allele in mice that express one copy of the oncogenic K-RasG12V 
mutation results in earlier onset and fast progression of lung tumors and reduced life span (33). 
These observations suggest that loss of the wild type K-Ras allele may facilitate transformation 
and tumorigenesis mediated by the oncogenic Ras mutations.  
 To address if the elimination of the wild type allele increases the oncogenic potential of 
the K-RasV14I expression, we crossed our K-Ras+/V14I mice with heterozygous K-Ras deficient 
mice, K-Ras+/-, developed in our laboratory. Hemizygous K-RasV14I/- mice (n=14 out of 61 mice 
obtained from crosses between K-Ras+/V14I and K-Ras+/- mice, 23%) were born at expected 
Mendelian ratio and at 4 months of age (n=12) displayed enlarged heart and splenomegaly 
mimicking the phenotype of the K-RasV14I mice (data not shown). K-RasV14I/- mice (n=29) died 
due to the development of hematological disorders and the survival rate was similar to the K-
Ras+/V14I mice (n=68), with a small not significant reduction of the half-life (54 weeks vs. 62 
weeks), which is still far from the half-life of K-RasV14I/V14I mice (n=30; 36 weeks) (Figure 43). 
Therefore, the elimination of the wild type allele did not affect the progression of the 
hematological disorder, since the survival of mice that express one copy of the K-RasV14I allele 
with or without the wild type allele is similar (Figure 43). Furthermore, we did not observe any 
other pathology in K-RasV14I/- mice different from the previously described in K-Ras+/V14I or K-
RasV14I/V14I mice (data not shown). 
 
 
 
 
 
 
 
 
 
 
Figure 43. Loss of the wild type copy of K-Ras had no effects in the survival rate. Survival curve of wild 
type (n=; 25open circles), K-Ras+/V14 (n=68; gray circles), K-RasV14I/V14I (n=30; solid circles) and K-RasV14I/- 
(n=29; blue circles) mice.  
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6.11.5 Cooperation between K-RasV14I mutation and tumor suppressors genes  
 
 Next, we examined whether the K-RasV14I mutation cooperated with other oncogenic 
mutations such as loss of tumor suppressor genes including p16Ink4a/p19Arf and Trp53.  
 p16Ink4a/p19Arf deficient mice developed spontaneous tumors at early age including 
lymphomas and sarcomas, mainly fibrosarcoma (191). Elimination of p16Ink4a/p19Arf in K-
RasV14I/V14I mice (n=9), but not in their heterozygous littermates (n=13), led to a 15% reduction 
in life span (Figure 44). K-RasV14I/V14I;p16Ink4a/p19Arf –/– mice died due to a faster 
development of hematopoietic malignancies, mainly lymphomas (3 out of 8 histological 
analyzed mice) and histiocytic sarcomas (7 out of 8 histological analyzed mice) spreading to 
different organs (Table 13 in Appendix I, Figure 45 and Figure 2 and 3 in Appendix I). All 
these tumors are characteristic of the p16Ink4a/p19Arf deficient mice (191). However, the 
incidence of these tumors was different. Only one histiocityc sarcoma (11%; 1 out of 9) was 
reported in p16Ink4a/p19Arf deficient mice (191). This is a very low percentage compared to 
the incidence of this malignance in K-RasV14I/V14I;p16Ink4a/p19Arf –/– mice (87%; 7 out of 9). 
Interestingly, no fibrosarcomas were found in the K-RasV14I/V14I;p16Ink4a/p19Arf–/– mice. 
Therefore, these results suggest that the elimination of p16Ink4a/p19Arf in mice that express 
two copies of the K-RasV14I mutation promotes the development of hematological abnormalities, 
preferentially histiocytic sarcomas, more than mesenchymal tumors like fibrosarcomas.  
 
 
 
 
 
 
 
 
 The K-RasV14I mutation also cooperated with loss of Trp53. K-Ras+/V14I;Trp53–/– mice 
(n=27) died significantly faster (50% survival at 15 vs. 20 weeks, a 25% reduction in life-span) 
than Trp53 null animals (n=9) (Figure 44). Trp53 deficient mice spontaneously developed a 
variety of neoplasm at 6 months of age, including lymphomas and sarcomas (52). These tumors 
had also been found in the K-Ras+/V14I;Trp53-/– mice (Table 14 in Appendix I, Figure 45). 
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Figure 44. K-RasV14I cooperates with loss of tumor suppressor genes. Left: survival curve of K-Ras+/+; 
p16Ink4a/p19Arf –/– (n=6, open triangles), K-Ras+/V14I; p16Ink4a/p19Arf –/– (n=13, gray triangles) and K-
RasV14I/V14I; p16Ink4a/p19Arf –/– (n=9, solid triangles) mice. Right: survival curve of K-Ras+/+;Trp53–/– (n=9, 
open squares) and K-Ras+/V14I;Trp53–/– (n=27, gray squares)  mice.  
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Therefore, the reduction in life span was not due to the appearance of different tumor types. 
Histological examination of K-Ras+/V14I;Trp53–/– mice (n=10) revealed the presence of more 
aggressive tumors. Lymphomas spread to more organs (Figure 4 in Appendix I) and the 
angiosarcomas were multicentric (Figure 5 in Appendix I). Furthermore, most of the mice 
(7/10) were affected by more than one tumor. These results suggest that this survival reduction 
is due to an increase in the number of tumors as well as to their more aggressive nature.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Thus far, we were not able to obtain K-RasV14I/V14I;Trp53–/– mice. From crosses between 
K-Ras+/V14I;Trp53–/– and K-Ras+/V14I;Trp53+/– mice, only rests of two pups were found just after 
birth and the genotype by PCR indicated that they were K-RasV14I/V14I;Trp53–/–. However, two 
embryos (2/24, 8%) were found at embryonic day E18.5 (Table 15 in Appendix I). One of these 
two K-RasV14I/V14I;Trp53–/– E18.5 embryos, a female, displayed cranial malformation. It has 
been described that a variable percentage (8-16%) of Trp53–/– females exhibited a variety of 
cranial malformation, including exencephaly, a neural tube defect in which the neural tube fails 
A!
Lymphoma and angiosarcoma!
BOG 128 Angiosarcoma + Bcell 
lymphoma!
CD31!
CD3!
Pax5!
CD31 !
antibody!
Pax5 !
antibody!
CD
3 
!
an
tib
od
y!
H&
E 
!
sta
ini
ng
!
B!
Histiocytic sarcoma! B cell lymphoma!
!"
!"!"
Figure 45. Tumors of K-RasV14I;p16Ink4a/p19Arf–/– and K-Ras+/V14I;Trp53–/– mice. (A) H&E stained paraffin 
sections of representative histiocytic sarcoma (left) and B cell lymphoma (right) of a K-RasV14I;p16Ink4a/p19Arf –/– 
mouse sacrificed at humane end point. Scale bars, 50 µm. (B) H&E stained paraffin section and CD31, CD3 and 
Pax5 immunostaining of an abdominal mass found in a K-Ras+/V14I;Trp53–/– mouse with a representative 
lymphoma and angiosarcoma. Inset shows detail of the area affected by both tumors. Arrowheads point to the 
lymphoma and asterisks indicate the angiosarcoma. H&E scale bar, 1000 µm. Immunostaining scale bars, 50 µm.  
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to close during development. This developmental alteration results in a reduction in the number 
of females at weaning (15, 178). All together suggest that the increased dosage effect of the K-
RasV14I allele in a Trp53 null background may led to a late embryonic lethality probably due to a 
combination of the cranial malformation, typically found in Trp53–/– females and the heart 
defects associated to K-RasV14I/V14I mice.  
 
6.11.6 Somatic expression of the K-RasV14I mutation  
 
 We interrogated if the expression of the K-RasV14I mutation initiated in the adulthood 
could induce the oncogenic transformation of some specific cell types, as the expression of the 
typical K-Ras oncogenic mutations (69, 90, 221). Following the same approach of the K-
Ras+/LSLG12Vgeo mouse model generated in our laboratory (69), the conditional K-Ras+/LSLV14I line 
was crossed with the tamoxifen inducible Cre strain, RERTn. The RERTn is a knock-in strain 
that expresses the inducible Cre recombinase under the control of the locus encoding the large 
subunit of the RNA polymerase II, thus providing its ubiquitous expression (69). This Cre 
recombinase is merged to the binding domain of the steroid hormone estrogen receptor (ER), 
previously modified (ERT2) in a way that prevents its binding to the endogenous steroids (30). 
The addition of the synthetic steroid 4-hydroxy-tamoxifen (4-OHT) provokes the dissociation of 
the Cre recombinase from the Heatshock protein 90 (Hsp90) that anchor it in the cytoplasm, 
resulting in the translocation of the enzyme to the nucleus. Therefore, treatment of K-
Ras+/LSLV14I; RERTnert/ert mice with 4OHT or Tamoxifen results in the activation of the inducible 
Cre-ERT2 recombinase leading to removal of the STOP transcriptional sequences that prevent 
expression of the targeted K-RasV14I allele.  
 To induce the ubiquitous expression of our mutation in somatic cells, we treated K-
Ras+/LSLV14I; RERTnert/ert (n=20) and K-Ras+/+; RERTnert/ert (n=10) mice with Tamoxifen (TAM-
diet) for three months starting at weaning (P21). K-Ras+/LSLV14I; RERTnert/ert mice (n=7) survived 
for at least 16 months without any obvious alterations. Histological analysis 15 different tissues 
of a small group of mutant (n=7) and control (n=4) mice at 16 months of age did not reveal the 
presence of any neoplastic lesion (data not shown). No lung lesions were found, in contrast to 
the results obtained in the K-Ras+/LSLG12Vgeo; RERTnert/ert mice (129).  Furthermore, splenomegaly 
was found in four out of the six analyzed mice, indicative of the development of MPD or other 
hematological alterations. This data suggest that the expression of the K-RasV14I mutation in 
somatic cells is not sufficient to induce oncogenic transformation in most of the tissues and only 
the hematopoietic compartment seems to be susceptible to transformation by the postnatal 
somatic expression of the mutation 
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6.11.7 Cooperation between K-RasV14I mutation and the oncogenic mutation PI3KCAH1047R 
 
 Mutations in genes that encode components of the PI3K signaling pathway are common 
in human cancer. The PI3KCA gene that encodes for the catalytic subunit p110α of class IA PI3 
kinase, is frequently mutated in human tumors, including colon, brain, breast, ovarian and lung 
tumors. The majority of the reported mutations occur in three hotspots: two (E542K and 
E545K) in the helical domain and one (H1047R) in the kinase domain. The H1047R mutation 
results in an increased catalytic activity, with a subsequent enhancement of the downstream 
signaling and oncogenic transformation in vitro (95).  
 To test if PI3K mutation could cooperate with the K-RasV14I mutation to promote tumor 
development, we used the Pi3kcaLmgLH1047R inducible knock-in mouse model (developed by the 
Experimental Therapeutic Unit at the CNIO). The Pi3kcaLmgLH1047R knock-in mouse model was 
generated by replacement of the exons 18, 19 and 20 by an equivalent cDNA flanked by loxP 
sites, followed by a cDNA containing exons 18, 19 and the 20 with the H1047R mutation. 
Therefore upon Cre recombinase activity, the floxed DNA fragment containing the wild type 
forms is deleted allowing the expression of the mutated cDNA (lox-minigene-lox; LmgL). This 
substitution can be monitored by the presence of IRES GFP-Luc reporter cassette (Figure 46). 
We found out that the germline expression of one mutant Pi3kcaH1047R allele is not compatible 
with embryo development, since no mutant mice were obtained from crosses between the 
Pi3kca+/LmgLH1047R mice and the EIIaCre strain. For this reason, to study the cooperation between 
Pi3kcaH1047R and K-RasV14I mutations, we decided to express both mutations from adulthood. To 
avoid premature mice death due to a strong cooperation between both mutations, in this pilot 
study we decided to express both mutations at P60. To this aim we crossed both conditional 
mouse models with the RERTn strain.  
 
 
 
 
 
 
 
 
 
 
 
Ex17! Ex18!Ex19! Ex20!
Pi3kca wild !
type allele!
Targeting 
vector! 18!19! 20!3ʼUTR! 18!19! 20! 3ʼUTR!IRES GFP!Neo!
*!
Ex17!
18!19! 20!3ʼUTR! 18!19! 20! 3ʼUTR!IRES GFP!Neo!
*!Pi3kcaH1047R 
allele!
Figure 46. PI3K targeting vector and modified PI3K allele by homologous recombination. Stapled boxes 
represent the exon (Ex) 17, 18, 19 and 20; white boxes, the exons 18, 19 and 20 of the cDNA; black box, 3’UTR; 
octagonal box (Neo), Neomycin resistance cassette; gray box, IRES-GFP reporter cassette; gray triangles, Frt sites; 
black triangles, lox-P sites and asterisk, mutation in exon 20 (H1047R). 
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 We treated K-Ras+/LSLV14I; RERTnert/ert; Pi3kca+/LmgLH1047R mice (n=8) and the control K-
Ras+/+; RERTnert/ert; Pi3kca+/LmgLH1047R mice (n=4) Tamoxifen (Tam diet) starting at P60 for 1 
month and mice were kept for survival studies. Double mutant and Pi3kca single mutant mice 
displayed the same survival rate indicating no cooperation between both mutations (Figure 47). 
Blood analysis (Table 16 in Appendix I) and preliminary histological characterization of 15 
tissues revealed that K-Ras+/LSLV14I; RERTnert/ert; Pi3kca+/LmgLH1047R and K-Ras+/+; RERTnert/ert; 
Pi3kca+/LmgLH1047R mice developed hematological alterations. Since both single mutant and 
double mutant mice succumbed by hematological disorders and displayed the same survival 
rate, these preliminary results suggests that the hematological disorders induced by the 
expression of the K-RasV14I mutation is mainly done through the Pi3K pathway. More studies 
are needed to confirm these observations. Furthermore, the analysis of the alterations developed 
by K-Ras+/LSLV14I; RERTnert/ert treated with Tamoxifen starting at P60 for 1 month is also needed. 
 
 
 
 
 
 
 
 
 
 
6.12 THERAPEUTIC STRATEGIES: MEK INHIBITOR TREATMENT OF K-RasV14I 
MICE AT DIFFERENT DEVELOPMENTAL STAGES 
 
 Since the Ras/MAPK pathway is frequently found mutated in human tumors, most 
efforts have been focused on the design of small-molecule inhibitors of the different members 
of the pathway. The NCFC syndromes result from germline mutations in these same targets. 
Thus, the same molecular inhibitors of the Ras/MAPK pathway being developed as cancer 
therapeutics may provide opportunities to therapeutically treat these developmental disorders or 
ameliorate disease progression of some symptoms (165). Proof of principle for using MEK 
inhibitors in these syndromes has been demonstrated in Noonan mouse models that express 
Raf1 (237) or Sos1 (39) mutations.   
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Figure 47. K-RasV14I mutation does not cooperate with the Pi3kcaH1047R mutation. Survival curve of K-Ras+/+; 
RERTnert/ert; Pi3kca+/LmgLH1047R (n=4, open circles) and K-Ras+/LSLV14I; RERTnert/ert; Pi3kca+/LmgLH1047R (n=8, solid 
circles) mice treated for 1 month with Tam diet at P60. 
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 We interrogated whether inhibition of K-Ras signaling using the MEK inhibitor 
PD0325901 could ameliorate the defects observed in K-RasV14I mice. PD0325901 is a non-ATP 
competitive MEK inhibitor that selectively binds to and inhibits both MEK1 and MEK2 
kinases. MEK contains a unique inhibitor-binding pocket adjacent to the ATP-binding site. 
Binding of the inhibitor into this hydrophobic pocket induces conformational changes in 
unphosphorylated MEK that locks the kinase into a closed but catalytically inactive form, 
inhibiting the phosphorylation and activation of the downstream target ERK (190). 
 To this aim, we performed three different treatment protocols (Figure 48):  
1. Prenatal treatment: pregnant mothers were treated daily by i.p injection with 
1mg/kg of MEK inhibitor PD0325901 or vehicle from E7.5 until P9. Starting at 
P10 the drug was injected to the pups at the same concentration every other day 
until P21. This treatment protocol was performed to determine whether the 
MEK inhibitor could prevent the defects observed in the K-RasV14I mice.  
2. Postnatal treatment: mice were treated daily by i.p injection with 5mg/kg of 
MEK inhibitor PD0325901 or vehicle at P21 for 6 weeks to determine whether 
the MEK inhibitor could eliminate or ameliorate some of the typical alterations 
of the K-RasV14I mice. 
3. Adult treatment: 4-month-old mice that already display signs of MPD, were 
treated daily by i.p injection with 5mg/kg of MEK inhibitor PD0325901 or 
vehicle for 1 month to determine whether MEK inhibitor might be of 
therapeutic value to treat the MPD.  
 
 
 
 
 
 
6.12.1 Prenatal MEK inhibitor treatment prevents the developmental defects 
  
 In an initial experiment, pregnant mothers (n=8) were treated with the MEK inhibitor 
PD0325901 from E7.5 until P9 and starting at P10, the pups were directly injected. Two hours 
after the last injection tissues were taken from some mice (n=2) to determine the effect of the 
MEK inhibitor on K-RasV14I signaling using phosphorylation of the Erk1/2 kinases as a read out. 
1!
E0! E7.5! P0! P21! 2 months! 4 months! 5 months!P10!
2!
3!
Figure 48. Treatment protocols. Arrows indicate the duration of the treatments. Pink arrows: prenatal treatment 
or treatment 1; green arrow: postnatal treatment or treatment 2; purple arrow: adult treatment or treatment 3. 
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As illustrated in Figure 49A, the MEK inhibitor efficiently inhibited Erk1/2 phosphorylation in 
both wild type and K-RasV14I/V14I animals, albeit the inhibition in the homozygous mice was only 
partial. In spite of the incomplete inhibition of K-Ras signaling in K-RasV14I/V14I mice, this 
treatment completely rescued the perinatal lethality. Whereas at weaning, the percentage of 
alive K-RasV14I/V14I mice treated with vehicle was only 13% (4/31), in those exposed to the MEK 
inhibitor the percentage of K-RasV14I/14I animals was the expected from Mendelian ratio (29%, 
16/56). The rescue of the perinatal lethality was a consequence of the elimination of the heart 
defects in neonatal mice. Hearts of P0 K-RasV14I/V14I mice exposed to the MEK inhibitor 
displayed the same size and morphology to their wild type littermates and vehicle treated 
controls (Figure 50A). Moreover, a small experiment treating C57BL/6J heterozygous mothers 
revealed that MEK inhibitor treatment also rescued the lethality observed in this genetic 
background. C57BL/6J K-RasV14I/V14I mice (3/6) were born and survived for at least 6 months.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 Treatment with the MEK inhibitor PD0325901 also rescued the growth defects of 
mutant mice up to weaning (n=30), the time when the treatment was discontinued. However, 
four weeks later, the weight of the K-RasV14I/V14I mice exposed to the MEK inhibitor was 
smaller (22.81±2.33 g; n=14) to that of wild type littermates (25.10±2.15 g; n=7) suggesting 
Figure 49. Exposure of K-RasV14I mice to MEK inhibitor results in inhibition of Erk1/2 phosphorylation. 
Protein extracts (40 µg) obtained from spleen, heart and lung of wild type (+/+) and K-RasV14I/V14I (V14I/V14I) 
mice exposed to vehicle or PD0325901 (A) from E7.5 to P21 or (B) for 6 weeks starting at P21 and sacrificed two 
hours after the last injection were resolved by SDS-PAGE, transferred to nitrocellulose membranes and blotted 
with antibodies against Erk1/2 and phosphoErk1/2. The migration of the corresponding proteins is indicated by 
arrowheads. 
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that the effect in the body weight of the MEK inhibitor was reversible. However, at this time the 
body length remained comparable. Thus, in contrast to the body weight, MEK inhibitor 
completely rescued the reduced length of mutant mice (Figure 50B). In addition, 4-month-old 
K-RasV14I/V14I mice (n=9), exposed to the MEK inhibitor displayed normal skulls (Table 17 in 
Appendix I). Similar results were obtained when we analyzed the cardiac phenotype. Four-
month-old homozygous mice (n=13) displayed normal hearts with normal numbers of 
cardiomyocytes (Figure 51). Moreover, MEK inhibitor treatment also rescued the increase of 
Sca-1+/PDGFRa+/CD31- cardiac stem cells in K-Ras+/V14I mice sacrificed from P10-P14 (Figure 
6 in Appendix I). These observations indicate that the deleterious effects caused by abnormal 
K-RasV14I signaling does not affect bone development or heart homeostasis beyond weaning.  
 
 
 
 However, K-RasV14I/V14I mice (n=13) treated with the MEK inhibitor had enlarged 
spleens and an expansion of myeloid cells (Gr1+ and CD11b+/Gr1+), similar to those animals 
treated with vehicle. Likewise, they also had increased numbers of LSK progenitor cells in BM. 
Similar results were obtained in K-Ras+/V14I mice (n=10) treated with the MEK inhibitor (Figure 
52). These results indicate that treatment with the MEK inhibitor PD0325901 did not prevent 
the development of MPD. In spite of these results, K-RasV14I/V14I mice (n=9) treated with the 
inhibitor during embryonic and postnatal development (E7.5 to P21) had a survival advantage 
with a median survival 30% longer than that of littermates treated with vehicle (48 vs. 37 
weeks) (n=6). Similar results were observed in heterozygous K-Ras+/V14I mice (n=12) (Figure 
53A). These observations indicate that MEK inhibitor slows progression but does not prevent 
Figure 50. Prenatal treatment with the MEK inhibitor PD0325901 prevents cardiac alteration at P0 and the 
development of growth defects. (A) H&E stained paraffin transverse sections of neonatal (P0) wild type (+/+) and 
K-RasV14I/V14I (V14I/V14I) mice exposed to vehicle or PD0325901 from E7.5. Scale bar, 200 µm. (B) Top: body 
weight of wild type (open bars), K-Ras+/V14I (gray bars) and K-RasV14I/V14I (solid bars) male mice exposed from 
E7.5 to P21 to vehicle (n=8, n=11; n=10, respectively) or PD0325901 inhibitor (n=7, n=16; n=14, respectively) 
from E7.5 to P21. Bottom: body lenght of wild type (open bars), K-Ras+/V14I (gray bars) and K-RasV14I/V14I (solid 
bars) male mice exposed from E7.5 to P21 to vehicle (n=8, n=11; n=10, respectively) or PD0325901 inhibitor (n=7, 
n=16; n=14, respectively) from E7.5 to P21. Error bars indicate SD. *P < 0.05; **P < 0.01; ***P < 0.001.  
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the hematological disorder. In addition, K-RasV14I mice succumbed by the development of MPD 
in combination with other hematological alterations (lymphomas, histiocytic sarcomas and 
leukemias). Therefore, these observations also indicate that the MEK inhibitor treatment 
reduces the progression of these secondary alterations, resulting in longer survival.  
 
 
 
 
 
 
 
 
 
 
 
 
 
6.12.2 Postnatal MEK inhibitor treatment does not rescue any defects of K-RasV14I mice 
 Next, we examined the effect of interfering with K-RasV14I signaling in mice at 
postnatal stages when mice already showed growth defects, craniofacial dysmorphia and cardiac 
alterations. To this end, mice were treated with the PD0325901 inhibitor or vehicle at P21 for 6 
weeks. Under these experimental conditions the MEK inhibitor also inhibited phosphorylation 
of the Erk1/2 kinases to the same extent as in mice treated during embryonic development 
(Figure 49B). However, this treatment did not ameliorate or correct any of the developmental 
defects characteristic of K-RasV14I mice, including decreased size and body weight (data not 
Figure 51. Prenatal treatment with the MEK inhibitor PD0325901 prevents developmental defect in K-
RasV14I mice. (A) Representative hearts appearance of 4-month-old wild type (+/+) and K-RasV14I/V14I (V14I/V14I) 
male mice exposed to vehicle or PD0325901 from E7.5 to P21. Scale bar, 5 mm. (B) Heart/Body weight ratio of 4-
month-old wild type (+/+, open bars), K-Ras+/V14I (+/V14I, gray bars) and K-RasV14I/V14I (V14I, solid bars) male 
mice exposed from E7.5 to P21 to vehicle (n=6, n=10; n=9, respectively) or PD0325901 inhibitor (n=5, n=10; 
n=13, respectively). (C) Relative number of cardiomyocytes in the right (left) and left (right) ventricle of 4-month-
old wild type (+/+, open bars), K-Ras+/V14I (+/V14I, gray bars) and K-RasV14I/V14I (V14I/V14I, solid bars) male 
mice exposed from E7.5 to P21 to vehicle (n=11, n=13; n=6, respectively) or PD0325901 (n=4, n=8; n=8, 
respectively). Error bars indicate SD. *P < 0.05; **P< 0.01; ***P < 0.001. 
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shown), craniofacial dysmorphia (Table 18 in Appendix I) and cardiac defects (Figure 7 in 
Appendix I). Moreover, these treated mice also underwent the same expansion of myeloid cells 
in spleen and of LSK progenitor cells in the BM (Figure 8 in Appendix I). However, exposure 
to MEK inhibitors increased the medial survival of K-Ras+/V14I mice from an average of 50 
weeks (n=11) to 72 weeks (n=13), a 44% increase. No such effect in survival was observed in 
homozygous K-RasV14I/V14I mice (n=5) (Figure 9 in Appendix I). 
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Figure 52. Prenatal treatment with the MEK inhibitor PD0325901 does not prevent hematological disorders 
in K-RasV14I mice. (A) Spleen/body weight ratio of 4-month-old wild type (+/+, open bars), K-Ras+/V14I (+/V14I, 
gray bars) and K-RasV14I/V14I (V14I/V14I, solid bars) mice exposed from E7.5 to P21 to vehicle (n=6, n=10; n=9, 
respectively) or PD0325901 inhibitor (n=5, n=10; n=13, respectively). (B) Flow cytometry analysis of Gr1+ and 
CD11b+ cells in spleens obtained from 4-month-old mice wild type (+/+) and K-RasV14I/V14I (V14I/V14I) mice 
exposed to vehicle or to PD0325901 from E7.5 to P21. (C) Percentages of Gr1+/CD11b+ myeloid cells in spleens of 
4-month-old wild type (+/+, open bars), K-Ras+/V14I (+/V14I, gray bars) and K-RasV14I/V14I (V14I/V14I, solid bars) 
mice exposed from E7.5 to P21 to vehicle (n=6, n=8; n=8, respectively) or to PD0325901 inhibitor (n=6, n=10; 
n=10, respectively). (D) Flow cytometry analysis of HSCs of BM of 4-month-old of wild type (+/+) and K-
RasV14I/V14I (V14I/V14I) mice exposed from E7.5 to P21 to vehicle or PD0325901 inhibitor using antibodies against 
c-Kit and Sca-1. The percentage of LSK cells is indicated. (E) Percentage of LSK cells in 4 month-old wild type 
(+/+, open bars), K-Ras+/V14I (+/V14I, gray bars) and K-RasV14I/V14I (V14I/V14I, solid bars) mice exposed from 
E7.5 to P21 to vehicle (n=6, n=8; n=8, respectively) or to PD0325901 inhibitor (n=6, n=10; n=10, respectively). 
Error bars indicate SD. *P < 0.05; **P < 0.01; ***P < 0.001. 
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6.12.3 Adult inhibitor treatment does not have any therapeutic effects to treat MPD  
  
 Finally, we used the MEK inhibitor to treat 4-month-old K-Ras+/V14I (n=11) and K-
RasV14I/V14I (n=2) mice already displaying signs of MPD to determine whether MEK inhibitors 
might be of therapeutic value to treat this disease. MPD was diagnosed by detection of enlarged 
spleens using CT scans as well as by altered blood counts (leukocytosis and anemia). 
Unfortunately, this treatment also failed to provide any significant decrease in spleen size as 
well as in average survival (Figure 53B). Thus, suggesting that additional pathways, other than 
the canonical Raf/Mek/Erk signaling cascade, must contribute to the development of MPD. 
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Figure 53. Exposure of K-RasV14I mice to MEK inhibitor results in increased survival. (A) Left: Survival of 
K-Ras+/V14I (+/V14I) mice exposed from E7.5 to P21 to vehicle (n=8, gray circles, solid line) or PD0325901 (n=12, 
gray triangles, dotted line). ***P < 0.001. Right: Survival of K-RasV14I/V14I (V14I/V14I) mice exposed from E7.5 to 
P21 to vehicle (n=6, solid circles, solid line) or PD0325901 (n=9, solid triangles, dotted line). (B) Survival of K-
Ras+/V14I (+/V14I) mice exposed from 4 to 5 months of age to vehicle (n=6, gray circles, solid line) or to 
PD0325901 (n=11, gray triangles, dotted line).  
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 Mutations in RAS genes and other members of the RAS signaling pathway have been 
implicated in a group of developmental disorders called Neuro-Cardio-Facio-Cutaneous 
(NCFC) syndromes or ‘RASopathies’. These rare conditions share different phenotypic features 
and include, among others, the Noonan syndrome (NS). NS is an autosomal dominant disorder 
characterized by a broad number of alterations including facial dysmorphia, short stature, 
congenital heart disease, skeletal abnormalities and learning disabilities (171). Six genes of the 
RAS-MAPK signaling pathway have been associated with NS including PTPN11, SOS1, K-
RAS, N-RAS, RAF1 and B-RAF and mutations in other two genes, SHOC2 and CBL, have been 
discovered in closely related conditions (165). Recently, mutations in RIT1, a member of the 
RAS subfamily, have been also described in Noonan patients (10). The broad spectrum of 
phenotypic alterations and mutations, together with the low incidence of some of these 
mutations, make difficult to establish a good phenotype-genotype correlation (171). The 
generation of genetically engineered mouse models (GEMMs) could help to better understand 
the role of each mutation in the development of this disorder. Role of PTPN11, SOS1 and RAF1 
mutations in NS have been clarified by others groups by the generation of GEMMs (14, 39, 
237). All these mouse models display alterations characteristic of NS patients, although 
interestingly, each of these mutant mice show specific features, as described in NS patients (14, 
39, 237). 
To better understand the role of K-RAS in NS we have generated a strain of mice 
carrying the K-RasV14I mutation. This mouse model faithfully reproduced the phenotypic 
abnormalities observed in NS patients, including smaller size, craniofacial dysmorphia as well 
as cardiac and hematopoietic defects. These alterations are reminiscent of the alterations 
described in the other NS mouse models (13, 14, 39, 237).  
 
7.1 K-RasV14I EXPRESSION IS COMPATIBLE WITH EMBRYO AND POSTNATAL 
DEVELOPMENT 
  
 Germline expression of the classical oncogenic K-Ras mutations, K-RasG12V or K-
RasG12D, is not tolerated during development and embryos die due to placental, cardiovascular 
and hematopoietic defects (69, 194, 221). Nevertheless, the expression of one copy of the 
mutated allele K-RasV14I was compatible with embryo and postnatal development, since the 
heterozygous mice were born at the expected Mendelian ratios and reached adulthood. 
Biochemical analysis using recombinant V14I proteins (186, 188) and our data with E13.5 
embryos suggest that the K-RasV14I mutant protein resulted in an intermediate increase of the 
active Ras status compared to the wild type and the oncogenic protein. Our results further 
illustrate that this intermediate activation levels allows embryo development.  
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 Interestingly, increased dosage of the mutant protein affects embryonic development 
since the number of homozygous mice was significantly lower than expected. Homozygous 
mice died at perinatal stages due to cardiovascular problems. These mice displayed 
cardiomegaly already evident at midgestation (E13.5). However, we did not detect any of the 
alterations found in the K-RasG12D embryos such as septal defects, valve malformation, DORV 
or excess endocardial cushion (194).  
 This allele dose effect was also observed in other Noonan mouse models (13, 14, 39, 
237). Homozygous Ptpn11D16G/D61G mice were not viable due to the development of severe 
cardiac defects, including septal defects, DORV and markedly enlarged outflow tract and 
atrioventricular valve primordial. And Ptpn11+/D61G mice also displayed high embryonic 
lethality (14). Any of these alterations were found in our K-RasV14I mice. Thus, suggesting that 
the K-RasV14I mutation used in this study is less aggressive than this Ptpn11 mutation. 
Interestingly, these differences can be attributed not only to the mutation but also to the 
different activation levels, since the expression of a less activated version of the Shp2 protein, 
the Ptpn11N308D, results in complete viability of heterozygous mice and only small percentage of 
homozygous mice succumb by heart failure, similar to our model (13). Like to the K-RasV14I 
mice, heterozygous Sos1+/E846K mice were viable and only a small percentage of Sos1E846K/E846K 
mice survive. These homozygous mice die at various stages from E10.5 to the neonate stage due 
to the development of cardiac defects including septal defects and aortic stenosis (39). These 
alterations were not found in the K-RasV14I mice.  
The incomplete penetrance of the perinatal lethality of K-RasV14I mice in a B6/129 mix 
background suggests the presence of modifiers alleles, in one or the other strain, that modulate 
the phenotypic consequences of the K-RasV14I expression. This incomplete penetrance 
disappeared when mutant mice were backcrossed to C57BL/6J background for five generations 
since homozygous C57BL/6J K-RasV14I mice were no longer viable at this generation. In 
contrast, no changes in the perinatal lethality were found when mutant mice were backcrossed 
to 129S2/Sv background. Similar results were obtained when the Ptpn11D16G or the Raf1L613V 
mice were backcrossed to C57BL/6J. In this background, after five and three generations 
respectively, the allele expression was lethal (13, 237). However, in contrast to our results in the 
129S2/Sv background, Ptpn11+/D16G mice backcrossed to 129S6/SvEv displayed nearly normal 
viability (13). Thus suggesting than in the K-RasV14I mice there is also a small contribution of 
the 129S2/Sv background to the perinatal lethality.  
 
7.2 GROWTH DEFECTS AND CRANIOFACIAL ALTERATIONS: TWO 
IMPORTANT FEATURES IN NCFC SYNDROMES 
  
Similar to Noonan patients and to mouse models that express NS-associated mutations 
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in Ptpn11, Sos1 and Raf1 (13, 14, 39, 237), the K-RasV14I mice showed reduce body weight and 
size similar to Noonan patients. Moreover, the CFC mouse model carrying the B-RafV600E 
mutation (223) and mouse models that express a LEOPARD-associated Ptpn11 substitution 
(136) or the Costello syndrome H-RasG12V mutation also display reduced body size at least in 
the first month of life (40, 189). These results suggest a crucial role of the RAS-MAPK pathway 
in growth during early development.  
Interestingly, in our mouse model, the body weight defect was due to a reduction in the 
fat and leans content. In addition, we found that the growth alterations were affected by genetic 
backgrounds. This phenotype became ameliorate in heterozygous C57BL/6J and 129S2/Sv 
mice, while in homozygous 129S2/Sv mice were more dramatic. These results suggest the 
presence of modifiers alleles in the 129S2/Sv strain that modulate the effect of the K-RasV14I 
expression in growth during the development.  
The K-RasV14I mice also displayed a typical facial appearance reminiscent of NS 
patients and similar to those described in the Ptpn11D16G, Ptpn11N308D, Sos1E846K and Raf1L613V 
mouse models (13, 14, 39, 237). As growth defects, this phenotype was also more dramatic in 
homozygous 129S2/Sv mice. 
Therefore, two of the most common alterations found in Noonan patients, the 
craniofacial dysmorphia and the growth defect are common features of the NS mouse models. 
Interestingly, other frequent alteration, such as skeletal abnormalities, has not has no been 
described neither in our mouse model nor in the other NS mouse models (14, 39, 237). 
 
7.3 CARDIAC ALTERATIONS: DIFFERENTIAL EFFECTS OF THE SPECIFIC 
MUTATIONS 
 
 The K-RasV14I mice displayed heart hyperplasia due to increased cardiomyocyte 
proliferation associated with an increased thickening of the aortic valve. Indeed heart function 
in these mice appeared to be normal or enhanced as illustrated by the MRI studies. This 
phenotype is affected by the different genetic backgrounds and is significantly different from 
those observed in NS models carrying mutations in other loci. For instance, about 50% of the 
lower affected Ptpn11+/D61G (14) and the Ptpn11N380D mice (13) display septal defects with no 
association to cardiac hypertrophy. Sos1+/E846K developed left ventricular hypertrophy with 
incomplete penetrance of aortic stenosis and ventricular fibrosis (39). And Raf1+/L613V mice had 
normal valvuloseptal development but exhibit eccentric cardiac hypertrophy (237). The 
variability in the cardiac alterations found in the NS mouse models suggests differential effects 
of each specific RAS-MAPK mutations alone or in combination with the presence of modifiers 
genes that remain to be indentified. This variability is also reminiscence of the Noonan patient-
cardiac alterations. Approximately 20% of Noonan patients display HCM (152). However, the 
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mutated NS alleles are differentially associated with HCM. For instance, HCM is found in 
approximately 95% of patients bearing RAF1 mutations (157, 168). However, K-RAS is rarely 
associated with HCM (151, 188, 243) and only 10% of patients with PTPN11 mutation (205) 
and 20% of those with mutations in SOS1 develop HCM (211). Therefore, these alleles 
negatively associated to HCM in patients (K-RAS and PTPN11) have not been associated with 
the cardiac hyperthrophy development in mouse models. Neither Ptpn11D61G (14) nor K-RasV14I 
mice exhibit this alteration.  
This variability of the cardiac alterations can be also extended to the rest of 
‘Rasopathies’. In the case of HCM, while Noonan patients with K-RAS mutations are rarely 
associated to this alteration (151, 188, 243), H-RAS causes HCM in most of the CS patients (12, 
121). Thus, the H-RasG12V mice generated in our laboratory, displayed concentric hypertrophy in 
the left ventricle associated with heart fibrosis (189). In contrast to the Sos1E846K (39) and 
Raf1L613V NS-mouse models (243), this hypertrophy is secondary to pressure overload caused by 
the AngII-dependent hypertension displayed by these mice. Interestingly, H-RasG12V mice also 
display an enlargement of the auricles and the right ventricle due to an increase in the number of 
cardiomyocytes similar to the K-RasV14I mice. This alteration is a cell autonomous effect 
induced by expression of H-RasG12V mutation and not a secondary effect of the hypertension 
(237).  
 In the past ten years, the existence of cycling ventricular cardiomyocytes in normal and 
pathological adults mammalian hearts have been documented (20, 94, 163). The existence of 
cardiac stem cells with proliferative and regenerative capacities in the myocardium of several 
species, including humans, has also been described (9). Interestingly, we found an increase in 
the cardiac stem cells and in the cycling cardiomyocytes in our NS mouse model, as well as a 
promotion of a more undifferentiated state at postnatal stages (P10-P14). These results indicate 
that K-Ras might be an important role in the homeostasis of cardiac stem cells. In fact, Xenopus 
studies suggest that Ptpn11 is required for the maintaining of the cardiac precursor population. 
In the absence of the Shp2 signaling early cardiac markers are downregulated and cardiac stem 
cells fail to initiate cardiac differentiation (110). Therefore, these studies together suggest a 
dependence of the cardiac stem cells to the RAS-MAPK pathway.  
 In addition, the cardiac hyperplasia found in the K-RasV14I mice is similar to that 
described in the B-Raf +/V600E model, which recapitulates some of the clinical features present in 
CFC patients developed heart hyperplasia similar to our model (223).  
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7.3.1 K-RasV14I expression in adult myocardial cells does not induce an alteration of the 
heart development 
 
 The expression of the K-RasV14I mutation in adult myocardial cells did not induce the 
cardiac hyperplasia described in mice that germline expressed this mutation. No alterations in 
heart appearance or histology were found when K-RasV14I expression takes place in the adult 
cardiomyocytes. These results indicate that the expression of the NS-associated mutation cause 
cardiac alterations only during embryo development. Similar results were obtained when the 
oncogenic mutation K-RasG12D was expressed in the same cells types (47). While the germline 
expression of the oncogenic K-RasG12D mutation results in cardiac abnormalities, the expression 
of the same mutation in adult myocardial cells does not cause cardiomyopathy in mice. In the 
case of PTPN11-NS associated mutation, mice that express the Ptpn11D61Y mutation (13) and 
transgenic mice overexpressing the Shp2 Q79R mutant protein in adult myocardial cells do not 
display cardiac defects (145). However, the overexpression of the Q79R mutation in the same 
type of cells during gestation led to the development of ventricular noncompaction and 
ventricular septal defects (145). Therefore, these results indicate that expression of the different 
RAS-MAPK results in development of cardiac alterations only when they take place during 
heart organogenesis.  
 We cannot rule out the role of other type of cells, for instance endothelial cells, in the 
development of the cardiac hyperplasia of K-RasV14I mice. In fact, the expression of the 
Ptpn11D61Y mutation in endothelial cells during embryonic development induced cardiac 
abnormalities, while any alterations were induced when the same mutation was expressed in 
myocardial cells (13).  
 
7.4 ROLE OF K-RasV14I AND K-RasG12V MUTATIONS IN THE DEVELOPMENT OF 
HEMATOLOGICAL ALTERATIONS 
 
 Somatic K-RAS and N-RAS mutations are found in myeloid malignancies including 
JMML (112). Approximately 25% of JMML patients present mutation in these alleles. JMML is 
a myeloproliferative disorder characterized by leukocytosis with tissue infiltration and in vitro 
hypersensitivity of myeloid progenitors to GM-CSF (112). Infants with NS show a spectrum of 
hematological abnormalities and are predisposed to JMML (91). Interestingly, mice that 
expressed the oncogenic mutations K-RasG12D (27, 37) and N-RasG12D (120) in the 
hematopoietic compartment driven by the Mx1-Cre expression develop myeloid malignancies.  
 K-RasV14I mice developed MPD characterized by leukocytosis, anemia and 
thrombocytopenia. Mutant mice also displayed splenomegaly associated with an expansion of 
the myeloid cells and BM progenitors demonstrated hypersensitivity to cytokines. This 
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phenotype is affected by the different genetic backgrounds and is similar to the JMML 
developed by Noonan patients. In contrast, while K-RAS is found mutated in myeloid 
malignances, mice in which oncogenic K-Ras is activated germline by a CMV-Cre transgene did 
not develop myeloid. The expression of K-RasG12V resulted in frequent embryonic lethality, but 
a significant number of mice reached adulthood. These mice did not develop myeloid 
malignancies and succumb by breathing difficulties due to lung tumor development (69). 
Subsequent studies performed in our laboratory, reveal that the efficiency of the CMV-Cre strain 
used in this experiments was very low allowing the survival of some mice. Therefore, it is not 
possible to determine the time and the percentage of the activation of this mutation in each cell 
type. For this reason, it is possible that the K-Ras allele was not activated in the susceptible-
initiating cells and for this reason no myeloid malignancies were found in this mouse model.  
 Postnatal expression of the K-RasG12V mutation in mice using the RERTn strain also 
results in lung tumor development. In mice analyzed at 1 year of age, only bona fide tumors in 
lung tissues were detected. No myeloid malignancies were found in these mice (129). However, 
unpublished data of our laboratory reveals that these mice, similar to our mouse model 
displayed leukocytosis due to an expansion of the neutrophils, eosinophils and basophils 
population. Therefore, it is possible that these mice do not live long enough to develop 
hematological alterations. To compare both substitutions in the same scenario, we used the 
same approach to induce the somatic expression of the K-RasV14I mutation. In this case, in 
contrast to the oncogenic mouse model, mice that expressed the K-RasV14I mutation postnatally 
live longer and only displayed hematopoietic alterations with slower progression than when the 
mutation were induced germline. Splenomegaly was found with low penetrance in a 67% (4/6) 
of 16-month-old mice. Therefore, it is possible that the susceptibility of the initiating-cell to the 
oncogenic K-Ras transformation in adult stages in mice is lower.  
 These results demonstrate that somatic expression of the K-RasV14I induces the 
development of myeloid malignancies. Therefore, the presence of this somatic substitution in 
patients with myeloid malignancies could be possible. In fact, high-throughput sequencing 
screening of patients with myeloid alterations revealed the presence of the K-RasV14I mutation in 
one patient with acute myeloid leukemia (AML) out of 329 analyzed patients. However, the 
etiology (germline or somatic) of this mutation is unknown, since the analysis of the presence of 
the mutation in other cell type was not evaluated (222).  
 Finally, we expressed the K-RasV14I and the K-RasG12V mutations in the hematopoietic 
compartment using the inducible Mx1-Cre strain to clarify the role of these mutations in the 
development of hematological alterations. By this approach we were able to induce the 
development of myeloid malignancies in the case of the K-RasG12V mice and to accelerate the 
progression of the disease in the case of the K-RasV14I strain, in comparison with the results 
obtained with the RERTn strain. These different results obtained with both Cre lines can be 
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explain by the different targeted cells by these two strains. The RERTn line induces the 
expression of the mutation in most of the tissues (69, 129). In contrast, the Mx1-Cre strain 
targets mostly the hematopoietic compartment and with low efficiency other tissues like heart, 
kidney, lung and duodenum (107). An alternatively explanation is that the Mx1-Cre line is not a 
true inducible strain. In 2004, Chan and colleagues published that K-Ras+/LSLG12D; Mx1-Cre+/T 
mice in absence of interferon administration also developed MPD (37). This result suggests that 
with the Mx1-Cre, we induced the expression of the mutations before postnatal stages when the 
initiating-cells are more susceptible to tumor transformation. And at this stage, oncogenic K-
Ras mutations can initiate the development of the myeloproliferative alterations. 
 
7.5 THE HEMATOLOGICAL DISORDER DISPLAYED BY K-RasV14I MICE IS 
SIMILAR TO THOSE INDUCED IN MICE THAT EXPRESSED MUTATION OF THE 
RAS-MAPK PATHWAY   
 
K-RasV14I mice developed MPD similar to that observed in Nf1+/− mice (84) or mice that 
expressed in the hematopoietic compartment the oncogenic mutations K-RasG12D (27, 37), N-
RasG12D (120) or Ptpn11D61Y (36); as well as mice carrying a null Nf1 mutation of hematopoietic 
cells (114). This MPD was also induced by the expression of the K-RasV14I mutation only in 
hematopoietic cells upon the expression of the Mx1-Cre strain. In both cases (germline or 
hematopoietic lineage expression), the MPD is less aggressive than those induced by the 
oncogenic K-RasG12D mutation, which induce as early as 3-4 months of age the death of mice 
(27, 37). This difference in the aggressiveness may reflect the different activaty properties of 
both mutations. Our results illustrate that the K-RasV14I protein is less active than the oncogenic 
protein K-RasG12V. In fact, mice that express the oncogenic mutation N-RasG12D in the 
hematopoietic compartment developed an attenuated MPD phenotype compared to the K-
Ras+/LSLG12D; Mx1-Cre mouse model due to lower Ras protein expression and Ras-GTP levels in 
the Mac1+ cells (120). The MPD observed in this strain was also attenuated compared to the K-
RasV14I mice. Moreover, the myeloid malignancie developed by our K-RasV14I mouse model is 
similar to the hematological alterations described in the other NS mouse model, but the disease 
in these strains, in contrast to our mouse model, is well tolerated (14, 39, 237). 
 In addition, the MPD displayed by the K-RasV14I mice was reproduced in primary 
transplanted mice, similarly to the Ptpn11D61G mice (239) and mice carrying the oncogenic 
mutation K-RasG12D mutation (27, 37) or a null Nf1 mutation of in hematopoietic cells (114). 
This result indicates that the pathogenic effect of the K-RasV14I expression initiate at stem cell 
levels.  
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7.5.1 Aberrant hematopoiesis induced by K-RasV14I mutation: mutation specific or RAS-
MAPK pathway specific? 
 
 The expression of the K-RasV14I mutation is associated with an expansion of the LSK 
cells similar to the mice that expressed the K-RasG12D in the hematopoietic compartment (225) 
and similar to the mice that express the N-RasG12D in hematopoietic cells (120). The N-RasG12D 
mouse model displays an expansion of the multipotent progenitor population (MPP) (Lin-, Sca-
1+, c-Kit+, Flk2-), but normal levels of the HSC-enriched LSKF- cells (Lin-, Sca-1+, c-Kit+, Flk2-
). Both type of cells were gated from the LSK (Lin-, Sca-1+, c-Kit+) cells (120), the population 
that we analyzed in our mouse model. Therefore, we can assume that the LSK cells are also 
increased, since one subpopulation (MPP) is increased and the other (LSKF-) is unchanged. 
Similar expansion of the LSK cells was also observed in the mice Ptpn11D61G Noonan mice 
(239).  
 In our K-RasV14I mouse model, the expansion of the HSC is associated with an increase 
of the myeloid progenitors CMP and GMP, similar to the mice that expressed the K-RasG12D 
(225) and N-RasG12D mutation (120) in hematopoietic cells. However, while in our mouse model 
no alterations were found in the MEP progenitors, mice that express the oncogenic K-Ras and 
N-Ras mutations displayed an increase in this population (120, 225). These mice express the 
mutation only in the hematopoietic cells and more efficiently upon interferon administration 
(120, 225). Since, the K-RasV14I mouse model expresses germline the mutation in all type of 
cells, analysis of the progenitor population in the K-Ras+/LSLV14I; Mx1-Cre mice could clarify if 
this difference reflects different properties of the mutations or it is due to an unlike patter of 
expression of the mutation due to different genetic strategies. Our results also differ from the 
data obtained with the Ptpn11D61G mice, which displays an increase of GMPs and MEPs 
populations in combination with a decreased of CLP, while no alterations in the CMPs 
percentages were found (239). These differences suggest a different role of these genes in 
hematopoietic development.  
 Finally, in the K-RasV14I mouse model the expansion of the HSC population was due to 
a decreased programmed cell death rather than to an enhanced cell proliferation. No information 
about apoptosis of the hematopoietic cell progenitors in the K-RasG12D mice was published. 
However, while in mice that express the K-RasG12D mutation in hematopoietic cells similar 
percentages of BrdU positive cells were found in total BM cells, the Mac1+ fraction displayed 
an increased marked proliferation (27). No information about the proliferation status of the LSK 
cells was found in this mouse model, although they described that the myeloid CMP, GMP and 
MEP progenitor displayed a significant increase in BrdU uptake (120). These results suggest 
that K-RasG12D mice displayed an elevated proliferation rate only in myeloid lineage, no in other 
BM population. The different approaches used in the K-RasG12D mice and in our mouse model 
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makes us difficult to compare the unlike data. Analysis of the proliferation status and apoptosis 
of the LSK, GMP and CMP populations in mouse models that express the K-RasV14I or the K-
RasG12V mutations in hematopoietic cells could clarify these results. Interestingly, in mice that 
express the oncogenic N-RasG12D mutation in hematopoietic cells the percentage of proliferating 
cells within myeloid progenitor populations (CMP, GMP and MEP) is similar to the control 
mice, but more cell divisions were found in the LSK fraction. Again, no information about the 
apoptosis status was published (225). These results differ from the data obtained with the K-
RasV14I and the K-RasG12D mouse model (120) and are indicative of a different role of the K-Ras 
and N-Ras genes in hematopoietic progenitors. Similar to our results, decreased programmed 
cell death in HSC population was also observed in the Ptpn11D61G mice (239). However, in this 
mouse model this decrease is also associated to an expansion of the cycling HSC. They found 
an enhanced entry of the quiescent stem cell (G0 phase) into the cell cycle in the mutant mice 
(239). Though the approaches used in both analyses are different, it seems that both mutations 
(K-RasV14I and Ptpn11D61G) have different role in HSC homeostasis.   
 
7.6 IS THE K-RASV14I MUTATION A MILD ONCOGENIC SUBSTITUTION? 
 
 Our study is the first evidence that the expression of the NS K-RasV14I mutation is 
associated with an increased risk of tumor development. K-Ras+/V14I and K-RasV14I/V14I mice 
presented reduced life span with a half-life of 62 and 36 weeks, respectively mainly due to the 
development of hematopoietic alterations including lymphomas and histiocytic sarcomas. These 
hematological alterations were developed in combination with the MPD. Similar results were 
found in mice that express the oncogenic N-RasG12D mutation in the hematopoietic 
compartment. These mice developed an indolent MPD at 6 months of age that in some mice 
became fatal. The rest of the mice ultimately succumb due to a variety of hematologic cancers, 
which occur at approximately equal frequencies, including a disorder that was a reminiscent of 
human myelodysplastic syndrome (MDS), lymphoid expansion or lymphoproliferation and 
histiocytic sarcoma (225).  
 Interestedly, K-RasV14I mice also developed adenomas and adenocarcinomas mainly in 
intestine, liver and lung. These lesions were only found in K-Ras+/V14I mice, probably due to 
their longer survival, but their incidence was very low compared to the K-RasG12D mice. Mouse 
models that express the oncogenic K-RasG12D or K-RasG12V mutation in adult stages develop lung 
tumor with complete penetrance (69, 86, 221). A possible explanation for this differences is the 
unlike patter of expression of both mutations. The K-RasV14I substitution, in contrast to the 
oncogenic ones is expressed throughout development in all cell types. Therefore, during this 
time the cells can adapt to the mild activate signaling from the K-RasV14I protein and assume 
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this signal as the normal levels. On the other hand, it is possible that the intermediate active 
levels of the K-RasV14I protein were not enough to induce the oncogenic transformation.  
 Here, we demonstrated that, in contrast to the K-RasG12D or K-RasG12V mouse models 
(69, 86, 221), mice that expressed the K-RasV14I mutation at postnatal stages either in all cells or 
only in lung did not develop lung tumors. Moreover, any other type of solid tumors was not 
found when the K-RasV14I mutation was expressed in adult stages in all the cells. These results 
suggest that our NS-associated mutation does not have enough oncogenic potential to elicit lung 
tumors or any other tumor types in which K-RAS is preferentially mutated: pancreatic ductal 
adenocarcinoma (PDAC) and colorectal cancer. However, as the oncogenic K-Ras mutations 
(70, 80), the K-RasV14I substitution cooperated with chronic pancreatitis to induce low-grade 
and high-grade intraepithelial neoplasias (PanIN), the preneoplastic lesions, observed during 
PDAC development. This cooperation was found either when the mutation was expressed 
germline in all the cells or only in 30% of acinar cells starting at embryonic day E16.5. The 
percentage of low- and high-grade PanIN lesions was bigger in the germline model, probably 
due to the bigger amount of acinar cells in which this mutation was expressed. Moreover, in 
contrast to the mouse models that express the oncogenic mutation (69, 70, 80), no PDAC 
lesions were found in our K-RasV14I mouse model indicating the lower oncogenic capacity of 
the K-RasV14I mutation.  
  We also demonstrated that Nicotine administration induces the development of lung 
adenocarcinomas and with lower incidence, PDAC lesions in small cohort of K-RasV14I/V14I 
mice. Unpublished studies performed by Hermann P.C. and colleagues demonstrated that, 
similar to our results, nicotine enhanced pancreatic tumorigenesis in mice that express the 
oncogenic K-RasG12V mutation in acinar cells. However, in contrast to our result, nicotine does 
not increase lung tumor number or size and does not affect overall survival (128) in mice that 
expressed a K-Ras oncogenic mutation by spontaneous recombination (90).  
 Interestingly, K-RasV14I mutation was identified in 12 cases of human colorectal cancer 
(5, 61, 76, 87, 159, 201, 214, 226, 238). In some patients (3/12) this mutation was detected in 
trans with the typical oncogenic mutation (5, 76, 226) and only in one of the cases the mutation 
was confirmed as a somatic one by the absence of this substitution in non-neoplastic tissues 
(226). No lesions were found in large intestine of our K-RasV14I mouse model neither when the 
mutation was expressed germline nor when it was expressed in adult stages. Similar results 
were obtained in mice that express the oncogenic mutation by spontaneous recombination (90) 
or upon the inducible Cre recombinases: RERTn (69) or Ah-Cre (179). None of these mouse 
models develop spontaneous colorectal adenomas and adenocarcinomas. These results are in 
agreement with the model of human colorectal tumor progression, in which loss of APC 
function initiates the formation of a benign lesions and followed oncogenic activation of K-RAS, 
loss of TP53 and 18q locus altogether contribute to malignant disease progression (57). 
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Therefore, the expression of the K-RasV14I mutation in absence of Apc, using conditional knock-
out mouse model (197) may to clarify the role of this mutation in colorectal cancer progression. 
In fact, intestinal K-RasG12V expression accelerates intestinal tumorigenesis and confers invasive 
properties after Apc loss (179).  
 Finally, in human, allelic loss of the wild type K-Ras allele is found in most of lung 
adenocarcinomas and large cells carcinomas samples which K-Ras oncogenic mutation (119). 
Studies in chemically induced models of lung or skin tumorigenesis have demonstrated that the 
acquisition of activating mutations in the K-Ras or H-Ras allele is associated with loss the 
corresponding wild type alleles during tumor progression (28, 78). Furthermore, Zhang and 
colleages demonstrated that loss of the wild type K-Ras allele enhanced mutant lung 
tumorigenesis (244). Moreover, unpublished data of our laboratory indicates that the conditional 
elimination of the wild type allele in adult K-RasLSLG12V/lox animals that express one copy of the 
oncogenic K-RasG12V mutation results in reduction of mice life span due to acceleration of lung 
and pancreatic tumorigenesis. In our mouse model (K-RasV14I/-), germline elimination of the 
wild type K-Ras allele had no effect in the mice survival. Hemizygous mice died due to 
hematological alterations, but displayed the same survival rate to the heterozygous mice. 
Therefore, in contrast to the results obtained in the lung context, the elimination of the wild type 
allele has not important effect in the progression of the hematological disorders. Since K-
RasV14I/- mice were born without the wild type copy of K-Ras, cells can adapt to this absence 
and maybe for this reason the loss of wild type allele does not cooperate with the activating 
mutation to accelerate tumor development or to induce other tumor types Generation a 
conditional K-RasLSLV14I/lox mouse model that allow us eliminate the wild type copy in adult 
stages could prove this hypothesis. 
 
7.6.1 The K-RasV14I mutation cooperated with loss of tumor suppressor genes but does not 
cooperate with activating Pi3kca mutation 
 
 The K-RasV14I mutation cooperated with loss of tumor suppressor genes including 
p16Ink4a/p19Arf and Trp53. Germline expression of K-RasV14I significantly accelerated tumor 
development in mice lacking the p16Ink4a/p19Arf tumor suppressor genes. Although no 
unpublished tumors were identified in these mice, the pattern of these lesions was different. For 
instance, the incidence of histiocytic sarcoma in K-RasV14I/V14I; p16Ink4a/p19Arf –/– mice was 
bigger than the percentage described in the p16Ink4a/p19Arf –/– strain. And, in contrast to the 
published results, we did not find any mesenchymal tumors, such as fibrosarcomas. Although a 
small percentage of these differences might be explained by the unlike genetic background of 
both strains, it seems that the loss p16Ink4a/p19Arf tumor suppressors cooperate with K-RasV14I 
mutation to promote the development of hematological abnormalities, preferentially histiocytic 
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sarcomas, more than mesenchymal tumors. Cooperation between p16Ink4a/p19Arf loss and K-
Ras mutations were also found in pancreatic tumor mouse models. In these mice, loss of 
p16Ink4a/p19Arf tumor suppressor genes in early pancreatic precursor during embryo 
development (4) or in embryonic acinar cells (68) cooperates with K-Ras oncogenes to induce 
invasive and metastatic PDAC.  
 Gemline expression of K-RasV14I mutation also accelerated tumor development in mice 
lacking the Trp53 tumor suppressor gene. K-Ras+/V14I;Trp53 –/– mice died significantly faster 
than Trp53–/– mice due to the development of more aggressive tumors. However, we found the 
same typical lesions described before in the Trp53 null mice. Cooperation between Trp53 loss 
and K-Ras mutation was also found in mice that expressed a K-Ras oncogenic mutation by 
spontaneous recombination (90). In these mice, the elimination of Trp53 significantly reduces 
their lifespan due to the development of more malignant lung tumors, thymic lymphomas and 
skin papillomas, the typical lesion associated with the expression of this oncogenic mutation. 
Moreover, haemangiosarcomas and fibrosarcomas were also described in about 30% of double 
mutant mice (90). Moreover, cooperation between Trp53 deficiency and the oncogenic 
mutations were also found in mice that expressed the K-RasG12V oncogene in embryonic acinar 
cells (70). In these mice, the elimination of Trp53 results in a reduction of the mice survival due 
to faster PDAC development (70). Same results were found in mice that concomitant express 
the K-RasG12D mutation and the Trp53R172H mutation in pancreatic cells, under the Pdx1-Cre 
expression (81). In addition, Trp53 loss promotes the progression of K-RasG12D-induced lung 
adenocarcinomas (85).  
 In contrast, we performed a pilot experiment to address if there is cooperation between 
K-RasV14I and Pi3kcaH1047R mutations. Our results demonstrated that the concomitant activation 
of both mutations in adult stages did not accelerated tumor development. Interestingly, 
preliminary studies suggest that K-Ras+/LSLV14I; RERTnert/ert; Pi3kca+/LmgLH1047R and K-Ras+/+; 
RERTnert/ert; Pi3kca+/LmgLH1047R displayed hematological alterations, suggesting that the 
hematological disorders induced by expression of mutation of K-Ras signal through the Pi3K 
pathway. However, unpublished data from the Experimental Therapeutic Unit of CNIO indicate 
that, in contrast to our results, Pi3kcaH1047R cooperate with K-RasG12V accelerating lung tumor 
development. This difference might be explained by the unlike activating status of the 
oncogenic K-RasG12V and the NS-associated K-RasV14I mutations.  
 
7.7 IS THE MEK INHIBITOR PD0325901 A GOOD DRUG TO PREVENT OR 
AMILORATE NOONAN SYNDROME ALTERATIONS?   
 
 Several studies suggest that targeting RAS/MAPK signaling might be a powerful 
therapeutic strategy to prevent or ameliorate some of the typical alterations found in Noonan 
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patients. First studies showed that genetic ablation of Erk1/2 in mice overexpressing the Shp2 
Q79R mutation in myocardial cells during the gestation (145) or the elimination of Erk1 in mice 
overexpressing the same mutation in endothelial-derived cells (105) prevent the cardiac 
alteration and the endocardial cushion phenotype, respectively found in these strains. Moreover, 
prenatal treatment during the pregnancy with the U0126 MEK inhibitor abrogates the 
craniofacial abnormalities described in mice that express the Ptpn11D61G mutation under the Wnt 
promoter (146). Our results illustrate that exposure of the developing embryo to well tolerated 
doses of the PD0325901 MEK inhibitor rescued the perinatal lethality of homozygous mice and 
prevented the appearance of the growth and cardiac defects, as well as the facial dysmorphia. 
Similar experiments were carried out in the Sos1E846K mice (39). In this mouse model, same 
prenatal treatment with the PD0325901 MEK inhibitor rescued the embryonic lethality, as in the 
case of the K-RasV14I mice. By contrast, while in our mouse model this treatment completely 
normalizes the cardiac alterations at P0 and 4 months old, in the Sos1E846K mice the same 
protocol of treatment only reduces the penetrance of heart defects. Some homozygous 
Sos1E846K/E846K treated mice succumbed due to the development of cardiac abnormalities. As we 
discussed before, the cardiac phenotype of both NS mouse model (Sos1E846K and K-RasV14I) are 
different. While Sos1E846K mice developed left ventricular hypertrophy with incomplete 
penetrance of aortic stenosis and ventricular fibrosis, our mouse model displayed cardiac 
hyperplasia with an increase in the thickening of the aortic valve. These differences might 
indicate the contribution of different effectors to the cardiac defects and might explain the 
different effect of the MEK inhibitor. For instance, in hearts, the Sos1E846K mutation increases 
Rac activity inducing Stat3 activation through autocrine IL-6. This Stat3 activation persists in 
mice treated with the PD0325901 inhibitor and for this reason some of cardiac defects still exist 
in mice exposed to the inhibitor. The completely normalization of the heart hyperplasia in our 
mouse model might suggest the only contribution of the RAS/MAPK pathway to this 
phenotype. Moreover, in contrast to our results this prenatal treatment improves, although did 
not correct, size and craniofacial dysmorphia (39). The complete normalization of the heart 
hyperplasia and facial dysmorphia in our mouse model suggests the only contribution of the 
RAS/MAPK pathway to this phenotype. 
 We also described that treatment with the MEK inhibitor of mice that already displayed 
all the NS typical features did not ameliorate or correct any of the developmental defects 
characteristic of K-RasV14I mice. Similarly, the same postnatal treatment does not rescue the 
facial dysmorphia in the Raf1L613V mouse model. However, this phenotype was normalized 
when the treatment started at P0 (237). These observations, taken together, indicate that an early 
identification of the developmental disorder, ideally by prenatal testing, is needed for the 
successfully treatment of cranial alteration with MEK inhibitors. In contrast, the same postnatal 
treatment normalized the cardiac and growth defects in the Raf1L613V mouse model. 
  Discussion 
	   	   	  138	  
 Although moving mice results to clinical trials is difficult, treatment of the germline 
phenotypic features of ‘RASopathies’ with pathway modulation or small-molecule inhibition in 
under way. The first randomized clinical trial examined the effect of simvastatin treatment on 
congnitive function in children with NF1. Simvastatin is a 3-hydroxy-3-methylglutamyl (HMG) 
coenzyme A (CoA) reductase inhibitor that interferes with the cholesterol biosynthesis pathway 
as well as RAS isoprenylation. Unfortunately, this treatment did not improve cognitive function 
in NF1 children (102). A second clinical trial was performed with better outcome to evaluate the 
effect of lovastatin, another HMG-CoA reductase inhibitor, on the neourocognitive disabilities 
of NF1 patients (1, 35). In addition to these clinical trials, a phase II trial is in progress to assess 
the safety and efficacy of MEK162 in adult NS HCM patients (NCT01556568 by Novartis).  
 
7.8 EFFECT OF THE MEK INHIBITOR PD0325901 IN THE MDP DEVELOPMENT  
 
 About 10% of NS patients exhibit MPD, which are usually transient. Less frequently, 
these patients develop severe MPD, JMML or other forms of leukemia (91). Moreover, somatic 
mutations in K-RAS and N-RAS oncogenes are identified in approximately 25% of patients with 
JMML (112) and mutations in other members of the RAS signaling pathway that also result in a 
hyperactivation of the pathway, were found in 90% of these patients (56). Therefore, targeting 
RAS/MAPK signaling might be a good therapeutic strategy for these hematological disorders. 
The K-RasV14I mice developed MPD similar to JMML, thus it is an excellent tool to test the 
efficiency of different drugs, for instance the MEK inhibitor PD0325901 in the development of 
this hematological alteration.  
 Our results illustrate that MEK inhibitor PD0325901 treatment starting at embryo stages 
or at weaning had no effects in MPD as assessed in mice sacrificed at 4 months of age. Spleen 
weight as well as the expansion of the myeloid cells was comparable in mice treated with the 
MEK inhibitor or vehicle. Indeed, treated mice also underwent the same expansion of LSK cells 
in BM. However, exposure to MEK inhibitor increased the median survival of K-RasV14I mice 
in spite of the treatment protocol. In contrast, no benefit in survival was found in mice treated at 
4 months of age, when the mice presented MPD. These results indicate that MEK inhibitor 
treatment slows the progression of the MPD or the secondary hematological alterations also 
found in this mouse model, but only when mice were treated at early stages of the disease.  
 Two recent studies demonstrated that MEK inhibitor PD0325901 treatment in mice that 
express the oncogenic K-RasG12D mutation (126) or a null Nf1 mutation in hematopoietic cells 
(38) results in longer mice survival. In these experiments, similar to our third protocol of 
treatment, mice that display signs of the hematological alteration were daily treated (5 mg/kg). 
The different results that we found might be explained by the different via of administration and 
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duration of the treatment. While our mice were treated for 1 month by intraperitoneal injection, 
these studies were performed by oral gavage until mice became moribund. The different 
administration might determine the bio-disponibility of the compound and consequently the 
efficacy of the treatment. For instance, whereas CI-1040 MEK inhibitor administration was 
ineffective in Nf1lox/lox; Mx1-Cre mice (113), PD0325902 treatment induced a prolonged 
survival (38) due to the higher stabiliy of the last compound (12 hours vs the 4 hours of the CI-
1040 inhibitor). On the other hand, these experiments were performed using mice that express 
the oncogenic mutation only in a percentage of hematopoietic cells and more efficiently at 
postnatal stages. Therefore, targeting mutant hematopoietic cells in this scenario might be easier 
and more effective than in our mice, which express the mutation in all the cells by germline, 
since the normal hematopoietic cells can replace the BM. 
 Furthermore, they showed that MEK inhibitor PD0325901 treatment results in a rapid 
improvement of the aberrant composition of peripheral blood as well as reduction of the spleen 
weight. However, in both cases the effects of the MEK inhibitor are associated with persistence 
of the mutant cells due to an incomplete elimination of the HSC (38, 126). This incomplete 
elimination might explain why we did not see any benefits in the MPD features in mice treated 
at embryo stages or at 4 weeks age. These mice were analyzed at 4 months of age, several 
months (4 months in the case of the prenatal protocol and 1 and a half in the case of the 
postnatal protocol) after the end of the treatment. Since the MEK inhibitor treatment does not 
eliminate the HSC, this pool of resistance stem cell can repopulate again the BM and induce the 
development of the disease. Therefore, the small benefit in survival found in these studies may 
reflect only the slow progression of the disease during the treatment period. Combination with 
drugs that inhibit other additional pathway, for instance the PI3K pathway, might be required 
for elimination of the mutant cells and for the success of the treatment. The observation that 
mice that expressed the Pi3kcaH1047R mutation alone or in combination with the K-RasV14I 
mutation developed hematological disorders suggest that this pathway could be important for 
the initiation and/or the development of this disease. Take into account these results, a 
combination of PI3K and MEK inhibitor might be the election therapeutic combination for 
treatment of myeloproliferative disease.  
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1. La mutación K-RasV14I tiene como resultado una activación intermedia de la proteína en 
comparación con la mutación oncogénica K-RasG12V, permitiendo que sea compatible 
con el desarrollo embrionario y postnatal. Sin embargo, la expresión de dos copias 
afecta al desarrollo embrionario resultando en una reducción significativa del número 
de ratones homozigotos obtenidos de cruces entre ratones heterocigotos, indicativo de 
que el efecto de esta mutación es dosis génica dependiente. 
 
2. Los ratones que expresan la mutación K-RasV14I desde línea germinal reproducen 
fielmente muchas de las alteraciones del desarrollo asociadas al Síndrome Noonan 
(SN), entre las que se encuentran retraso de crecimiento, dismorfia cráneo-facial, 
alteraciones cardiacas y el desarrollo de un desorden mieloproliferativo. 
 
3. La expresión de la mutación K-RasV14I desde línea germinal induce hiperplasia del 
corazón asociada con un engrosamiento de la válvula aórtica. Esta hiperplasia se debe a 
un incremento en el número de cardiomiocitos en división y a un incremento en el 
número de células madre cardiacas durante el desarrollo embrionario. Ninguna de esta 
alteraciones aparecen cuando la mutación se expresan en células del miocardio en 
estadios adultos. Sin embargo, esta alteraciones no se traducen en una disminución de la 
función cardiaca, como se puede deducir de los estudios de resonancia magnética. 
 
4. La expresión de la mutación K-RasV14I desde línea germinal tiene como resultado el 
desarrollo de un desorden mieloproliferativo como consecuencia de una expansión de 
las células LSK, debido a la disminución en su muerte celular programada, así como 
una expansión en los progenitores mieloides. Este desorden mieloproliferativo se 
reproduce en estudios de transplantes primarios de médula ósea, lo que corrobora el 
origen de esta alteración en las células madre. Este desorden hematológico aparece 
también en ratones que expresan postnatalmente la mutación en células 
hematopoyéticas. 
 
5. Los ratones K-RasV14I presentan una predisposición tumoral mayor. La supervivencia de 
los ratones mutantes se encuentra reducida debido al desarrollo de múltiples neoplasias, 
distintas al desorden mieloproliferativo, entre las que se encuentran linfomas, sarcomas 
histiocíticos y carcinomas. Además, esta mutación coopera con genes supresores de 
tumores como Trp53 o p16Ink4a/p19Arf, acelerando la progresión tumoral.  
 
6. Eventos de tipo no genético que causan daño tisular y/o respuesta inflamatoria también 
cooperan con el desarrollo de lesiones preneoplásicas y de tumores en los ratones que 
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expresan la mutación K-RasV14I desde línea germinal. Así, la pancreatitis crónica 
inducida por tratamiento con ceruleina indujo la aparición de lesiones pancreáticas pre-
neoplásicas y la administración de nicotina propició el desarrollo de adenocarcinomas 
en pulmón y en páncreas. 
 
7. La expresión postnatal de la mutación K-RasV14I en todos los tipos celulares únicamente 
induce el desarrollo de desórdenes hematológicos, pero no de lesiones típicas inducidas 
por la expresión de las mutaciones oncogénicas K-RasG12V  y K-RasG12D, tales como 
lesiones pancreáticas o pulmonares. Las lesiones pulmonares tampoco se encontraron 
cuando la mutación se expresa en estadios postnatales en células pulmonares, indicando 
que las propiedades oncogénicas de la mutación K-RasV14I no son suficientes para 
inducir el desarrollo de tumores en pulmón. 
 
8. La expresión embrionaria de la mutación K-RasV14I en células acinares en condiciones 
de pancreatitis crónica, induce el desarrollo de lesiones pancreáticas pre-neoplásicas, 
como en el caso de las mutaciones oncogénicas. Sin embargo, a diferencia de los 
ratones K-RasG12V o K-RasG12D, no se encontraron adenocarcinomas, indicando una 
menor propiedad oncogénica de la mutación K-RasV14I.  
 
9. El tratamiento prenatal con el inhibidor de MEK PD0325901 rescata la letalidad 
perinatal, así como previene el desarrollo de los defectos en el crecimiento y las 
alteraciones cráneo-faciales y cardiacas, alteraciones características de los pacientes con 
SN descritas en el modelo K-RasV14I. Sin embargo, ninguna de estas alteraciones se 
previenen o mitigan en los ratones tratados al destete. Estos resultados sugieren que los 
tratamientos solo serán efectivos si se realizan durante el desarrollo embrionario; para 
lo que se hace indispensable disponer de diagnóstico prenatal en estos pacientes. 
 
10. El tratamiento con el inhibidor de MEK PD0325901 no tiene ningún efecto en la 
prevención del desarrollo del desorden mieloproliferativo, independientemente del 
tiempo de inicio del tratamiento. Únicamente se observa un pequeño beneficio en la 
supervivencia en ratones tratados antes del desarrollo de la enfermedad (estadio prenatal 
y al destete) debido un retraso en la progresión de la misma.  
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1. K-RasV14I mutation induces an intermediate activation state of the protein compared to 
the K-RasG12V oncogenic substitution, property that allows embryonic and postnatal 
development. However, the expression of both copies of the mutated allele results in a 
reduccion of the number of homozygous mice obtained from crosses between 
heterozygous parentals, indicating that increased dosage of the mutant K-RasV14I protein 
affects embryonic development.  
 
2. Mice that germline express the K-RasV14I mutation faithfully reproduced multiple NS-
associated developmental defects such as growth delay, craniofacial dysmorphia, 
cardiac defects and development of MPD.  
 
3. Germline K-RasV14I expression induces heart hyperplasia associated with an increased 
thickening of the aortic valve. This hyperplastic condition is due to an increase in the 
number of cycling cardiomyocytes and cardiac stem cells during embryonic 
development, since the expression of the mutation in adult myocardial cells had no 
consequences. However, theses alterations does not affect the heart function, as 
illustrated by MRI studies.  
 
4. Germline K-RasV14I expression results in a MPD due to an expansion of the LSK cells 
by decreasing the programmed cell death, and an expansion of myeloid progenitor. This 
MPD was reproduced in primary bone marrow transplantation indicating this stem cell 
origin. Same hematological alteration is also induced by the expression of the K-RasV14I 
mutation only in hematopoietic cells at postnatal stages. 
 
5. K-RasV14I mice display an increased predisposition to tumor development. Mutant mice 
present a reduced life span due to the development of multiple malignancies, different 
to MPD, mostly lymphomas, histiocytic sarcomas and carcinomas. Moreover, K-RasV14I 
mice efficiently cooperate with tumor suppressors genes such as Trp53 and 
p16Ink4a/p19Arf accelerating the tumor development.  
 
6. Non-genetic events involving tissue damage and/or an inflammatory response also 
cooperate with the development of neoplastic lesions and tumors in mice that express 
germline the K-RasV14I mutations. Thus, chronic pancreatitis, driven by caerulein 
treatment induces PanIN lesions and nicotine administration promotes the development 
of pancreatic and lung adenocarcinomas.  
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7. Postnatal expression of the K-RasV14I mutation in all type of cells induces the 
development of a hematological disorder, but not the typical lesions induced by the 
expression of the oncogenic K-RasG12V and K-RasG12D mutation, such as pancreatic and 
lung tumors. These lung lesions were not either found when the K-RasV14I mutation is 
expressed at postnatal stages in lung, indicating that this mutation does not have enough 
oncogenic properties to elicit lung tumors. 
 
8. The expression of the K-RasV14I mutation in acinar cells at embryonic stages under 
chronic pancreatitis conditions induces the development of PanIN lesions, similar to the 
oncogenic mutations. However, in contrast to the K-RasG12V and K-RasG12D mice, no 
PDAC lesions were found indicating that the oncogenic properties of the K-RasV14I 
mutation are smaller than the oncogenic ones.  
 
9. Treatment of pregnant mothers with the MEK inhibitor PD0325901 rescues the 
perinatal lethality and prevents the development of growth defects, craniofacial 
alterations and cardiac defects, the typical NS-associated features described in the K-
RasV14I. However, any of these alterations were prevented or ameliorated when the 
treatment starts at weaning indicating that prenatal testing, that allow the initiation of 
the treatment at early stages, is needed for the success of this treatment.  
 
10. MEK inhibitor PD0325901 has no effect in preventing MPD development 
independently of the time of the initiation of the treatment. Only a small benefit in the 
survival was found in mice treated before the development of the disease or at early 
stages (prenatal stages or at weaning, respectively) due to a delay in the progression of 
the disease.  
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Figure 1 K-RasV14I/V14I mice develop lung and pancreatic lesions upon nicotine administration. H&E stained 
paraffin section representative lung type III adenocarcinoma (left) and sarcomatoid PDAC (right) from a K-
RasV14I/V14I exposed to nicotine from P60. Arrowhead points to lung type III adenocarcinoma and asterisk points ot 
PDAC lesions.  
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Figure 2 K-RasV14I;p16Ink4a/p19Arf–/– mice develop histiocytic sarcomas. (A) H&E stained paraffin section and 
F4/80, Pax5 and CD3 immunostaining of a representative histiocytic sarcoma from a K-RasV14I/V14I; 
p16Inka/p19Arf–/–Scale bars: 50 µm. (B) H&E stained paraffin sections spleen, pancreas, duodenum, liver, urinary 
bladder and uterine horn infiltrates for a histiocytic sarcoma from a K-Ras+/V14I; p16Inka/p19Arf–/– mouse. Scale 
bars: 50 µm. 
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Figure 3 K-RasV14I; p16Ink4a/p19Arf–/– mice develop B cell lymphomas. H&E stained section and Pax5 and 
CD3 immunostaining of a representative B cell lymphoma from K-RasV14I/V14I; p16INK4a/p19ARF–/– mouse. Scale 
bars: 50 µm. 
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B!
Figure 4 K-RasV14I; p53–/– mice develop T cell lymphomas. (A) H&E stained section and CD3 and Pax5 
immunostainig of a T cell lymphoma from K-Ras+/V14I; Trp53–/– mouse. Inset shows detail area of spleen. Spleen 
scale bars: 200 µm. Immunostaining scale bar: 50 µm. (B) H&E stained sections of liver, kidney and lung infiltrate 
for the T cell lymphoma from K-Ras+/V14I; p53–/– mouse. Scale bars: 50 µ 
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Heart angiosarcoma!A! Cheek angiosarcoma!B!
Figure 5 K-RasV14I; p53–/– mice develop angiosarcoma. (A) H&E stained section of a heart from a K-Ras+/V14I; 
Trp53–/– mouse with a representative angiosarcoma. . Inset shows detail area of the angiosarcoma. Scale bars: 500 
µm. (B) H&E stained section of a cheek angiosarcoma from a K-Ras+/V14I; Trp53–/– mouse. Inset shows detail area 
of the angiosarcoma. Scale bars: 1000 µm. 
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Figure 6 Prenatal treatment with MEK inhibitor PD0325901 prevents the expansion of cardiac stem cells. 
Relative percentage of Sca-1+/PDGFRα+/CD31- cells in hearts from wild type (+/+, open bars) and K-Ras+/V14I 
(+/V14I, gray bars) P10-14 pups exposed from E7.5 to sacrificed time to vehicle (n=7, n=8, respectively) or 
PD0325901 (n=3, n=4, respectively) 
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Figure 7 Postnatal treatment with the MEK inhibitor PD0325901 does not correct the cardiac abnormalities 
in K-RasV14I mice (A) Representative hearts appearance of 4-month-old wild type (+/+), K-Ras+/V14I (+/V14I) and 
K-RasV14I/V14I (V14I/V14I) male mice exposed to vehicle or PD0325901 for 6 weeks starting at P21. Scale bar, 
5mm. (B) Heart/Body weight ratio of 4-month-old wild type (+/+, open bars), K-Ras+/V14I (+/V14I, gray bars) and 
K-RasV14I/V14I (V14I, solid bars) male mice exposed for 6 weeks starting at P21 to vehicle (n=9, n=10; n=10, 
respectively) or PD0325901 inhibitor (n=9, n=11; n=10, respectively). Error bars indicate SD. *P < 0.05; **P< 
0.01; ***P < 0.001. 
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Figure 8 Postnatal treatment with the MEK inhibitor PD0325901 does not correct the hematological 
disorders in K-RasV14I mice (A) Representative spleen appearance of 4-month-old wild type (+/+) and K-
RasV14I/V14I (V14I/V14I) mice exposed to vehicle or PD0325901 for 6 weeks starting at P21. Scale bar, 5mm. (B) 
Spleen/body weight ratio of 4-month-old wild type (+/+, open bars), K-Ras+/V14I (+/V14I, gray bars) and K-
RasV14I/V14I (V14I/V14I, solid bars) mice exposed for 6 weeks starting at P21 to vehicle (n=9, n=10; n=10, 
respectively) or PD0325901 inhibitor (n=9, n=11; n=10, respectively). (C) Percentages of Gr1+/CD11b+ myeloid 
cells in spleens of 4-month-old wild type (+/+, open bars), K-Ras+/V14I (+/V14I, gray bars) and K-RasV14I/V14I 
(V14I/V14I, solid bars) mice exposed for 6 weeks starting at P21 (n=9, n=8; n=10, respectively) or PD0325901 
inhibitor (n=9, n=9; n=10, respectively). (D) Percentage of LSK cells in 4 month-old wild type (+/+, open bars), K-
Ras+/V14I (+/V14I, gray bars) and K-RasV14I/V14I (V14I/V14I, solid bars) mice exposed for 6 weeks starting at P21to 
vehicle (n=9, n=7; n=8, respectively) or PD0325901 inhibitor (n=8, n=8; n=8, respectively). Error bars indicate SD. 
*P < 0.05; ***P < 0.001. 
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Figure 9. Postnatal treatment with the MEK inhibitor PD0325901 results in an increased survival in K-
Ras+/V14I mice. Left: Survival of K-RasV14I/V14I (V14I/V14I) mice exposed to vehicle for 6 weeks starting at P21 
(n=4, solid circles, solid line) or PD0325901 for 6 weeks starting at P21 (n=5, solid triangles, dotted line). Right: 
Survival of K-Ras+/V14I (+/V14I) mice exposed to vehicle for 6 weeks starting at P21 (n=11, gray circles, solid line) 
or PD0325901 for 6 weeks starting at P21 (n=13, gray triangles, dotted line).  
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TABLE 1. Distribution and frequency of RAS mutations in human tumors 
 
Organ/Tissue K-RAS H-RAS N-RAS 
Billiary tract 25.70% 0% 2.04% 
Breast 1.56% 0.34% 0.58% 
Cervix 7.13% 8.21% 1.32% 
Endometrium 14.64% 0.63% 2.58% 
Ganglia (autonomic) 0.49% 0.16% 1.37% 
Leukemias & Lymphomas 4.86% 0.25% 9.64% 
Large intestine 34.74% N/A 3.84% 
Liver 3.38% 0.16% 1.32% 
Lung 16.36% 0.61% 0.66% 
Ovary 12.50% 0% 0.86% 
Pancreas 57.52% 0% 0.76% 
Prostate 5.67% 3.34% 0.91% 
Skin 2.17% 7.43% 15.54% 
Small intestin 20.65% 0% 0% 
Soft tissue 4.68% 4.09% 3.93% 
Stomach 6.26% 2.01% 1.13% 
Testis 3.82% 3.85% 2.83% 
Thyroid 2.05% 3.84% 6.42% 
Urinary tract 4.34% 9.85% 1.16% 
Total tumor samples 130480 33460 56321 
Positive tumor samples 21,75% 2,86% 5,74% 
 
Data obtained from the Sanger Catalogue of Somatic Mutation in Cancer: http://sangeer.ac.uk/cosmic (September 2013). Values 
presented as the total percentage of clinical samples analyzed for that particular tumor type. Boldface corresponds to most frequent 
mutated organ/tissue. N/A=not available. 
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TABLE 2. K-RAS mutations found in Noonan patients 
 
 
Exon 
NT 
substitution 
Aa 
substitution Diagnosis References 
1 40 G>A V14I 10 NS 46, 99, 115, 122, 147, 188, 243 
1 65 A>G Q22R 1 NS/severe 1 NS 115, 243 
1 77 A>T N26I 1 NS + lupus erythematosus 118 
1 101 C>T P34L 1 NS 243 
1 101 C>A P34Q 1 NS 243	  
1 108 A>G I36M 3 NS 115, 122, 243 	  
2 173 C>T T58I 
1 NS /JMML 
1 NS 
1NS/ craniosynostosis 
104, 147, 188   
2 178 G>A G60S 1 NS/ craniosynostosis 104 
2 179 G>T G60V NS lethal course 153 
3 214 A>C M72L 1 NS/craniosynostosis 2 NS 26 
3 347 A>G N116S 1 NS 167	  
4B 455 T>G V152G 1 NS/CS 33 
4B 458 A>T D153V 1 NS/CFC syndrome 1 NS 33, 188 
4B 460 A>T D153V 2 NS 243 
4B 466 T>A F156I 1 NS/CFC syndrome 1 NS 147, 243 
 
NS: Noonan syndrome; JMML: Juvenile Myelomonocytic leukemia; CS: Costello syndrome; CFC syndrome: cardiofaciocutaneous 
syndrome. 
 
 
 
TABLE 3. Fat and lean content measured using densitometer analysis 
	   	   	   Lean content (g) 	   n 1 month 2 month 3 month 4 month 
K-Ras+/+ 4 12.45 ± 3.02	   19.42 ± 0.62	   22.25 ± 1.09	   23.75 ± 0.07	  
K-Ras+/V14I 10   9.36 ± 0.84	   19.00 ± 1.50	   22.53 ± 1.94	   24.29 ± 2.23	  
K-RasV14I/V14I	   5   7.64 ± 1.30*	   17.56 ± 1.01*	   21.40 ± 0.74	   24.68 ± 1.88	  	   	   Fat content (g) 	   n 1 month 2 month 3 month 4 month 
K-Ras+/+ 4  1.42 ± 0.55	   2.90 ± 0.26	    4.00 ± 1.04	     6.25 ± 1.58	  
K-Ras+/V14I 10  0.95 ± 0.19	   2.79 ± 0.50	    3.68 ± 0.97	     4.77 ± 1.47	  
K-RasV14I/V14I	   5  0.76 ± 0.26 *	   2.28 ± 0.26	    2.46 ± 0.49 *	     2.98 ± 0.75 **	  	  
Numbers shown are the media ± SD. Statistical significance was assessed by two-tailed Student’s test. *P < 0.05.  
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TABLE 4. Bone Mineral Density (BMD) and Bone Mineral content (BMC) measured using densitometer analysis 
 	   	   Bone Mineral Density (g/cm2) 	   n 1 month 2 month 3 month 4 month 
K-Ras+/+ 4  0.03 ± 0.004	    0.05 ± 0.003	   0.05 ± 0.001	   0.52 ± 0.001	  
K-Ras+/V14I 10  0.03 ± 0.002	    0.04 ± 0.002	   0.05 ± 0.002	   0.05 ± 0.002	  
K-RasV14I/V14I	   5  0.03 ± 0.002	    0.04 ± 0.002	   0.05 ± 0.002	   0.05 ± 0.001	  	   	   Bone Mineral Content (g) 	   n 1 month 2 month 3 month 4 month 
K-Ras+/+ 4  0.16 ± 0.05	   0.34 ± 0.03	     0.41 ± 0.01	      0.43 ± 0.04	  
K-Ras+/V14I 10  0.11 ± 0.01	   0.35 ± 0.04	     0.42 ± 0.03	      0.45 ± 0.04	  
K-RasV14I/V14I	   5  0.09 ± 0.02 *	   0.31 ± 0.02	     0.40 ± 0.03 	      0.46 ± 0.02	  	  
Numbers shown are the media ± SD. Statistical significance was assessed by two-tailed Student’s test. *P < 0.05.  
 
 	  
 
TABLE 5. Hearing threshold for click stimulation in 4-month-old mice 
 	   n Hearing threshold for click stimulation (dB SPL) 
K-Ras+/+ 8 24 ± 3	  
K-Ras+/V14I 7 25 ± 4	  
K-RasV14I/V14I	   4 29 ± 5	  
 
Numbers shown are the media ± SD. dB SPL, decibel Sound Pressure Levels. 
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TABLE 6. MRI heart parameters of 4-month-old males 	  	   4 months 	   K-Ras+/+ 
(n=5) 	   K-Ras+/V14I (n=4)	   	     K-RasV14I/V14I (n=3)	   	   p value +/+ vs +/V14I	   	   p value +/+ vs V14I/V14I	  
 LVM (mg)   68.40 ± 19.06 	       84.75 ± 23.10 	          112 ± 10.82 	   0.2815 NS 	     0.0120 *	  
 WTd (mm)   0.85 ± 0.08 	       0.86 ± 0.37 	       0.90 ± 0.13 	   0.5952 NS 	   0.5024 NS	  
 WTs (mm)   1.32 ± 0.13 	       1.35 ± 0.22 	       1.59 ± 0.20 	   0.7763 NS	   	   0.0152 * 	  
 WTn (%) 46.68 ± 7.46 	       48.03 ± 16.52 	     68.48 ± 9.18 	   0.8733 NS 	   0.0079 **	  
 EDV (µl)   44.40 ± 13.89 	       55.25 ± 15.78 	            74 ± 10.39 	   0.3084 NS 	    0.0196 **	  
 ESV (µl) 13.40 ± 5.37 	     17.75 ± 9.64 	     20.33 ± 3.51 	   0.4160 NS 	    0.0968 NS	  
 FS (%) 55.09 ± 6.84 	       55.59 ± 19.06 	       79.07 ± 19.75 	   0.9583 NS	   	   0.0458 * 	  
 EF (%)   70.2 ± 5.17 	     69.50 ± 8.06 	     73.00 ± 2.65 	   0.8782 NS	   	   0.4256 NS	  
 HR (bpm)   411.2 ± 39.11 	          394 ± 60.42 	     466.67 ± 20.43 	   0.6196 NS	   	    0.0671 NS	  
 CO (ml/min)   12.5 ± 2.91 	       14.9 ± 4.66 	     24.97 ± 2.65 	   0.4228 NS	   	    0.0011  ** 	  	  	  
LVM: left ventricle mass; WTd: wall thicknesses in diastole, WTs: wall thicknesses in systole; WTn: systolic wall thickening; EDV: end 
diastolic volume; ESV: end systolic volume; FS: fractional shortening; EF: ejection fraction; HR: hear rate; CO: cardiac output. Numbers 
shown are the media ± SD. Statistical significance was assessed by two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; NS, 
not significant. 
 
 	  
TABLE 7. Blood cell counts of 4-month-old mice 	  	   K-Ras+/+ 
(n=10) 	   K-Ras+/V14I (n=15)	   	   K-RasV14I/V14I (n=10)	   	   p value +/+ vs +/V14I	   	   p value +/+ vs V14I/V14I	  
WBC (109/l) 9.76 ± 3.12 	    12.16 ± 2.15 	    16.77 ± 5.57 	   0.0825 NS 	   0.0100 **	  
LYM (109/l) 8.43 ± 2.91 	      8.53 ± 1.86 	      7.37 ± 2.94 	   0.9363 NS	   	   0.5148 NS	  
MID (109/l) 0.43 ± 0.26 	      0.53 ± 0.31 	      0.83 ± 0.87 	   0.5316 NS 	   0.3306 NS	  
GRA (109/l) 0.81 ± 0.39 	      2.28 ± 2.14 	      8.87 ± 4.97 	   0.0747 NS	   	   0.0122 *	  
RBC (1012/l) 9.36 ± 0.33 	      9.07 ± 1.47 	      6.21 ± 2.08 	   0.1441 NS 	   0.0010 *** 
PLT (109/l) 714 ± 265 	   547.7 ± 276 	   344.5 ± 129 	   0.2557 NS 	   0.1009 NS 	  
WBC: white blood cells; LYM: lymphocytes; MID: monocytes and some eosinophiles; GRA: granulocytes; RBD: red blood cells; 
PLT: platelets. Numbers shown are the media ± SD. Statistical significance was assessed by two-tailed Student’s t-test. *P < 0.05; 
**P < 0.01; ***P < 0.001; NS, not significant. 
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TABLE 8. Blood cell counts of animals transplanted with BM cells 
	   K-Ras+/+ (n=20) 	   K-Ras+/V14I (n=14)	   	   p value +/+ vs V14I	  
WBC (109/l) 8.85 ± 3.69 	   10.17 ± 2.88 	   0.2737 NS 
LYM (109/l) 6.53 ± 2.89 	    5.17 ± 1.88 	   0.1228 NS	  
MID (109/l) 0.30 ± 0.37 	    0.28 ± 0.19 	   0.9046 NS 
GRA (109/l) 2.12 ± 0.83 	    4.72 ± 1.75 	   <0.0001	   ***	  
RBC (1012/l) 8.66 ± 1.09 	    5.96 ± 1.77 	   <0.0001 *** 
PLT (109/l) 766 ± 382 	    209 ± 211 	   0.0006 *** 
 
Values from mice sacrificed between 30 to 34 weeks after transplantation. WBC: white blood cells; LYM: lymphocytes; MID: 
monocytes and some eosinophils; GRA: granulocytes; RBD: red blood cells; PLT: platelets. Animals transplanted with wild-type 
cells were sacrificed at the same age. Numbers shown are the media ± SD. Statistical significance was assessed by two-tailed 
Student’s t-test. ***P < 0.001; NS, not significant. 
 	  
TABLE 9. Viable progeny from matings between K-Ras+/V14I mice in the different pure genetic backgrounds	  	  
 
K-Ras+/+ K-Ras+/V14I K-RasV14I 
 
 
 
Stage 
 
 
 
n 
C57BL/6J (F5) 
        
P0 14 4 (28%) 10 (71%) 0 (0%) 
P21 50 21 (42%) 29 (58%) 0 (0%) 
 
 
  
 
 
 
 
129S2/Sv (F5) 
P21 100 33 (33%) 54 (54%) 13 (13%) 
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TABLE 10. Morphometric measurements of skulls from 4-month-old C57BL/6J and 129S2/Sv mice 	  	   C57BL/6J mice (F5) 	   K-Ras+/+ 
(n=6) 	   K-Ras+/V14I (n=7)	   	   p value +/+ vs +/V14I 	  
Length (mm)  23.72 ± 0.28 	   23.51 ± 0.50 	                                 0.3798 NS 
Width (mm)    9.59 ± 0.15 	     9.77 ± 0.25 	                                 0.1585 NS	  
Height (mm)    5.71 ± 0.09 	     6.06 ± 0.35 	                                 0.0458 * 
Volume (mm3) 367.08 ± 16.6  	   425.48 ± 18.71 	                               <0.0001 ***	  	   129S2/Sv mice (F5) 	   K-Ras+/+ 
(n=5) 	   K-Ras+/V14I (n=4)	   	   K-RasV14I/V14I (n=7)	   	   p value +/+ vs +/V14I	   p value  +/+ vs V14I/V14I	  
Length (mm)  22.77 ± 0.27 	     23.01 ± 0.68 	     20.97 ± 0.90 	   0.4779 NS	     0.0013 **	  
Width (mm)    9.42 ± 0.12 	       9.70 ± 0.32 	     10.22 ± 0.21 	   0.1191 NS	   <0.0001 ***	  
Height (mm)    5.81 ± 0.19 	       6.02 ± 0.34 	       6.56 ± 0.18 	   0.2692 NS	   <0.0001 ***	  
Volume (mm3) 337.58 ± 28.5  	   395.37 ± 27.4 	   394.93 ± 16.4 	    0.0179  *	     0.0013 **	  
 
Morphometric measurements from micro-CT scans of the skulls of a cohort of 4-month-old mice (see Figure 1D for skull 
images). Numbers shown are the media ± SD. Statistical significance was assessed by two-tailed Student’s t-test. *P < 
0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
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TABLE 11. Blood cells counts of 4-month-old C57BL/6J and 129S2/Sv mice 
 	   C57BL/6J mice (F5) 	   K-Ras+/+ 
(n=6) 
	   K-Ras+/V14I 
(n=11)	   	   p value +/+ vs +/V14I	  
WBC (109/L)  9.96 ± 0.14 	                  13.80 ± 5.56 	     0.1413 NS 
LYM (109/L)  8.42 ± 2.96 	                  10.71 ± 5.36 	     0.3505 NS	  
MID (109/L)  0.38 ± 0.44 	   0.38 ± 0.18 	     0.9969 NS 
GRA (109/L)     1.17 ± 0.41  	   2.71 ± 1.56 	   0.0089 **	  
RBC (1012/L)                10.62 ± 1.03 	   8.38 ± 1.26 	   0.0022 ** 
PLT (109/L) 959.6 ± 425.1 	   230.0 ± 163.3 	   0.0142 * 	   129S2/Sv mice (F5) 	   K-Ras+/+ 
(n=9) 
	   K-Ras+/V14I 
(n=10)	   	   K-RasV14I/V14I (n=6)	   	   p value +/+ vs +/V14I	   p value  +/+ vs V14I/V14I	  
WBC (109/L)  7.33 ± 2.19 	      9.07 ± 2.76 	        15.64 ± 7.04 	   0.1510 NS	     0.0332 *	  
LYM (109/L)  6.13 ± 1.73 	      7.57 ± 2.78 	   8.84 ± 3.83 	   0.1995 NS	   0.1530 NS	  
MID (109/L)  0.19 ± 0.12 	      0.29 ± 0.15 	   0.90 ± 0.74 	   0.1369 NS	   <0.0981 NS	  
GRA (109/L)     1.02 ± 0.69  	      1.21 ± 0.59 	   6.04 ± 5.17 	    0.5173 NS	     0.0630 NS	  
RBC (1012/L)   10.43 ± 1.68  	         10.85 ± 0.88 	        10.36 ± 0.67 	   0.9241 NS 0.4952 NS 
PLT (109/L)   305.0 ± 153.7  	    363.89 ± 190.7 	      182.67 ± 147 	   0.3721 NS 0.2247 NS 
 
WBC: white blood cells; LYM: lymphocytes; MID: monocytes and some eosinophiles; GRA: granulocytes; RBD: red 
blood cells; PLT: platelets. Numbers shown are the media ± SD. Statistical significance was assessed by two-tailed 
Student’s t-test.  
*P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                     Appendix I  
	   194	  
 
TABLE 12 Summary of pathological alterations found in K-RasV14I/V14I and K-Ras+/V14I mice 
K-Ras+/V14I mice (AVB line) 
Mouse 
ID Sex
 Age at death 
(weeks) 
Spleen/ 
BW	   WBC (109/L)	   LYM (109/L) MID (109/L) GRA (109/L)	   RBC (1012/L)	   PLT (109/L)	   Pathology 
218 M 109 31.9 8.36 4.65 0.72 2.99 2.35 1173 Lymphoma, lung adenoma and adenocarcinoma  
172 F 97 24.8 12.94 3.49 0.56 8.89 7.85 274 Histiocytic sarcoma 
162 M 90 7.1 ND ND ND ND ND ND Lung adenocarcinoma. Adenoma and adenocarcinoma in liver 
224 M 83 5.2 7.54 1.65 0.41 5.84 8.97 1489 Lymphoma 
207 F 83 30.0 ND ND ND ND ND ND Lymphoma and histiocytic sarcoma 
384 F 83 46.1 ND ND ND ND ND ND Lymphoma 
247 F 82 42.4 9.53 2.93 0.58 6.01 6.73 593 Histiocytic sarcoma 
271 M 78 10.7 17.66 11.10 0.41 6.16 8.94 1429 Tubular adenoma in duodenum. Hydronephrosis 
230 M 77 8.5 ND ND ND ND ND ND Lymphoma and hepatocarcinoma. Adenoma in epididymis 
354 M 77 9.5 16.53 9.52 0.12 6.89 8.99 786 Lymphoma and vasculitis  
199 M 76 3.2 5.86 3.65 0.12 2.09 9.3 1371 B cell lymphoma 
345 F 75 41.8 16.4 9.52 0.10 6.78 3.88 472 Lymphoma and intestinal adenoma 
216 M 73 53.2 14.5 8.14 0.52 5.83 3.87 283 Myeloproliferative disorder (MPD) 
310 F 68 43.8 6.11 2.89 0.51 2.71 1.34 45 Histiocytic sarcoma 
279 F 65 26.1 10.65 2.92 0.62 7.11 5.72 450 Lymphoma 
276 M 63 34.6 11.66 6.4 0.31 4.96 6.19 565 Lymphoma and angiosarcoma. Areas of infarctation in the heart 
333 M 62 43.9 ND ND ND ND ND ND Histiocytic sarcoma 
357 F 60 18.0 12.22 7.16 0.29 4.77 6.86 336 B cell lymphoma and systemic vasculitis  
342 F 59 35.2 ND ND ND ND ND ND Lymphoma 
222 F 57 11.1 16.21 10.46 0.66 5.09 7.14 877 B cell lymphoma and systemic vasculitis  
329 F 37 8.1 8.08 5.98 0.13 1.98 6.54 460 Lymphoma 
595 F 32 161.7 29.79 12.49 1.47 15.83 3.88 49 Myeloid Leukemia 
509 M 31 37.0 18.97 9.16 1.51 8.31 5.28 786 Myeloproliferative disorder (MPD) 
344 F 27 40.2 32.22 3.37 1.14 27.7 5.96 174 
Myeloid Leukemia. Acute 
glomerulonephritis. Adenoma in 
doudenum 
487 F 26 29.6 ND ND ND ND ND ND Lymphoblastic lymphoma 
766 F 26 22.5 20.52 9.33 0.32 10.87 9.10 646 Lymphoma. Areas of infarctation in the heart 	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Table 12 continuation 
 
K-RasV14I/V14I mice (AVB line) 
Mouse 
ID Sex
 Age at death 
(weeks) 
Spleen/ 
BW	   WBC (109/L)	   LYM (109/L) MID (109/L) GRA (109/L)	   RBC (1012/L)	   PLT (109/L)	   Pathology 
275 M 65 36.9 23.8 14.57 1.28 7.94 6.95 472 
Lymphoma and 
myeloproliferative disorder. 
Hydronephrosis 
349 F 55 30.5 24.9 11.51 1.55 11.83 7.86 289 Lymphoma. Hydronephrosis 
246 M 52 34.5 38.01 9.98 2.88 25.15 6.55 472 
Myeloproliferative disorder. 
Areas of infarctation in the heart. 
Pyelonephritis 
640 M 51 34.2 ND ND ND ND ND ND Histiocytic sarcoma and lymphoma. 
402 F 41 49.2 ND ND ND ND ND ND Histiocytic sarcoma 
374 F 37 154.6 39.35 16.32 2.08 20.95 3.31 280 
Lymphoma and 
myeloproliferative disorder. 
Tumor in adenohypophysis 
579 F 33 46.5 36.90 12.65 2.13 22.12 4.01 550 Lymphoma 
683 M 30 9.6 ND ND ND ND ND ND Lymphoma. Pyelonephritis and nephropathy 
448 M 26 14.3 9.49 3.77 0.34 5.38 7.7 675 Pyelonephritis and hydronephrosis 
455 M 26 19.7 11.46 2.82 0.35 8.29 4.6 200 Lymphoma. Pyelonephritis 
846 M 19 54.4 ND ND ND ND ND ND Histiocytic sarcoma and lymphoma 
426 F 17 32.6 7.93 2.89 0.26 4.78 6.77 498 
Myeloproliferative disorder. 
Glomerulonephritis and 
pyelonephritis 
 
M: male; F: female. Spleen/BW: spleen weight (mg)/ body weight (g). WBC: white blood cells [4-12]; LYM: lymphocytes 
[2-9]; MID: monocytes and some eosinophils [<0.6]; GRA: granulocytes [0.7-6]; RBD: red blood cells [9-15]; PLT: 
platelets [250-750]. ND: not determined. Numbers inside the brackets are the reference values. 
 
 
 
 
 
TABLE 13. Summary of tumors observed in K-RasV14I; p16Ink4a/p19Arf –/– and K-Ras+/V14I; p16Ink4a/p19Arf –/–mice 
K-RasV14I; p16Ink4a/p19Arf –/– mice  (BYP line) 
Mouse ID Sex Age at death (weeks) Spleen/BW	   Tumor type 
191 F 23 42.4 Histiocytic sarcoma 
170 F 23 34.2 Histiocytic sarcoma	  
174 M 20 30.6 Histiocytic sarcoma and lymphoma 
181 F 20 28.5 Histiocytic sarcoma 
179 M 19 39.5 Histiocytic sarcoma 
167 M 18 56.9 Histiocytic sarcoma and B-cell lymphoma 
199 F 17 60.1 Histiocytic sarcoma and thymus lymphangioma 
189 F 16 51.7 Lymphoma 	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Table 13 continuation 	  	  
K-Ras+/V14I; p16Ink4a/p19Arf –/– mice (BYP line) 
Mouse ID Sex Age at death (weeks) Spleen/BW	   Tumor type 
148 F 37 40.7 Histiocytic sarcoma 
154 F 30 4.9 Histiocytic sarcoma and lymphoma	  
159 M 30 48.2 Histiocytic sarcoma and B cell lymphoma	  
123 F 27 66.4 Histiocytic sarcoma 
128 F 27 93.9 Histiocytic sarcoma 
149 F 25 34.7 Histiocytic sarcoma  
109 M 23 32.8 Fibrosarcoma 
183 F 23 62.4 Histiocytic sarcoma and lymphoma 
144 M 22 45.3 Histiocytic sarcoma 
184 F 22 51.7 Sarcoma 	  
M: male; F: female. Spleen/BW: spleen weight (mg)/ body weight (g). 
 
 
 
TABLE 14. Summary of tumors observed in the K-Ras+/V14I; Trp53–/– mice 
K-Ras+/V14I; Trp53–/– mice  (BOG line) 
Mouse ID Sex Age at death (weeks) Spleen/BW	   Tumor type 
133 M 20 12.8 Lymphoma and angiosarcoma 
136 M 19 74.2 Lymphoma and angiosarcoma	  
128 F 18 60.3 B cell lymphoma and angiosarcoma	  
40 M 16 36.9 Lymphoma, heart angiosarcoma and PIN	  
67 M 15 21.8 Angiosarcoma 
110 M 15 25.7 B cell lymphoma, lymphoblastic lymphoma in thymus and brain tumor 
38 M 15 40.6 Lymphoma and heart angiosarcoma 
162 M 15 5.6 Lymphoblastic lymphoma, angiosarcoma and hemangioma 
138 M 14 18.1 Lymphoma and angiosarcoma 
125 M 11 51.3 T cell lymphoma 	  
M: male and F: female. Spleen/BW: spleen weight (mg)/ body weight (g). 	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TABLE 15 Progeny from matings between K-Ras+/V14I; p53-/- and K-Ras+/V14I; p53+/- mice 	  
Progeny from matings between K-Ras+/V14I; p53-/- and K-Ras+/V14I; p53+/- mice 
 
 
 
Stage 
 
 
 
n K-Ras+/+;  
p53+/- 
K-Ras+/V14;  
p53+/- 
K-RasV14I/V14I;  
p53+/- 
K-Ras+/+;  
p53-/- 
K-Ras+/V14;  
p53-/- 
K-RasV14I/V14I;  
p53-/- 
E18.5 24 2 (8%) 10 (42%) 4 (17%) 2 (8%) 4 (17%) 2 (8%) 
P0 23 2 (9%) 6 (26%) 3 (13%) 4 (17%) 6 (26%) 2 (DIC) (9%) 
P21 103 27 (26%) 29 (28%) 3 (3%) 16 (16%) 28 (27%) 0 (0%) 	  
Progeny is indicated. Numbers in parentheses indicate the percentage of embryos or mice compared with the analyzed total number. 
DIC: Dead in cage.  
 
 
 
 
 
 
TABLE 16 Blood cells counts of K-Ras+/LSLV14I; RERTnert/ert; Pi3kca+/LmgLH1047R and K-Ras+/+; RERTnert/ert; Pi3kca+/LmgLH1047R 
sacrificed at humane end point 
 
K-Ras+/LSLV14I; RERTnert/ert; Pi3kca+/LmgLH1047R mice (MJA line) 
Mouse 
ID Sex
 Age at death 
(weeks) 
WBC 
(109/L)	   LYM (109/L) MID (109/L) GRA (109/L)	   RBC (1012/L)	   PLT (109/L)	  
52 M 86 3.75 2.27 0.03 1.45  8.55 1316 
37 M 83 9.82 4.55 0.24 5.03 11.27 1528 
44 M 77 11.70 8.68 0.27 2.75 9.73 580 
53 F 69 15.53 4.88 0.13 10.52 7.76 102 
K-Ras+/+; RERTnert/ert; Pi3kca+/LmgLH1047R mice  (MJA line) 
Mouse 
ID Sex
 Age at death 
(weeks) 
WBC 
(109/L)	   LYM (109/L) MID (109/L) GRA (109/L)	   RBC (1012/L)	   PLT (109/L)	  
36 M 83 9.44 3.50 1.08 4.86 7.13 741 
57 F 82 10.38 7.94 0.07 2.37 8.30 40 
46 F 61 17.36 13.03 0.53 3.80 6.10 116 
53 F 69 15.53 4.88 0.13 10.52 7.76 102 	  
M: male; F: female. WBC: white blood cells [4-12]; LYM: lymphocytes [2-9]; MID: monocytes and some eosinophils [<0.6]; GRA: 
granulocytes [0.7-6]; RBD: red blood cells [9-15]; PLT: platelets [250-750]. Numbers inside the brackets are the reference values. 
 
 
 
                                                                                                                                                                                                     Appendix I  
	   198	  
 
TABLE 17. Morphometric measurements of skulls of 4-month-old mice treated from E7.5 to P21 with either vehicle or 
the MEK inhibitor PD0325901 	   Vehicle 	   K-Ras+/+ 
(n=4) 	   K-Ras+/V14I (n=5)	   	   K-RasV14I/V14I (n=5)	   	   p value +/+ vs +/V14I	   	   p value +/+ vs V14I/V14I	  
Length (mm)   24.10 ± 0.52 	     24.19 ± 0.21 	     22.73 ± 0.72 	   0.7561 NS 	   0.0154	   * 	  
Width (mm)     9.66 ± 0.09 	       9.65 ± 0.18 	       9.99 ± 0.26 	   0.9769 NS	   	   0.0411	   * 	  
Height (mm)     5.62 ± 0.13 	       5.61 ± 0.04 	       6.48 ± 0.30 	   0.9155 NS 	   0.0012	   * 	  
Volume (mm3) 359.41 ± 22.8 	   372.84 ± 29.6 	   418.47 ± 8.37 	   0.4816 NS	   	   0.0009	   *** 	  	  	   PD0325901 	   K-Ras+/+ 
(n=5) 
	   K-Ras+/V14I 
(n=6)	   	   K-RasV14I/V14I (n=9)	   	   p value +/+ vs +/V14I	   	   p value +/+ vs V14I/V14I	  
Length (mm)  23.59 ± 0.30 	     23.64 ± 0.40 	     23.39 ± 0.41 	   0.8249 NS 	   0.2431 NS	  
Width (mm)    9.50 ± 0.08 	       9.51 ± 0.26 	       9.54 ± 0.31 	   0.8808 NS	   	   0.8651 NS	  
Height (mm)    5.52 ± 0.23 	       5.64 ± 0.26 	       5.65 ± 0.21 	   0.4233 NS 	   0.9445 NS	  
Volume (mm3) 343.06 ± 29.0  	   360.38 ± 36.4 	   345.19 ± 45.6 	   0.3998 NS	   	   0.4759 NS	  
 
Morphometric measurements from micro-CT scans of a cohort of 4-month-old mice treated with vehicle and MEK inhibitor 
PD0325901 from E7.5 to P21. Numbers shown are the media ± SD.	   Statistical significance was assessed by two-tailed 
Student’s t-test. *P < 0.05; **P < 0.01; NS, not significant. 
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TABLE 18. Morphometric measurements of skulls from 4 month-old mice treated either with vehicle or with the MEK 
inhibitor PD0325901 from P21 during 6 weeks.  
 	   Vehicle 	   K-Ras+/+ 
(n=5) 
	   K-Ras+/V14I 
(n=7)	   	   K-RasV14I/V14I (n=6)	   	   p value +/+ vs +/V14I	   	   p value +/+ vs V14I/V14I	  
1. Length (mm)   24.12 ± 0.45 	     23.78 ± 0.29 	     22.72 ± 0.65 	   0.1460 NS 	   0.0079	   ** 	  
2. Width (mm)     9.65 ± 0.08 	       9.73 ± 0.18 	       9.96 ± 0.24 	   0.3530 NS	   	   0.0228	   * 	  
3. Height (mm)     5.63 ± 0.11 	       5.68 ± 0.23 	       6.51 ± 0.29 	   0.6531 NS 	   0.0001	   ***	  
4. Volume (mm3) 358.23 ± 19.9 	   375.31 ± 27.4 	   410.64 ± 28.3 	   0.2650 NS	   	   0.0074	   ** 	  	  	   PD0325901 	   K-Ras+/+ 
(n=5) 
	   K-Ras+/V14I 
(n=9)	   	   K-RasV14I/V14I (n=4)	   	   p value +/+ vs +/V14I	   	   p value +/+ vs V14I/V14I	  
1. Length (mm)  23.92 ± 0.21 	     23.93 ± 0.24 	     22.42 ± 0.92 	   0.9404 NS 	   0.0448 *	  
2. Width (mm)    9.37 ± 0.27 	       9.52 ± 0.29 	       9.93 ± 0.37 	   0.3794 NS	   	   0.0346 *	  
3. Height (mm)    5.50 ± 0.16 	       5.50 ± 0.20 	       6.36 ± 0.28 	   0.9668 NS 	   0.0006 ***	  
4. Volume (mm3) 329.04 ± 30.0  	   358.32 ± 36.7 	   389.31 ± 36.5 	   0.1914 NS	   	   0.0609 NS	  
 
Morphometric measurements from micro-CT scans of a cohort of 4 month-old mice treated with vehicle and PD0325901 MEK 
inhibitor from P21 during 6 weeks. Numbers shown are the media ± SD.	  Statistical significance was assessed by two-tailed Student’s 
t-test. *P < 0.05; **P < 0.01; NS, not significant. 
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